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Abstract 
A number of reports have linked early pubertal development to adverse health 
conditions among women. Despite race disparities in pubertal timing and later 
cardiovascular disease (CVD)-related health in adulthood, few studies have 
investigated if associations of early maturation with cardiometabolic risk factors 
differ for African-American and white women. Furthermore, there are limited 
longitudinal data tracking the trajectory of change in cardiometabolic risk factors 
after puberty and into adolescence and adulthood. The three primary aims of this 
thesis were to 1) examine the relationship between earlier age at menarche and 
CVD risk factors at different points in the life course, 2) account for the role of 
adiposity in associations, and 3) explore possible race differences in 
associations. These aims were explored using data from three prospective cohort 
studies that included different age groups: the National Growth and Health Study 
(NGHS) for ages 9-19 years, the Coronary Artery Risk Development in Young 
Adults (CARDIA) study for ages 18-54 years, and the Atherosclerosis Risk in 
Communities (ARIC) study for ages 45-75 years. The results from the three 
manuscripts included in this thesis suggested that earlier age at menarche was 
associated with a more adverse cardiometabolic profile over the life course, but 
higher lifetime accumulated adiposity among early maturing women explained 
most associations. Earlier menarche was more strongly related to adulthood 
adiposity and metabolic syndrome among white compared with African-American 
women, but there were no other differences by race. Targeted efforts to prevent 
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obesity starting before puberty, as well as among early maturing girls even if 
normal weight, might be helpful for primordial prevention of cardiovascular 
disease.  
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Chapter 1: Introduction and Specific Aims 
 
A number of reports have linked early pubertal development to long-term 
health, including cardiometabolic disorders such as obesity, type 2 diabetes, and 
cardiovascular disease [3, 8-12]. At the same time, there is a documented trend 
toward earlier maturation among girls in developed countries, most dramatically 
for African-American women, which may have important implications for women’s 
health [13-15]. Racial differences in pubertal timing coincide with well-
documented health disparities in the prevalence of cardiometabolic disorders that 
are associated with obesity [16-19]. Although declines in the average age at 
menarche correspond with increases in childhood obesity in the United States, it 
remains unclear if obesity is the sole driving force behind the trend [18, 20]. 
Independent of adiposity, hormonal changes and hyperinsulinemia associated 
with early onset of puberty may affect future disease risk [3, 21-23]. 
A recent National Heart, Lung, and Blood Institute (NHLBI) task force set forth 
a priority to reduce cardiovascular disease (CVD) risk starting in childhood and 
adolescence, and they published risk reduction guidelines with the goal of 
delaying progression to clinical CVD until later in life [24]. The task force noted 
that ethnic disparities in CVD risk begin in childhood, and they emphasized the 
importance of prevention of these disparities early in life [25]. Identifying which 
children and adolescents are most at risk for future metabolic disorders makes it 
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possible to prevent or delay future CVD through comprehensive programs that 
address nutrition, physical activity, and prevention of smoking [26]. 
Despite disparities in pubertal timing and later CVD-related health, few 
studies have investigated if the cardiometabolic consequences of early 
maturation differ for African-American and white women. One study showed that 
the effect of early menarche (age at first menstruation) on accrual of adiposity 
during adolescence was similar for African-American and white girls, although 
African-American girls had significantly higher adiposity after age 12 overall [20]. 
Another study noted that timing of puberty was associated with adulthood 
adiposity among white but not African-American women after adjusting for 
childhood adiposity [27]. Our own analysis of ARIC data showed that early age at 
menarche (8-11 years vs. 13 years) was associated with prevalent diabetes at 
baseline, and incident diabetes during 9 years of follow-up for white women, but 
not for African-American women [6]. At baseline, we found a significant (p-
value=0.04) race*menarche age interaction for odds of prevalent diabetes. 
However, there were no differences in age at menarche between African-
American and white women in the ARIC cohort, and so relationships might be 
different in more contemporary, younger cohorts in which the current disparities 
in pubertal timing are evident. A recent review paper of studies on pubertal timing 
and CVD and its risk factors noted that although current data are scarce, the 
balance of evidence is that early puberty is associated with greater risk for CVD 
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and some of its risk factors, but generalizability beyond populations of European 
decent is limited because of the lack of ethnic diversity in available studies [28]. 
This dissertation addresses the NHLBI priorities and gaps in the literature by 
investigating the role of early age at menarche, which is a discrete and objective 
marker of reproductive maturation, in cardiometabolic risk in childhood and 
adulthood among African-American and white women. The primary objectives of 
this thesis are to 1) comprehensively examine the relationship between earlier 
age at menarche and a wide variety of inter-related CVD risk factors at different 
points in the life course, 2) account for the role of adiposity in associations, and 
3) to explore possible race differences in associations. The hypotheses are that 
1) earlier age at menarche will be associated with a more adverse 
cardiometabolic profile, 2) lifetime accumulated adiposity will largely explain the 
associations, and 3) there will be differences by race in the association of earlier 
menarche with the cardiometabolic risk factors. The goal is to help determine if 
puberty might be a sensitive time point in the life course for interventions to 
prevent overt disease in adulthood, as well as race disparities in cardiometabolic 
diseases. The results may also clarify mechanisms underlying the relationship 
between early pubertal maturation and cardiometabolic diseases, such as type 2 
diabetes.   
The objectives of this thesis will be addressed in three distinct manuscripts 
with the following primary aims.   
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Manuscript #1:  Examine the cardiometabolic consequences of early 
pubertal development among African-American and white adolescents. 
Manuscript #2: Describe race/ethnic specific associations of age at 
menarche with type 2 diabetes, prediabetes, and metabolic syndrome, as well 
as with other cardiometabolic risk factors such as lipids, adiposity, insulin, and 
blood pressure in early- and mid-adulthood. 
Manuscript #3: Use a Mendelian randomization approach to explore the 
causal effect of age at menarche on risk for type 2 diabetes in later adulthood. 
 
Given race disparities in pubertal timing, as well as in adulthood 
cardiometabolic disorders, Manuscript #1 investigates the longitudinal changes in 
cardiometabolic risk factors by age at menarche, comparing African-American 
and white girls using data from the National Growth and Health Study (NGHS). 
Manuscript #2 describes the association of age at menarche and cardiometabolic 
risk factors by race among young adults in the Coronary Artery Risk 
Development in Young Adults (CARDIA) study. Next, because menarche takes 
place early in the life course, and there are likely many confounding and 
mediating factors between menarche and onset of chronic diseases in adulthood, 
a Mendelian randomization approach and Atherosclerosis Risk in Communities 
(ARIC) Study data will be used to evaluate the association of early menarche and 
one specific risk factor for CVD, type 2 diabetes, using a genetic risk score 
(GRS) as a proxy for age at menarche (Manuscript #3). The Mendelian 
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randomization method helps clarify a causal role of early maturation in risk for 
type 2 diabetes.  
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Chapter 2. Background 
Overview 
 
This chapter begins with a brief summary of the neuroendocrinology, 
stages, and other correlates of puberty to provide a foundation for understanding 
how early pubertal development might relate to later cardiometabolic conditions. 
Next, there is a summary of the literature on the descriptive epidemiology and 
risk factors for early menarche, and detail about what is known about race 
differences in these factors. In the following section, definitions used throughout 
this dissertation for cardiometabolic risk factors are presented, along with the 
descriptive epidemiology for these risk factors. Finally, there is a review of the 
literature that links early menarche with later cardiometabolic disease, and the 
possible mechanisms underlying associations. 
Neuroendocrinology of Puberty 
 
Along with fetal development and pregnancy, the process of puberty is 
one of the most rapid and profound developmental transitions in life [7]. Central 
to the process of puberty is the hypothalamic-pituitary-gonadal (HPG) axis, or 
specifically the hypothalamic-pituitary- ovarian (HPO) axis in females. The HPO 
axis regulates hormone signaling, eventually resulting in ovulation and menarche 
(Figure 1) [7, 29].  
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Figure 1. The hypothalamic-pituitary- ovarian (HPO) axis  
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The hypothalamus is the main enabling center for the HPO axis [7]. The 
HPO axis receives input from neural centers, and the hypothalamus is 
susceptible to olfactory, photoperiod, and tactile stimuli [7]. Signals from the 
hypothalamus result in increased frequency and amplitude of the gonadotropin-
releasing hormone (GnRH) pulse generator during puberty [30].  GnRH in turn 
stimulates the production and release of reproductive hormones, follicle 
stimulating hormone (FSH), and luteinizing hormone (LH), in the pituitary. The 
whole process takes place in a pulsatile fashion, regulated by levels of circulating 
steroid hormones.   
The feedback system that controls the HPO axis is determined by 
genetics and established during gestation [7]. Pulsatile gonadotropin is 
detectable in prepubertal children at very low levels. Changes in the HPO axis 
are first detectable on average around 8-9 years in girls, when there is a sleep-
associated increase in LH pulse frequency and amplitude [31]. As puberty 
advances, the pulsatile pattern of LH secretion extends over 24 hours. Increased 
LH stimulation at the beginning of puberty results in increased production of 
ovarian steroids, which in turn results in the development of pubic and axillary 
hair, breast enlargement, linear growth acceleration, pelvic remodeling, and 
increasing adiposity. In response to increasing estradiol level, menarche is 
initiated.  
The exact process that leads to puberty by disinhibiting pulsatile GnRH 
release in the hypothalamus remains unclear [32]. Several factors are likely 
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involved in the timing and progression of puberty, including neuroregulation of 
the hypothalamo-gonadotropic and -leptinergic axes [32], and genetics have a 
strong influence [7, 33]. Twin and family studies have reported high heritability for 
one stage of pubertal development, age at menarche [34], and recent advances 
in genetics using genome-wide association studies (GWAS) have identified a 
number of single nucleotide polymorphisms (SNPs) in genes associated with 
both age of menarche and body composition [35]. 
Emerging factors in the regulation of reproductive maturation are the Kiss1 
gene, which produces Kisspeptin, and its receptor, G Protein Coupled Receptor 
54 (GPR54) or Kiss1r [30, 36]. Kisspeptin and GPR54 are expressed in 
hypothalamic GnRH neurons, suggesting that they may act as regulators of 
GnRH neuronal function [30, 37]. A recent study showed that estradiol is 
essential for kisspeptin expression in GnRH neurons during the prepubertal 
period [38]. The results imply that a estradiol-kisspeptin positive feedback 
relationship leads to the GnRH neuron amplification, enabling the emergence of 
pulsatile gonadotropin secretion that spurs onset of puberty [30]. 
Stages	  of	  Puberty	  
 
Adrenal development, or adrenarche, precedes the pubertal changes in 
the HPO axis by about 1-2 years [7]. Adrenal androgens help convert estrogens 
in peripheral tissues and hypothalamus. This in turn contributes to the maturation 
of the HPO axis by desensitizing the hypothalamus via rising levels of steroids.   
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Among girls, the earliest sign of puberty is usually the development of a 
palpable breast bud (thelarche), although the development of pubic hair 
(pubarche) may sometimes precede thelarche [39]. Menarche occurs after 
thelarche and pubarche, relatively late in the pubertal process. Although there is 
only a moderate correlation between timing of menarche and onset of puberty 
(.37-.38) [40], individuals with early or late timing of secondary sexual 
characteristics at one point of time are likely to maintain the same relative timing 
throughout puberty, so early menarche probably signals earlier onset of other 
pubertal markers [41]. 
The timing of puberty and changes in body composition are well 
coordinated. The HPO axis works in a synergistic fashion with the somatotropic 
axis to stimulate the adolescent growth spurt associated with puberty [7].  The 
somatotropic axis is involved with linear acceleration in skeletal growth, the 
accumulation of lean body mass, and maintenance of many tissues. The 
hypothalamus secretes hormones that control the release of growth hormone 
(GH) from the pituitary. Similar to GnRH, GH is secreted in a pulsatile fashion. 
The effects of GH on skeletal growth are mediated by production of insulin-like 
growth factors (IGF) in target tissues, and IGF-1 levels correlate well with Tanner 
stage and gonadal steroid levels [42]. Higher levels of IGF-1 and adrenal 
androgens at age 8 years are also associated with earlier menarche, 
independent of body size, supporting the functional roles of these hormones in 
regulating puberty timing in girls [42]. 
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Gonadal steroid production is important for regulating the adolescent 
growth spurt [7]. Adrenal androgens regulate acceleration in growth, while 
estrogens regulate deceleration [43]. The secular trends in age at menarche 
coincide with trends in height, and advances in pubertal timing are correlated 
more closely with accelerated skeletal development and attainment of adult 
pelvic size, rather than earlier accumulation of adipose tissue [44, 45]. The end of 
puberty is marked by the attainment of the final adult height and menarche. 
However, ovarian function continues to mature in women until the early to mid-
twenties [46]. 
Other	  Correlates	  of	  HPO	  maturation	  
 
Insulin acts on the HPO axis and affects the timing of puberty. During mid-
puberty, insulin levels rise as a consequence of a decrease in insulin sensitivity 
and then return to normal by the end of puberty [47, 48]. Insulin exhibits a 
stimulatory effect on ovarian cells resulting in an increased production of 
reproductive hormone steroid activity in the ovaries [49]. It also suppresses IGF 
binding proteins, raising levels of IGF-1.  Insulin may act on the pituitary to 
increase the sensitivity of gonadotropins to GnRH [50].   
Changes in insulin sensitivity are closely related to Tanner stage, and are 
correlated with pubertal timing. Data suggest that higher insulin levels are 
associated with higher estradiol levels [50]. In addition, hyperinsulemic states are 
associated with early puberty, while hypoinsulemic states are associated with 
delayed puberty [7]. It is possible that insulin resistance (IR) could support rapid 
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transit through puberty, as obese girls with IR and hyperleptinemia are reported 
to experience earlier onset of puberty and more rapid progression through 
puberty [32]. 
Leptin is a hormone produced in adipocytes of subcutaneous adipose 
tissue and is involved in energy balance, including appetite and metabolism [7]. 
Leptin receptors are found in the hypothalamus and in various peripheral tissues, 
including the ovary.  Insulin regulates leptin production, and leptin levels are 
correlated with fat mass.  Cross-sectional and longitudinal data show that leptin 
levels increase with increasing adiposity in girls during puberty [51, 52]. However, 
the role of leptin in HPO maturation has been debated, and there is currently little 
evidence that leptin is involved in initiating puberty and directly influencing the 
HPO axis [7]. The pubertal increase in leptin is likely a consequence, and not a 
precursor, of increased fat mass, as well as gonadal and insulin activation. 
Early Menarche 
 
Definition	  
 
Menarche (first appearance of menstrual bleeding) is an important 
reproductive event in a woman’s life.  It signals the beginning of reproductive 
capacity, and its timing has a number of health and psychosocial consequences. 
Most retrospective epidemiologic studies use age at menarche as a proxy to 
estimate the timing of pubertal development in females. Even prospective studies 
sometimes rely on self- or parental-reported age at menarche as a measure of 
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pubertal timing because it is an objective measure and may be less prone to 
observational error than other, more subjective measures such as Tanner 
staging, especially when truncal obesity is present [10]. Furthermore, women 
recall age at menarche fairly accurately into adulthood [53, 54]. In one 
longitudinal study, approximately 84% of women, mean age 50, were able to 
recall their age at menarche to within one year of the actual date [53, 54].  
Therefore, self-reported age at menarche as a marker for pubertal development 
is used in this dissertation. To be consistent with other epidemiological studies of 
the association of pubertal timing and cardiometabolic risk factors [3, 55], early 
menarche will be defined as before 12 years of age throughout this dissertation. 
Epidemiology	  	  
 
Currently in the United States, the mean age at menarche is 12.3 years 
[56], although there are variations by race/ethnicity and geographic location. 
African-American girls tend to undergo menarche 2 to 3 months earlier than 
white girls [14], and girls in urban areas experience earlier menarche than those 
raised in rural areas [57, 58].  
One main feature of the epidemiology of menarche is that the average age 
has declined over time (Figure 2) [15, 59, 60]. Cross-sectional and longitudinal 
data suggest that average age at menarche in the general population of the 
United States decreased from approximately 14.8 years in the late 1800’s to 13 
years by 1950 (approximately the 1930-1940 birth cohort in Figure 2), probably 
as a result of improvements in nutrition and overall health [15, 60-62]. Less 
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healthy lifestyle and environmental factors likely fueled the further decline [15].  
According to one estimate, there has been a statistically significant one month 
per decade drop in average age at menarche over the last 30 years in the United 
States [63]. 
 
Figure 2. Mean age at menarche by birth cohort, NHANES 1999-2004 
 
Adapted from data in references [15, 64] 
Race/Ethnic	  Differences	  
 
Up until the mid-1900’s, average age at menarche was similar for African-
American and white women in the United States, with some evidence that age at 
menarche was slightly older for African-American females (Figure 2) [15]. 
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Beginning around the 1960’s-1970’s, average age at menarche declined more 
quickly for African-American compared with white women [15]. According to 
NHANES data, average age at menarche declined from 13.6 years among 
African-American women born prior to 1920, to 12.0 years for the 1987-1993 
cohort, while among white women, the decline was from 13.3 to 12.5 years, 
respectively [15, 64]. Supporting the NHANES data, data from the Bogalusa 
Heart Survey [14] show that average age at menarche in the early 1970’s survey 
was not statistically different by race: 12.7 years for white and 12.9 years for 
African-American females. However, over the 20-year study period, average age 
at menarche declined for all race groups, most notably for African-American girls. 
As early menarche has been associated with a number of deleterious outcomes, 
it is important to investigate possible reasons for the downward trend in 
maturational timing in the population as a whole, as well as for race/ethnic 
differences in trends.  
It remains unclear if race/ethnic differences in pubertal timing are the 
result of childhood race/ethnic differences in fat mass, or if differences in pubertal 
onset drive later disparities in adiposity across race and ethnicity [19]. Some 
have suggested that African-American girls experience earlier onset of puberty 
on average because they tend to be heavier, taller, and have more advanced 
skeletal maturation after age 9 [14, 60, 65-67]. However, other studies have 
noted that these anthropometric characteristics do not fully explain racial 
differences in pubertal timing. Ethnic differences in adiposity are not present in 
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prepubescent white and African-American girls, but become apparent during 
adolescence and early adulthood [50].  For example, in the NGHS, African-
American girls were at a more advanced pubertal stage vs. white girls for each 
age, and also had higher adiposity [20]. However, African-American girls were 
not significantly more obese than white girls at age 9-10 when adjusting for 
maturity level [68]. In the Bogalusa Heart Survey (1973-1994), the rate of early 
menarche remained 1.4-fold higher among African-American girls than among 
white girls, even after adjustment for weight, height, and other characteristics 
[14]. This suggests that race is an independent risk factor for early menarche 
[30].   
Data also suggest that differences in insulin response and action may 
affect the HPO axis so that GnRH is stimulated earlier in African-American girls 
[50].  Compared with white girls, African-American girls have higher insulin 
response to glucose challenge, and subsequent higher levels of IGF-1, which is 
associated with skeletal and sexual maturation [69]. Despite comparable BMI 
and fat mass, Casazza et al reported that African-American girls have lower 
insulin sensitivity, but higher follicle-stimulating hormone and estradiol levels at 
all pubertal stages compared with white girls [19, 50]. The correlation between 
acute insulin response to glucose and estradiol among African-American girls led 
the authors to conclude that postprandial insulin concentrations may stimulate 
estradiol and contribute to earlier menarche in African-American children. 
Another study reported that beta cell function decreased across puberty in 
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African-American (p = 0.001) but not in white (p = 0.20) adolescents [70]. The 
progressive decline in beta cell function among African-American versus white 
adolescents may reflect a unique effect of puberty on beta-cell compensation in 
African-Americans [70], and so it is possible that earlier pubertal onset, 
measured according to timing of menarche, might have differential effects on risk 
of diabetes and other cardiometablic outcomes by race.  
The differences in pubertal timing and growth for African-American and 
white girls might partly explain important differences in health between African-
American and white women [71]. Overall, current data are extremely limited 
regarding the reasons for racial differences in the age of menarche, and results 
from existing studies are not conclusive. Some possible areas for further 
research into these differences are highlighted in the next section on risk factors 
for earlier menarche. 
Risk	  factors	  
 
Normal variation in menarcheal age may be the result of a female’s 
response to environmental (including diet, physical activity, family structure, 
endocrine disrupters, and other pollutants), socioeconomic, climatic, genetic, and 
other pre- and-postnatal factors [63]. The timing of menarche is set early in life by 
genetics, but it is likely modified by changes in body size and composition in 
childhood [72], as well as other environmental factors. Since genetics have not 
changed over the past century, it is clear that environmental factors, and their 
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possible interaction with genetics, must be responsible for downward trend in 
average menarche age, as well as disparities by race. 
Because timing of puberty is a complex interaction between factors, it is 
difficult to single out the effect of one factor on timing of menarche. It is widely 
recognized that physical activity and body composition are strong predictors of 
the initiation of menses [73]. Menarche tends to be delayed in circumstances of 
under nutrition or extreme physical activity, such as for athletes [61], via the 
negative hypothalamic effect on GnRH pulsatile exerted by intensive exercise 
[30]. The relatively recent changes in the nutritional and physical activity status of 
mothers and their offspring may be associated not only with obesity, but they 
could also alter timing of puberty in offspring, and their cardiometabolic risk in 
adulthood [74].  
Findings from a randomized group trial of an intervention to reduce obesity 
lend evidence to the role of the complex interaction of various lifestyle factors in 
the timing of menarche [73]. The Planet Health study was a school-based 
intervention designed to reduce obesity in adolescents aged 10-13 years by 
decreasing television viewing and consumption of high-fat foods, while increasing 
physical activity levels and consumption of fruits and vegetables. Researchers 
randomized schools to either a modified curriculum or no curricular changes for 
two school years, and found that girls at the schools with the modified curriculum 
experienced menarche at a later age [73]. The delay appeared to result from 
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increased physical activity, reduced television viewing, and changes in body 
composition (BMI and fat distribution).  
The role of other factors such as environmental pollutants, SES, stress, 
and specific dietary components require more research and replication, as 
findings have been mixed across studies [59, 63]. The following section briefly 
reviews the major factors known to be associated with timing of menarche, but 
with the caveat that these factors are likely interrelated. As mentioned earlier, 
there are few published studies looking at race/ethnic differences in risk factors 
for early menarche, other than for BMI and SES. 
Adiposity	  and	  Growth	  
 
Hundreds of studies have noted an association between overweight and 
earlier onset of puberty and menarche [63]. Although adiposity in adolescence 
and adulthood is widely accepted to be associated with early menarche, studies 
are conflicting about the causal role of early childhood adiposity on timing of 
menarche. Some evidence suggests that higher weight gain in infancy and 
higher levels of adiposity levels in childhood initiate estrogen production and 
cause earlier onset of puberty in girls [15, 75, 76]. Gynoid fat mass in particular is 
thought to be associated with onset of menarche [19].  Early work by Frisch and 
colleagues suggests the importance of the accrual of sufficient total body fat 
stores to support the energetic costs of pregnancy and lactation [77, 78].  
One proposed mechanism behind the causal role of adiposity in triggering 
puberty is shown in Figure 3. Underlying genetic and environmental factors may 
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lead to increased pre-pubertal adiposity resulting in early menarche, shorter 
stature, as well as increased weight gain in post-pubertal women [10]. Insulin 
resistance and the combination of various hormonal stimuli related to increased 
body fat, such as increased conversion of androgens to estrogen and increased 
bioavailability of circulating sex steroids, are thought to lead to earlier activation 
of the HPG axis [10]. It is also possible that leptin, which is secreted from body 
fat, acts on the hypothalamus to stimulate gonadotropin releasing hormone, 
luteinizing hormone, and follicle-stimulating hormone from the pituitary gland. It 
may also stimulate enzymes that act on androgen synthesis in adrenal glands, 
increasing the secretion of sex hormones [79-82]. However, others have noted 
the possibility that both adiposity and early menarche have a common 
antecedent, such as relatively high circulating insulin [50].  
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Figure 3. Possible pathway linking obesity to earlier puberty  
 
 
Adapted from reference [10] 
Other evidence suggests that adiposity may be a downstream 
consequence of pubertal maturation [7, 83]. Earlier pubertal onset may initiate 
adipose tissue accumulation during later stages of development, making 
temporality of the association between pubertal and adiposity development 
unclear [83, 84].  Secular trends in childhood obesity and timing of menarche in 
European countries also do not support adiposity as the main driver behind 
earlier age at menarche [85]. For example, a study in Copenhagen found that 
although the heaviest girls at age seven entered puberty earlier than thinner girls, 
there was a downward temporal trend in age at menarche in all BMI categories, 
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suggesting that the obesity epidemic is not completely responsible for earlier 
onset of puberty in the population [86].  Further supporting that adiposity itself 
does not accelerate age at menarche is that the inverse association between 
BMI and age at menarche is apparent in only white girls in some studies [23, 87]. 
Evidence suggests that among African-American girls, age at menarche is 
independent of adiposity [50, 60, 87]. Furthermore, it is unclear if prepubertal 
body composition is more relevant to the actual onset of puberty or to the 
duration of puberty [85]. 
Despite questions about the biologic mechanisms behind the relationship 
of increased childhood adiposity, younger age at menarche, and higher adult 
obesity [10, 88], there is strong evidence for genetic influences on both 
characteristics [89]. Genome-wide association studies (GWAS) have identified 
several loci for age at menarche which are also associated with measures of 
adult obesity and height. A study by Elks et al [35] described 11 obesity-related 
and 11-height related loci that are also associated with age at menarche in 
women of European ancestry.  
Of note is that studies of the role of adiposity and growth on timing of 
puberty all have limitations [71]. Several began measurements around the time of 
puberty [14, 90-92] or lacked multiple measures prior to puberty [93]. 
Nonetheless, patterns have emerged. Studies have consistently reported that 
there is greater adiposity both immediately pre-menarche and post- menarche, 
and shorter attained adult height in girls with earlier menarche [91]. One study 
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also found significant differences in the BMI trajectories beginning around 9 
years for early-, mid-, and late-onset of menarche [91], and several studies 
reported that accelerated height velocity begins at an earlier age among early 
versus late maturers [71, 94] 
No matter the timing of development during the life course, adiposity 
increases circulating levels of insulin, testosterone, and IGF-1, and higher 
adiposity is a well-known risk factor for cardiometabolic conditions [30]. 
Therefore, it is difficult to disentangle the effects of early maturation from 
adiposity on adulthood disease risk, especially in studies that rely on measures 
of adiposity in later adolescence or adulthood only. Clearly, any investigation of 
the association of age at menarche and cardiometabolic risk needs to consider 
the role of adiposity at various points in the life course. 
Fetal	  and	  Infant	  Growth	  
 
Size at birth, as a marker for the intrauterine environment, and rapid infant 
weight gain, particularly between birth and 2 months of age, are reported to be 
factors in the timing of menarche [27, 58, 95-99]. However, there is currently no 
consensus about the independent role of birth weight on the timing of menarche. 
Four studies report that lower birth weight infants have higher risk for earlier 
menarche [58, 65, 100, 101], while four studies reported that higher birth weight 
was associated with earlier menarche [95, 99, 102]. One other study reported 
that birth weight, standardized for gestational age, had different relationships with 
age at menarche depending upon how heavy or light a girl was at age 9 [103]. 
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Comparisons between studies of the role of birth weight and infant growth are 
limited because of variations in study populations, growth measurements, and 
analytic approaches [65]. Taken together, existing studies suggest that menarche 
timing may be influenced by exposures in utero and during early infancy, likely 
via programmed release of gonadotrophins, and then subsequently childhood 
growth, lifestyle, and environmental factors may mediate the effects of these 
factors [104]. 
Genetic	  
 
There is a strong genetic influence on timing of menarche. Data from twin 
and family studies show that age at menarche is 49% heritable [34]. 
Furthermore, a recent GWAS by the CHARGE-ReproGen consortium identified 
42 single nucleotide polymorphisms (SNPs) in genes associated with age of 
menarche [35]. The results from the GWAS studies suggest that genetic 
regulation of energy homeostasis and pubertal timing are closely related, and 
that there are likely other diverse pathways for pubertal timing and growth [35]. 
As mentioned earlier, genes probably interact with environmental and lifestyle 
factors to determine the age at menarche for individuals.    
 
Socioeconomic	  Status	  
 
The role of socioeconomic status (SES) in pubertal timing remains 
unclear, and data suggest race differences. One issue with existing studies is 
that researchers use various methods to operationalize SES, for example, 
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parental education, parental home ownership, income level, and poverty level. 
Further complicating things is that SES is often a proxy for many other factors, 
including diet, physical activity, family environment, and access to healthcare 
[104]. Therefore, few studies are able to separate out the effects of specific 
factors underlying the observed relationships between SES and timing of 
menarche [104]. 
Despite these limitations, there are some patterns that have emerged 
regarding the role of SES on the timing of menarche. One author that looked at 
the association of SES and early menarche in the NGHS found different 
associations of income and early menarche by race [105]. For white girls, those 
in the highest income category were at lower risk for early menarche, while the 
opposite was found for African-American girls (i.e. highest category associated 
with highest early menarche risk). The paper adjusted for BMI, but did not look 
for interaction by BMI, or at other adiposity measures. Another study in which 
maternal education was categorized according to whether or not the mother was 
a high school dropout reported that there was no significant effect, individually or 
in combination with child poverty, on age of menarche for African-American girls 
[65]. However, for white girls, having a mother who dropped out of high school 
was associated with earlier menarche. The opposite effects of SES on age at 
menarche might be mediated by differences in growth among African-American 
and white children, however, few studies have looked into this question [65, 104]. 
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Stress	  
 
Studies have found that high levels of stress associated with illness or war 
conditions tend to delay menarche [104, 106, 107], while stressful family 
environment, including absence of the biological father or presence of a step-
father, are associated with earlier onset of menarche [30, 108, 109]. One 
explanation for why different types of stress might have different effects on 
pubertal timing comes from Boyce and Ellis, who proposed the “stress reactivity 
theory” to explain both the delaying and accelerating effects of psychosocial 
stress on the timing of menarche [110]. Both highly protective and highly stressful 
childhood environments may trigger stress reactivity systems. If this triggering 
inhibits maturation of the HPO axis, then both conditions may be associated with 
later timing of menarche in some populations [104, 110]. 
Additionally, the effects of a stressor might depend on the timing of 
exposure; exposure early in life appears to result in earlier menarche, while 
exposure later in childhood is associated with later menarche [104]. One theory 
is that girls who are exposed to chronic stressful environments may have chronic 
activation of the HPA axis, which in turn could produce increased body fat, early 
adrenarche, and puberty [111-114]. 
As with SES, there seems to be race/ethnic differences in the effects of 
stress on timing of menarche. In one study, father absence was not associated 
with age at menarche for African-American girls, individually or in combination 
with child poverty, but for white girls having a father who was absent more during 
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childhood was associated with a younger age of menarche [65]. It is unclear why 
less stressful environments are less protective on health for African-American 
girls [65]. 
Diet	  
 
Age at menarche is dependent on nutritional status, and girls with severe 
dietary restriction tend to experience later menarche [115]. Other than in 
conditions of extreme restriction, studies of the effect of diet on maturational 
timing are somewhat limited, possibly because it is difficult to measure diet 
during childhood [104].   
Although very important for overall health, the role of diet in infancy on 
timing of puberty is unclear. Breastfeeding is known to be associated with lower 
risk of childhood obesity, but it is not consistently found to be associated with 
timing of menarche [85]. One study reported that formula feeding was associated 
with earlier menarche compared with breast-feeding among girls enrolled in 
Kaiser Permanente Oahu (Honolulu) [116]. In the Avon Longitudinal Study of 
Parents and Children (ALSPAC), use of soy formula was associated with early 
menarche compared with use of milk-based formula [29], although effects were 
subtle, confidence intervals crossed unity, and not many children were fed soy 
formula in the study.  
A review of the current evidence for the association of dietary factors in 
mid-childhood and timing of puberty [85] did not find support that total energy 
intake influences the timing of puberty. However, fat intake appeared to be 
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associated with timing of menarche. Higher intake of total fat or polyunsaturated 
fatty acids (PUFA) are associated with earlier menarche [117-119], while intake 
of saturated fatty acids, monounsaturated fatty acids (MUFA), or animal fat have 
been associated with later menarche [117, 120]. The mechanisms for the 
association between fat intake and menarche timing remain a mystery, however. 
The same review pointed out that animal protein intake, including from 
cow milk and dairy products, during prepuberty may be of particular relevance to 
timing of menarche due to the stimulatory effect on IGF-1 secretion [85, 121, 
122]. In fact, higher intake of animal protein is associated with earlier menarche 
after controlling for BMI [119, 123]. In the DOrtmund Nutritional and 
Anthropometric Longitudinally Designed (DONALD) study, which was a 
prospective study of 227 German boys and girls, the consumption of animal 
protein in the highest tertile was found to be associated with pubertal onset 7 
months earlier compared with animal protein consumption in the lowest tertile 
[85].   
In contrast with animal protein, vegetable protein appears to be associated 
with later menarche. In the DONALD study, children with the highest intakes of 
vegetable protein experienced pubertal onset up to 7 months later than those in 
the lowest tertile [85]. However, studies looking at vegetable protein intake in 
childhood may indirectly have addressed the effect of prepubertal dietary 
isoflavone/fiber/animal protein intake on pubertal timing because there is a high 
content of dietary isoflavone and fiber in plant-based foods, and there tends to be 
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a negative association of vegetable protein intake with animal protein intake [85]. 
Girls with high isoflavone intakes in the DONALD study experienced the onset of 
breast development and peak height velocity approximately 7-8 months later 
compared with girls who had low isoflavone intake [85]. The authors noted that 
this effect size was similar to that found in studies of potentially neuroactive 
steroid hormones, suggesting that diet may be an important modifiable risk factor 
for early onset of puberty among girls.  
Data on the influence of micronutrients such as vitamin C, beta-carotene, 
vitamin A, zinc, magnesium, thiamine, and iron, on the timing of puberty are 
controversial [85]. Vitamin A has been reported to be associated with both earlier 
[117], and later menarche [120]. One micronutrient that may merit more research 
is vitamin D. A prospective study in Bogota, Columbia reported that girls with low 
levels of vitamin D (< 50 nmol/L) had twice the risk of earlier menarche (HR: 
2.05; 95% CI: 1.03, 4.07; p-value = 0.04) compared with girls in the sufficient 
range (> or = 75 nmol/L) [124]. There is growing evidence that there are racial 
disparities in consumption of vitamin D, possibly because lactose intolerance is 
more common among the African-American population [125]. In the NGHS, white 
girls consumed significantly higher amounts of vitamin D than African-American 
girls, and so it might be worth investigating if differences in vitamin D 
consumption are associated with differences in pubertal timing by race [125].  
Before stronger conclusions can be drawn on micronutrients, research is needed 
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on the possible mechanisms mediating the associations of micronutrients with 
the timing of puberty [85]. 
Rather than studying individual micronutrients, some have looked at the 
association of dietary patterns in timing of puberty because of the possible 
combined effect of macronutrients, micronutrients, and food groups. The 
DONALD study found that higher dietary quality (lower intake of total fat and 
higher intakes of carbohydrates, fiber, and micronutrients) was associated with 
later puberty in girls [126]. Additionally, independent of BMI, children who had a 
higher dietary quality experienced their pubertal growth spurt 5 months later than 
children with poorer dietary quality.  
Eating patterns may also be of relevance to racial differences in pubertal 
timing because breakfast skipping is more common in African-American than in 
white adolescents [125, 127]. Breakfast frequency and quality are proposed to be 
related to appetite controls and blood sugar control in children and adults [128], 
and so it is possible that meal patterns may be related to both pubertal timing 
and later risk for cardiometabolic diseases.  
The role of sugar-sweetened beverages (SSBs) and early menarche has 
not been explored, but an association is mechanistically possible. Soft drinks are 
characterized by hyperglycemia, and are associated with higher risk for obesity in 
adults and children [129] as well as with elevated blood pressure and type 2 
diabetes [130, 131]. In a study of 12-19 years-olds who participated in the 1999-
2004 NHANES, the association of SSB intake and certain cardiometabolic 
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characteristics varied by race/ethnicity and gender [132]. This raises concern 
about soft drink intake early in life and later health disparities, particularly 
considering the rise in type 2 diabetes among children and adolescents [133, 
134].  The adverse effects of SSB intake may be of most concern during certain 
periods of life, such as puberty, which are characterized by physiological insulin 
resistance [135]. Because African-American adolescents were found in one study 
to be more likely to consume SSBs compared with white adolescents [136], 
SSBs are one dietary factor that may merit further investigation regarding its role 
in differences in the timing of puberty and/or cardiometabolic conditions.  
Physical	  activity	  
 
Menarche tends to occur later in athletes compared with the general 
population, suggesting that intense activity delays menarche [30, 137, 138]. Less 
intense levels of activity might also affect timing of menarche, possibly through 
decreased melatonin levels [30, 139]. A cross sectional study that included 
Colombian university women demonstrated that at least two hours of daily 
activity was associated with later age at menarche [140]. 
A study that began to follow girls at age 6-8 years to examine 
neighborhood characteristics and timing of menarche reported that availability of 
recreational outlets, such as parks, walking or hiking trails, sports/playing field, 
basketball courts, or tennis courts, was associated with later timing of thelarche 
and pubarche among African-American girls, but not white girls [141]. There is 
also research showing that African-American adolescents are less physically 
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active than white adolescents in the United States [142], and so physical activity 
and sedentary behavior is one area for further research into racial differences in 
pubertal timing. 
Environmental	  pollutants	  
 
Tens of thousands of manufactured compounds, many for which the 
toxicity remains unknown, are commonly found in our food supply, cosmetics, 
and surrounding environment [19]. Several studies have investigated the role of 
environmental pollutants in timing of menarche, although most have been cross-
sectional.  One analysis of multichemical exposure among Akwesasne Mohawk 
Nation adolescent girls suggested that PCBs (polychlorinated biphenyls) and 
levels of lead were associated with early menarche [143]. Polybrominated 
diphenyl ethers (PBDEs), which have been widely used as flame retardants since 
the 1970s, have exhibited endocrine disruption properties in experimental studies 
[144], as well as antiandrogenic activity. Cross-sectional NHANES data suggest 
high concentrations of serum PBDEs during adolescence are associated with a 
younger age of menarche [144].  Data from animals suggest that bisphenol-A 
(BPA) may also be associated with earlier puberty [145]. Therefore, it is possible 
that environmental endocrine disruptors may accelerate the timing puberty, and 
contribute to racial disparities if certain racial groups are more likely to be 
exposed to these chemicals [19]. More work is needed regarding environmental 
pollutants and their influence on puberty. The recently initiated National 
Children’s Study (NCS) should provide some clarification because one aim is to 
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examine the role of environmental pollutants in child growth, adiposity, and 
developmental timing (National Children’s Health Study. 
http://www.nationalchildrensstudy.gov/Pages/default.aspx Accessed July 21, 
2013). 
Sleep	  
Data suggest that the onset of menarche is affected by hours of sleep, 
possibly mediated by body weight and height [146]. The proposed mechanism is 
that lighting signals influence the HPO axis, and are mediated through the 
melatonin circuit. Supporting this theory is that girls who are blind have been 
shown to have earlier menarche [147], and several studies have shown that 
menarche is more frequent in winter than summer months, suggesting an 
inhibitory effect of photo stimulation [30]. Because racial differences have been 
noted in sleep patterns as early as ages 3-8 years [148], independent of 
demographic factors, differences in sleep patterns is another possible 
underexplored reason for the racial disparities in timing of menarche.   
Summary	  
 
Although adiposity is a well-studied risk factor for early menarche, it 
remains unclear if adiposity is a precursor or a consequence of the initiation of 
puberty, and it is possible that it is both of these situations. It is also unclear how 
race differences in adiposity, diet quality, physical activity, and sleep contribute to 
race differences in pubertal timing.  The opposing role of SES by race on timing 
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of puberty, and possible interactions with adiposity and other factors, also 
requires more investigation.  
Cardiometabolic Outcomes 
 
Definitions	  
 
The cardiometabolic risk factors included in this dissertation include 
obesity, type 2 diabetes, prediabetes (impaired fasting glucose), metabolic 
syndrome (a.k.a. insulin resistance syndrome), blood pressure, blood lipids, and 
insulin resistance. According to the American Diabetes Association [149], these 
factors, in addition to age, race, gender, genetics, family history, and unhealthy 
behaviors such as smoking, physical inactivity, and unhealthy diet, contribute to 
cardiometabolic risk (global diabetes/CVD risk). Table 1 outlines the definitions 
used in this dissertation for cardiometabolic risk factors for women (18 years or 
older) and girls.  Whenever possible, risk factors are modeled as continuous 
variables in analyses, and any deviations from the definitions described in this 
table are noted.  
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Table 1. Definitions for cardiometabolic risk factors for women and children 
a CDC. “About BMI for Adults”. Available at: 
http://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html. Accessed July 10, 2011. 
Risk Factor Definition for Woman (18+ 
years)  
Definition for 
Children/Adolescents 
Adiposity   
Body Mass Index (BMI) Obese:  ≥30 kg/m2 (a) 
Overweight: 25-29.9 kg/m2 (a) 
Obese: >95 percentile for age 
and sexb 
Overweight: >85 percentile for 
age and sexb 
Waist Circumference Obese: >88 cmc Obese: >90th percentile for age 
and sex d  
Prediabetes (Impaired 
Fasting Glucose)e 
100 - <126 mg/dl 100 - <126 mg/dl 
Type 2 Diabetese Non-pregnant, fasting blood 
glucose ≥ 126 mg/dl, A1C ≥ 
6.5%, 2-hour oral glucose 
tolerance ≥ 200 mg/dl, or 
use of diabetes medication.   
Non-pregnant, fasting blood 
glucose ≥ 126 mg/dl, A1C ≥ 
6.5%, 2-hour oral glucose 
tolerance ≥ 200 mg/dl, or use of 
non-insulin diabetes medication.   
Hypertensionf >140/90 mmHg >95th percentile  
Lipids   
Total Cholesterol > 240 mg/dlg >150 mg/dlh 
HDL-C < 40 mg/dlg <35 mg/dlh 
LDL >160 mg/dlg >160 mg/dlh 
Metabolic Syndrome   
Categorical Definition 3 or more of the followingi: 
1) Waist circumference 
>88 cm 
2) Blood pressure 
>130/85 mmHg 
3) HDL-C < 50 mg/dl 
4) Triglycerides >150 
mg/dl 
5) Fasting glucose > 
100 mg/dl or known 
T2DM 
3 or more of the followingj: 
1. Abdominal obesity (>85 
percentile for race/age) 
2. Triglycerides < 110 
mg/dl 
1) HDL-C < 50 mg/dl 
2) Systolic or diastolic BP 
>90% for age and height 
3) Fasting glucose  ≥ 100 
mg/dl  or known T2DM 
Cluster Score Definition Sum of the z-scores of all 
metabolic syndrome 
components (reference 
values from specific study 
population) 
 
Sum of the z-scores of all 
metabolic syndrome 
components (reference values 
from specific study population) 
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b CDC. "Body Mass Index: BMI for Children and Teens". Available at: 
http://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html. 
Accessed July 10, 2012. 
c National Cholesterol Education Program (2002). Third Report of the Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III Final Report). National 
Institutes of Health. p. II–17. 
d Fernández JR, Redden DT, Pietrobelli A, Allison DB. Waist Circumference Percentiles in 
Nationally Representative Samples of African-American, European-American, and Mexican-
American Children and Adolescents J Pediatr 2004;145:439-44. 
e The American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes 
Care. 2004;27(suppl 1):S5–S10 
f  Urbina E. Ambulatory Blood Pressure Monitoring in Children and Adolescents: 
Recommendations for Standard Assessment. (Hypertension. 2008;52:433-451.) 
g Executive Summary of The Third Report of The National Cholesterol Education Program 
(NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In 
Adults (Adult Treatment Panel III) JAMA 2001, 285:2486-249. 
h Kavey RE. American Heart Association Guidelines for Primary Prevention of Atherosclerotic 
Cardiovascular Disease Beginning in Childhood. Circulation. 2003;107:1562-1566. 
I Expert Panel On Detection, Evaluation, And Treatment Of High Blood Cholesterol In Adults (May 
2001). "Executive Summary of the Third Report of the National Cholesterol Education Program 
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in 
Adults (Adult Treatment Panel III)". JAMA: the Journal of the American Medical Association 285 
(19): 2486–97. DOI:10.1001/jama.285.19.2486. PMID 11368702. 
j Cook S, Weitzman M, Auinger P, et al. Prevalence of a metabolic syndrome phenotype in 
adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-
1994. Arch Pediatr Adolesc Med 2003;157:821-7. 
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Epidemiology 
 
Cardiometabolic risk factors are highly prevalent in the United States. 
They are associated with high levels of morbidity, as well as substantial health 
care costs, and tend to affect African-American women more often than white 
women. Cardiometabolic risk factors tend to cluster together and have a shared 
contribution to risk for CVD [150]. Obesity and hyperinsulinemia are the main 
characteristics of cardiometabolic diseases, and they link hypertension with 
dyslipidemia [150]. Impaired glucose regulation (i.e. prediabetes and type 2 
diabetes) is closely linked to the metabolic syndrome and its components 
beginning in early life [150]. The following section summarizes the descriptive 
epidemiology of obesity, hypertension, dyslipidemia, impaired glucose regulation 
(including prediabetes and type 2 diabetes), and metabolic syndrome. 
Obesity	  
 
 Obesity has been linked to a number of health conditions, including heart 
disease, stroke, and type 2 diabetes. There have been dramatic increases in 
prevalence of obesity over the past 20 years, although the rate of increase 
appears to be leveling off in recent years [151].  In the United States, 
approximately 36% of adults, and 17% of children 2-17 years of age, are 
currently obese according to 2009-2010 NHANES data [152, 153]. There are 
large disparities in the prevalence of obesity by race and geographic location. 
The prevalence of obesity is twice as high among African-American girls 
compared with white girls (29% vs 14%, respectively) [153]. In the United States, 
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prevalence is highest in the South and lowest in the West. Obesity takes a large 
economic toll on this country, with medical costs estimated at $147 billion in the 
United States, or 10% of all medical spending [154].  
 
Hypertension	  
 
Hypertension increases the risk for heart disease and stroke [155]. 
Currently, 33% of adults have hypertension, and only about 50% of those with 
hypertension have it under control [156]. The prevalence of hypertension is 
higher among African-American women than white women (45.7% vs. 31.3%), 
and African-American women tend to develop hypertension at a younger age 
[157]. Costs from hypertension-related health care, medications, and missed 
work days were projected to reach $93.5 billion in 2010 in the United States 
[157].   
 
High	  Total	  Serum	  Cholesterol	  
 
High total cholesterol increases the risk for heart disease. Approximately 
16.3% of adults and 8.5% of children currently have high cholesterol [158, 159]. 
The prevalence of high total cholesterol is higher among women (16.2%) than 
men (13.5%) in the United States, and it is the only cardiometabolic risk factor 
covered in this dissertation for which the prevalence of is higher in white women 
(16.9%) compared with African-American women (13.3%) [160]. There has been 
a large decline over time in the prevalence of high cholesterol, with prevalence 
falling by half from 33% in 1960-1962 to the current level of 16.3% [160].   
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Type	  2	  Diabetes	  and	  Prediabetes	  
 
Type 2 diabetes is a leading cause of kidney failure, heart disease, and 
stroke in the United States.  In 2010, 25.8 million adults age 20 years or older 
had type 2 diabetes (prevalence=8.3%), and 79 million had prediabetes 
(prevalence=35%) [161]. The prevalence of diabetes is slightly higher for men 
(11.8%) vs. women (10.8%), and much higher for African-American (18.7%) vs. 
white (10.2%) adults in the United States. Among adolescents aged 12-19, the 
prevalence of prediabetes or diabetes increased from 9% in 1999-2000 to 23% in 
2007-2008 [162]. In 2007, the direct and indirect cost of diagnosed diabetes was 
estimated at $174 billion in the United States ($116 billion for direct medical 
costs, $58 billion for indirect costs [disability, work loss, premature mortality]) 
[163]. That cost is expected to reach $3.4 trillion by 2020.  
Metabolic	  Syndrome	  
 
Metabolic syndrome is a highly prevalent disorder in the United States and 
includes a clustering of related factors that increase the risk for CVD and type 2 
diabetes [164]. There is currently debate not only about the best definition for 
metabolic syndrome, particularly for children, but also about the merits of this 
syndrome as a distinct condition [164]. The controversy is fueled by the fact that 
there remains no clear definition or pathogenic mechanism for the syndrome. 
Furthermore, changing levels of risk factors with growth and maturation 
complicate the diagnosis of metabolic syndrome in pediatric populations. Some 
have proposed that metabolic syndrome is simply a surrogate for a combination 
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of risk factors that increase risk for type 2 diabetes and CVD [164]. Gerald 
Reavan, who first proposed the syndrome in the 1980s and called it “Syndrome 
X”, argues that there is an underlying mechanism to the mutual involvement of 
the various risk factors [165]. However, he states that Syndrome X is not a 
disease, but rather that insulin resistant/hyperinsulemic individuals are at higher 
risk for a whole host of factors (e.g. dyslipidemia, high blood pressure, glucose 
intolerance) that in turn increase the risk for CHD.  
The prevalence of metabolic syndrome among the U.S. population varies 
depending on the definition used, but it is estimated at approximately 34% 
among adults according to NHANES 2003-2006 data using the National 
Cholesterol Education Program's Adult Treatment Panel III report (NCEP: ATPIII) 
revised criteria [166]. Prevalence is 1.5 times higher among African-American 
females compared with white females [166]. Among children and adolescents 
aged 2-19, prevalence ranges from 1.2% to 22.6% in the general population, 
depending on the definition used and population characteristics [167]. 
Previous Studies on Early Menarche and Cardiometabolic Risk 
Overview	  
 
Existing studies conflict about the independent association of early 
menarche and cardiometabolic risk [168]. Estimating the association of early 
pubertal development and later disease in adulthood is complicated by the fact 
that timing of menarche is associated with higher BMI and waist circumference in 
adolescence and adulthood (Figure 4) [83, 92, 169-171]. Some studies suggest 
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that the mechanisms behind early puberty itself, such as changes to the HPO 
axis and metabolism, apart from adiposity, might play a role in risk for 
cardiometabolic disorders later in life [8].   
Figure 4. Role of adiposity in the association of age at menarche and 
cardiometabolic disease 
 
One study that followed women from age 9 to 39 years to investigate the 
role of BMI in the association of age at menarche with a number of CVD risk 
factors concluded that age at menarche is risk marker, not an independent risk 
factor, for CVD [168]. In that study, BMI at age 9 appeared to lead to earlier 
menarche and to correspondingly higher adult BMI and greater CVD risk. 
However, childhood BMI was measured close to puberty in that study, and 
another group subsequently found that BMI measured earlier, between 4 and 6 
years of age, did not explain the relationship between age at menarche and 
adulthood BMI, type 2 diabetes, or lipids [4, 172, 173]. In the Fels Longitudinal 
Study, girls with early menarche (<12 years) had a more negative CVD risk 
profile during adolescence compared with girls with menarche 12 or older, even 
after adjustment for childhood and adolescent adiposity [174]. Therefore, it 
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appears that the role of adiposity in the association between early menarche and 
later cardiometabolic conditions may differ depending on when in the life course 
adiposity and cardiometabolic risk factors are measured, and possibly which 
adiposity measure is included (i.e. BMI, waist circumference, percent body fat). It 
is also not clear if the role of adiposity in these associations differ by 
race/ethnicity.  
Type 2 diabetes is a well-studied cardiometabolic outcome with regard to 
pubertal timing, with some studies reporting an inverse association, while others 
finding no statistically significant association (Figure 5) [1-6, 175].  
Figure 5. Summary of studies of the association of earlier age at menarche 
and type 2 diabetes  
 
References [1-6] 
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Studies reporting inverse associations tended to be large and to include 
both pre- and post-menopausal women [2-6], while those that did not find an 
association included only post-menopausal women and might have been 
underpowered [1, 175]. In all studies, associations were attenuated by adiposity 
to varying degrees. Women in the U.S. Nurses’ Health Study (NHS) I who 
reported menarche at age 11 or younger (vs. age 13) had a 34% increased risk 
for diagnosed type 2 diabetes (HR=1.34, 95%: CI 1.26-1.42) [1]. After adjustment 
for BMI and other social and lifestyle factors, the risk was 18% higher (HR=1.18, 
95% CI: 1.10-1.27). In the NHS II, which followed a younger cohort of women, 
those with menarche at or before 11 years (vs. age 13) had 98% increased risk 
for type 2 diabetes (HR=1.98, 95% CI: 1.79-2.20) before adjustment for adult 
BMI, and 40% (HR=1.40, 95% CI: 1.24-1.57) increased risk after adjustment for 
adiposity and other potential confounders [3]. In the European Prospective 
Investigation of Cancer (EPIC)-Norfolk study, the odds for diagnosed diabetes at 
baseline or during 8-years of follow-up was reduced by 10% (OR=0.90, 95% CI: 
0.95-0.86) for each 1 year delay in menarche [2]. The association was 
completely attenuated and no longer significant after adjustment for adult BMI 
(2% reduced odds for each year delay in menarche [OR=0.98, 95% CI: 0.97-
1.03]). In our own analysis of ARIC data, early menarche (<12 years of age vs. 
13 years) was associated with an increased odds of diabetes at baseline (OR 
1.72, 95% CI: 1.32-2.25) and increased risk for diabetes over follow-up (HR 1.43, 
95% CI: 1.08-1.89) for White women only, and that the association was 
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attenuated after adjustment for BMI [6]. The German Cooperative Health 
Research in the Augsburg Region (KORA) study found that the RR for diabetes 
per one-year delay in menarche was nearly the same before and after 
adjustment for BMI and other confounders (unadjusted: RR=0.83, 95% CI 0.73-
0.95; BMI-adjusted: RR=0.84, 95% CI 0.73-0.98) [5]. Finally, a study that 
followed women from birth to age 53 found that age at menarche was associated 
with diabetes before, but not after, adjustment for adulthood BMI (unadjusted: RR 
per year delay in menarche=0.73, 95% CI 0.56–0.96; adjusted for BMI: RR=0.85, 
95% CI 0.65–1.10) [4]. 
A number of studies have reported on the association of early menarche 
and other cardiometabolic risk factors in various age groups and populations. 
One recent review paper found that although data on cardiometabolic risk factors 
and puberty were too scarce for meta-analysis, existing studies suggest that 
earlier puberty is associated with hypertension, metabolic syndrome, and 
abnormal glycaemia, independent of childhood adiposity [28]. Although most 
studies have found that earlier age at menarche is associated with hypertension 
or raised blood pressure [8, 28, 55, 174, 176], at least one found no association 
[177] , and the association was retained after adjustment for adulthood BMI in 
only about half of the positive studies [28]. Studies have also reported that earlier 
menarche is associated with higher HOMA-IR [177, 178], higher risk for 
metabolic syndrome or higher number of metabolic syndrome components [176, 
177, 179], higher fasting insulin [8, 177, 178], and glucose intolerance [174, 176, 
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177]. Results on lipids have been mixed, with some reporting associations with 
higher triglycerides [176, 179] and/or lower HDL [8, 179], and others finding no 
association [174, 177]. In the Cardiovascular Risk in Young Finns Study, each 1-
year younger age at menarche was associated with elevated systolic blood 
pressure, higher insulin resistance, and greater risk of metabolic syndrome 
before, but not after adjustment for adiposity [168]. One recent study also 
reported that earlier menarche is associated with hyperuricemia [5]. Studies have 
not found associations with C-reactive protein (CRP) [144].  
Some studies have reported that earlier menarche increases the risk for 
CVD outcomes, but others have found no association. The review paper by 
Prentice et al included a meta-analysis of the existing data and estimated that 
menarche prior to age 12 increases the risk of CVD by 15% (RR 1.15, 95% CI 
1.02, 1.28) compared with menarche at or after age 12 years [28]. In a 
prospective study of college-educated white women, the RR of ischemic heart 
disease (IHD) through age 73 was 0.76 (95% CI 0.60-0.95) for each one year 
later age at menarche [180]. In the EPIC-Norfolk study, which included over 
15,000 women, young age at menarche (< 12 years vs. >=12 years) was 
associated incident CVD [HR 1.17 (95% CI 1.07, 1.27)], incident CHD [HR 1.23 
(95% CI 1.06, 1.43)], all-cause mortality [HR 1.22 (95% CI 1.07, 1.39)], and CVD 
mortality [HR 1.28 (1.02–1.62)] [55]. In the Korean Kangwha Cohort Study, risk of 
CHD mortality was 51% lower (95% CI, 0.25%-0.95%) among women who 
reported menarche at age 17-18 years versus women who were younger than 17 
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years at menarche [181]. The Seventh Day Adventist study reported that each 1-
year delay in menarche was associated with 4.5% (95% CI 2.3%–6.7%) lower 
total mortality; the association was stronger for mortality from ischemic heart 
disease [6.0% (95% CI 1.2%–10.6%)] and stroke [8.6% (95% CI 1.6%–15.1%)] 
[182]. However, there were also a number of studies that did not find 
associations with CVD-related outcomes [183-187].  For example, two studies 
found no statistically significant association with myocardial infarction [184, 185], 
and another found no association with coronary heart disease [183].  
Although race appears to be an independent risk factor for early 
menarche, as well as for cardiometablic conditions such as type 2 diabetes, the 
relationship of age at menarche with cardiometabolic risk among African-
American women has not been well studied. The review by Prentice et al [28] 
noted this lack of ethnic-specific information on the association of pubertal timing 
and CVD risk factors.  Most studies of the association of early menarche with 
cardiometabolic risk have included women of European descent only [1, 2, 4, 8, 
9, 168, 182], a few included women from Asian countries [28], and those that 
included a more diverse study population did not look at risk of disease 
separately for white and African-American women [3, 175, 183]. We previously 
showed that in ARIC, age at menarche was associated with prevalent diabetes at 
baseline and incident diabetes during follow-up for white, but not African-
American women [6]. Building on that work, we examine more closely the race-
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specific associations of early menarche and cardiometabolic risk factors earlier in 
life in Manuscripts #1 and #2 of this dissertation. 
In summary, there is evidence that early menarche is associated with 
cardiometabolic risk factors and cardiovascular disease outcomes, suggesting 
shared mechanisms between earlier pubertal development and cardiometabolic 
diseases [8]. However, there remain gaps in the literature regarding the role of 
adiposity, the differing influence of pubertal timing on cardiometabolic risk at 
different points in the life course, and race/ethnic differences. 
Mechanisms	  	  
 
 Relevant to the study of pubertal timing and cardiometabolic risk are a 
number of regulators of metabolism that affect gonadal function, including insulin, 
growth hormone, and IGF-1 [50]. During puberty, there are pro-inflammatory and 
pro-oxidative changes, and relative insulin resistance, which also play a role 
development of cardiometabolic conditions [188]. Early age at menarche is 
preceded by hyperinsulemia [23], and puberty is a critical period for adiposity 
development.  
 In adulthood, gonadal steroids are known to influence the cardiovascular 
system and lipid metabolism [189]. A large increase in risk for CHD after both 
natural and surgical menopause points to the cardioprotective properties of 
endogenous estrogens. Androgens are known to decrease HDL and increase 
LDL, but estrogen has the opposite effect on lipids, while also exhibiting 
antioxidant and anti-inflammatory properties. Estrogen also works to vasodialate 
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the vascular endothelium and boost insulin sensitivity, while endogenous 
androgen levels appear to contribute to type 2 diabetes risk [189]. The process of 
puberty has been found to modulate endothelial function and antioxidant 
mechanisms [190], and oxidative stress is thought to play a role in insulin 
resistance [191]. 
Data from an ancillary study to the NGHS indicate an important role for 
sex hormones, oligomenorrhea (menstrual cyclicity > or = 42 days), polycystic 
ovarian syndrome (PCOS) (a hyperandrogenic sub cohort of oligomenorrhea), 
and insulin at age 14 years in both metabolic syndrome and severe obesity in 
young adulthood [192]. One proposed link between early puberty and type 2 
diabetes in particular is that girls who mature earlier have an exaggerated insulin 
response that is disproportionate to their insulin resistance [23, 50]. Ibanez et al. 
demonstrated that both premature pubarche and premature adrenarche were 
associated with hyperinsulinemia in girls [193]. Although data have not yet 
supported this, one theory is that an exaggerated insulin response is causally 
related to earlier puberty [50], and also related to later risk of diabetes.   
Menarche and cardiometabolic conditions all have strong genetic 
underpinnings, and so it is possible that there is a common genetic basis for 
early menarche, higher adiposity, and later disease. Alternatively, it is possible 
that early menarche is simply a surrogate marker for obesity in childhood, which 
subsequently increases the risk for cardiometabolic conditions in adulthood [9, 
168]. Therefore, careful consideration for various measures of adiposity (e.g. 
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BMI, waist, percent body fat) is needed to clarify the confounding and/or 
mediating role of adiposity in associations between pubertal development and 
cardiometabolic risk.  
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CHAPTER 3. MANUSCRIPT #1 - AGE AT MENARCHE AND 
CARDIOVASCULAR DISEASE RISK FACTORS AMONG 
AFRICAN-AMERICAN AND WHITE ADOLESCENTS  
Introduction 
 
Earlier pubertal development among girls is associated with increased risk 
for adverse health conditions in adulthood including cardiovascular disease 
(CVD), metabolic syndrome, and type 2 diabetes [3, 11, 12, 28]. A recent meta-
analysis estimated that menarche prior to 12 years of age increased the risk for 
CVD in adulthood by 15% compared with menarche at or after 12 years of age 
[28]. The proposed mechanisms behind this association include increased body 
fatness among earlier maturing girls, as well as neuroendocrine hormonal 
changes that negatively impact metabolism [84, 177, 194]. The association of 
earlier maturation with long-term CVD health is relevant for public health because 
the average age at both breast development (thelarche) and first menstruation 
(menarche) have declined in recent decades in the United States for all 
race/ethnic groups, although most dramatically for African-American girls [15, 64, 
115, 195]. The racial differences in pubertal timing coincide with well-
documented health disparities in the prevalence of CVD risk factors such as 
obesity, type 2 diabetes, and metabolic syndrome among women [16-18].  
Although several studies have examined the role of earlier menarche on 
levels of risk factors for CVD at various points across the life course [3, 6, 8, 9, 
55, 168, 172, 174, 180, 182], most were conducted in adult populations and/or 
included participants of primarily European descent. Longitudinal studies of the 
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association between timing of menarche and cardiometabolic risk during 
adolescence are limited [174, 177], especially for African-American girls. Existing 
studies have reported somewhat mixed results regarding the relation of 
menarche timing with CVD risk factors, and they vary according to how early 
menarche was defined, the demographic characteristics of the cohort, and the 
time period during which the data were collected [28]. The secular trend towards 
earlier pubertal onset in the general population, and widening racial disparities in 
the timing of puberty in recent decades, suggest that a contemporary, large, 
racially diverse cohort of girls may help clarify the pattern and consequences of 
these trends on risk for CVD among women in adulthood. Studies examining the 
correlates of changes in CVD risk factors during adolescence are particularly 
important because this is a sensitive developmental stage for both adiposity 
accumulation [20] and formation of lifestyle habits [196] that are amenable to 
interventions that may delay or prevent development of CVD and its risk factors 
in adulthood.  
Using data from the NHLBI National Growth and Health Study (NGHS), 
this paper assesses race-specific associations of earlier age at menarche with 1) 
overall levels and age-related changes in blood lipids, systolic blood pressure, 
and adiposity from age 9 to19 years, and 2) levels of blood lipids, systolic blood 
pressure, adiposity, fasting glucose, insulin, and a metabolic syndrome cluster 
score at mean age 19. It also examines the potential confounding or mediating 
role of adiposity in the relationship between earlier pubertal maturation and other 
   52 
 
cardiometabilic risk factors. The longitudinal nature of the NGHS and its rich 
annual follow-up data offer a unique opportunity to examine the changes in CVD 
risk factors for African-American and white girls according to timing of menarche, 
thus helping to clarify if earlier maturation might contribute to racial disparities in 
cardiometabolic health later on in the life course. 
Materials and Methods 
Study	  Design	  and	  Population	  
This is a secondary analysis of publically available data from the NGHS, 
accessed with permission from the National Heart Blood and Lung Institute’s 
Biologic Specimen and Data Repository Information Coordinating Center (NHBLI 
BioLINCC) [197]. The goal of the multicenter NGHS was to study the 
development of obesity among African-American and white adolescent girls, and 
to examine the effects of obesity on cardiovascular disease risk factors [197].  
The three field centers participating in the study were: 1) University of California-
Berkeley, 2) Children’s Hospital Medical Center, Cincinnati, OH, and 3) 
WESTAT, Rockville, MD [198]. A total of 2,379 girls aged 9-10 years enrolled in 
the NGHS (1,213 African-American and 1,166 white) during the baseline visit in 
1987-1988 and were followed annually for 10 years. Participants were recruited 
from schools in Richmond, CA and Cincinnati, OH, and from families enrolled in 
a health maintenance organization (HMO) in the Washington, DC area. Sampling 
was designed to ensure a study population that represented the general 9-10-
year-old African-American and white female population in each of study 
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communities. Participation was limited to girls self-identifying as African-
American or white race and who were living in racially concordant households 
[198]. The number of participants varied from visit to visit because of the 
longitudinal nature of the study. Participation rates were high at visits two, three, 
and four (96%, 94%, and 91%, respectively), then declined to a low of 82% at 
visit seven, but then increased to 89% at visit 10 [127]. More details of the study 
design and population have been reported elsewhere [199].   
The NGHS was approved by the institutional review boards (IRBs) of the 
University of California at Berkeley, University of Cincinnati and Cincinnati 
Children’s Hospital Medical Center, Cincinnati, OH, and Westat/Group Health 
Association in Rockville, MD. All parents/legal guardians gave informed consent, 
and all participants over the age of 12 provided assent. Use of the publically 
available data in this secondary data analysis was approved by the IRB at the 
University of Minnesota.  
For all analyses, girls who were missing age at menarche (n=22), clinic 
location (n=1), parental smoking status (n=227), or who reported menarche less 
than 8 years of age (n=2) or diabetes (i.e. assumed type 1 diabetes, n=5) were 
excluded. After these exclusions, there were 2,122 girls (African-
American=1,046; white=1,076) who had valid measures available for any of the 
CVD risk factor outcomes. Subsets of this dataset were analyzed for each 
cardiometabolic outcome, and visits in which participants were missing any of the 
covariates were excluded. Table 2 shows the number of participants included in 
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the analyses at each visit, and Table 3 shows how the sample size varied for 
each outcome. For the cross-sectional analyses at mean age 19 years, we 
additionally excluded participants who were missing percent body fat (n=40) at 
visit 10, for a final year 10 sample size of 2,082 (African-American=1,030; 
white=1,052). Models that were stratified by pre-menarche BMI excluded girls 
who reported menarche at the baseline visit (n=69 for the longitudinal models; 
n=67 for the mean age 19 models). 
Clinical	  Measures	  and	  Data	  Collection	  
Age	  at	  menarche	  
Information on menarche was collected during the annual pubertal stage 
assessment by centrally trained and certified female examiners who asked girls 
whether their menstrual periods had started, and if so, to specify the date [200]. 
The reliability of self-reported age at menarche is well established [12, 201]. For 
participants who provided conflicting age at menarche responses at different 
visits, we used the first age that was reported in response to the question 
regarding the onset of menses. 
Cardiometabolic	  outcome	  variables	  
 
The outcome variables included total cholesterol, low density lipoprotein 
cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), triglycerides, 
systolic blood pressure, percent body fat, body mass index (BMI), glucose, 
insulin, and a metabolic syndrome cluster score (z-score). Complete lipid profiles 
were measured in the morning after an overnight fast (8 hours) at visits 1 (mean 
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age 10), 3 (mean age 12), 5 (mean age 14), 7 (mean age 16), and 10 (mean age 
19) as previously described in detail [199].  Total cholesterol, HDL-C, and 
triglyceride concentrations were analyzed enzymatically with a commercially 
available method, and LDL-C was calculated by using a Friedewald formula that 
was modified based on the Lipids Research Clinics data as follows [202, 203]: 
 
LDL Cholesterol = Total Cholesterol – HDL Cholesterol – (Triglycerides/6.5) 
  
Triplicate blood pressure measurements were taken with a standard mercury 
sphygmomanometer and cuff sizes appropriate to upper arm circumferences at 
each annual visit while subjects were seated with feet resting flat and the right 
arm resting at heart level. The average systolic blood pressure from the three 
measures at each visit was used in the blood pressure analyses for this study. 
During annual visits, trained study staff obtained anthropometric measures 
that included height, weight, waist circumference, and the sum of skinfold (SSF) 
thickness at triceps, subscapular, and suprailiac sites [41]. Measures were 
repeated twice for all anthropometric measures, and a third measure was taken if 
the two measures differed by more than a preset amount. The percent body fat 
was calculated according to the formulae of Slaughter et al [31], using the triceps 
and suscapular skinfolds. BMI was calculated using the average height in meters 
and weight in kg (weight/height2). Waist circumference (cm) was measured at the 
narrowest part of the torso [204]. 
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Fasting glucose was measured at year 10 (mean age 19) using the glucose 
oxidase method with the Hitachi 704 Chemistry Analyzer (Roche Diagnostics, 
Indianapolis, IN) [205]. Coefficients of variation for glucose ranged from 2% to 
7%. Fasting insulin was measured at visit 10 by the Endocrine Laboratory at the 
University of Cincinnati/ Children's Medical Center using competitive protein-
binding radioimmunoassay [205]. Coefficients of variation for insulin 
measurement ranged from 5% to 11% [205].  
 As done in other studies, we considered fasting insulin as the measure of 
insulin resistance [205, 206], instead of the homeostasis model assessment of 
insulin resistance (HOMA-IR). Huang et al [206] compared estimates of insulin 
resistance from HOMA-IR to results from a frequently sampled oral glucose 
tolerance test and concluded that the utility of HOMA-IR in accurately predicting 
insulin sensitivity is similar to using fasting insulin alone.  A study that included 
African-American and white adolescents and compared fasting insulin and other 
surrogates of insulin resistance to the gold standard euglycemic-hyperinsulinemic 
clamp reported that the correlation between fasting insulin and HOMA-IR was 
very high (r=0.99) [207]. However, the study also showed that although insulin 
and the surrogates that included this measure might be a marker of CVD risk, 
they were imprecise representations of insulin resistance based on the gold 
standard. As euglycemic-hyperinsulinemic clamp measures were not part of the 
NGHS, we rely on insulin as the measure of insulin resistance despite its 
shortcomings.   
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In addition, we created a metabolic syndrome cluster score [208] at visit 10 
(mean age 19) for those participants who had measurements available for all five 
components of the metabolic syndrome. The cluster score consisted of the sum 
of the z-scores of waist circumference (cm), systolic blood pressure (mmHg), 
triglycerides (mg/dl), inverse HDL cholesterol (mg/dl), and fasting glucose (mg/dl) 
divided by 5 at mean age 19 in the NGHS. The score was calculated as 
1/5*([waist circumference-85.6]/15.0 - [HDL-cholesterol-53.6]/11.8 + 
[triglycerides-80.8]/40.8 + [systolic blood pressure-108.5]/9.2 + [fasting glucose-
86.6]/7.8). A higher z-score represents higher overall risk.  
Covariates	  
 
Demographic information for participants and their parents or guardians 
was obtained at enrollment. Self-reported data included age, race/ethnicity (non-
Hispanic African-American or white according to United States census 
categories), parental education level, and parental smoking. Age was coded in 
whole years. Parental education was categorized into high school degree or less, 
some college, and college graduate.  Parental smoking was categorized into ever 
smoking (yes/no).  Female examiners performed pubertal maturation 
assessment at each visit according to Tanner for pubic hair stages and by the 
system of Garn and Falkner for areolar stages [200].  Pubertal stage was 
categorized into 6 categories at each annual visit, ranging from stage 
1=prepubertal to stage 5-6=post menarche. 
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Statistical	  Methods	  
 
Descriptive statistics for the baseline visit were calculated as means (SD) 
for continuous variables and percent for categorical variables according to the 
following categories of age at menarche: early=8.0-11.9, mid=12.0-13.9, 
late=14.0-17.0. Fasting insulin and triglycerides were not normally distributed and 
were therefore log-transformed for analyses. However, there were no qualitative 
differences between the transformed and non-transformed values for 
triglycerides and so the non-transformed data are presented and used in the 
metabolic syndrome cluster score for simplicity and ease of interpretation. Log-
transformed insulin values were used in all analyses.  
To account for correlated observations for lipids, blood pressure, and 
adiposity measures within participants over the study period, we used repeated 
measures mixed linear regression models (PROC MIXED in SAS) to examine 
how associations of age at menarche with the cardiometabolic risk factor 
measures changed over time (i.e. with age). Age at menarche was modeled as a 
continuous variable in whole years for results in the tables, and as a categorical 
variable (early, mid, and late) for ease of interpretation in Figures 6 and 7.  Each 
of the cardiometabolic risk factors was included as the dependent continuous 
variable in separate models. Higher order time variables were included in models 
to determine if there was a non-linear change in cardiometabolic risk factors 
during adolescence and retained only if statistically significant. Based on the best 
fit of predicted values over time, we modeled linear and quadratic slopes for 
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changes in total cholesterol, LDL-C, HDL-C, blood pressure, percent body fat, 
and BMI in separate models. Linear, quadratic, and cubic slopes best fit the 
pattern of change for triglycerides. The main menarche coefficients measured the 
effect of age at menarche on each risk factor overall during adolescence 
(menarche main effect). The coefficients for the menarche*time interactions 
measured the linear, quadratic, or cubic age-related change per year younger 
age at menarche.  
Models were run in a series, adding covariates only if they were 
associated with age at menarche category and CVD risk, but not likely to be 
intermediate variables between menarche timing and the outcomes. Model 1 
included terms for continuous age at menarche, follow-up visit number 1-10 (the 
time variable), age at each visit (time varying as the difference between current 
age at the visit and the mean age at each visit), parental education level, parental 
smoking, study center, and the products of the time variable with age at 
menarche. Models were further adjusted (Model 2) for percent body fat at each 
visit (except for the adiposity outcomes) to account for the role of adiposity in 
both earlier pubertal maturation and in the development of cardiometabolic risk 
factors. Adjusted mean levels of the cardiometabolic risk factors at each time 
point by age at menarche category (early, mid, late) for the Figures 6 and 7 
were derived from mixed models in which follow-up visit year was included as a 
categorical variable. The adjusted means provided goodness of fit information 
regarding the linear, quadratic, or cubic slopes.  
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For cross-sectional analyses at visit year 10 (mean age 19), multiple linear 
regression was used to test if there were differences in the mean values of 
continuous total cholesterol, LDL-C, HDL-C, triglycerides, systolic blood 
pressure, percent body fat, BMI, glucose, insulin, and the metabolic syndrome 
cluster score by age at menarche. Age at menarche was modeled as a 
continuous variable in whole years. As with the longitudinal models, Model 1 
covariates included age (at visit 10), center, parental education level, and 
parental smoking, and then percent body fat at visit 10 was added in Model 2 
(except for the adiposity outcomes). 
A formal test for statistical interaction by race in each of the longitudinal 
and cross-sectional models assessed differences in the influence of the timing of 
menarche on the CVD outcomes. Even if the formal interaction test was not 
significant, separate models were built for African-American and white girls as 
our a priori research question related to race-specific changes in CVD risk factors 
over time, and given the race differences in age at menarche and age-related 
growth in adiposity in the cohort. In addition, because adiposity is strongly 
associated with both age at menarche and CVD risk factors, the longitudinal and 
cross-sectional models were stratified by pre-menarche BMI category (<85th 
percentile vs. > 85th percentile for age), with a formal BMI category*menarche 
interaction test for differences in the associations between categories. These 
models were adjusted for age, clinical center, parental education, parental 
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smoking status, BMI at baseline (or at visit for the cross-sectional analysis at 
mean age 19), pubertal stage at baseline, and race. 
All analyses were conducted in SAS v9.2 (Cary, NC). The alpha error 
value was set at 0.05 and all p-values were two-sided. Because of the multiple 
comparisons included in these analyses, Bonferonni corrected p-values <0.005 
(p=0.05/10 outcomes) were considered to be statistically significant for the 
purposes of these analyses. 
Results 
 
The overall cohort of 2,122 girls had a mean age of 10.0 years at baseline 
(range=9.0-11.0 years) and 19.0 years at the final visit (range=17.6-21.5 years). 
The mean age at menarche was 12.3 years (SD=1.2) for the total sample, and 
was younger for African-American (12.0 years, SD=1.1) compared with white 
(12.6 years, SD=1.2) girls (t=12.2, p-value<0.0001). At baseline, mean BMI was 
18.5 kg/m2 (SD=3.8) and mean percent body fat was 21.2% (SD=8.3). Baseline 
adiposity was significantly higher among African-American (BMI: 19.2 kg/m2, 
SD=3.2; percent body fat: 21.6%, SD=9.1) compared with white (BMI: 17.9 
kg/m2, SD=3.2; percent body fat: 20.7%, SD=7.5) girls (BMI: t=-8.08, p<.0001; 
percent body fat: t=-2.41, p=0.02).   
Table 4 shows the baseline characteristics of the study population by age 
at menarche category. For both African-American and white girls, earlier 
menarche was associated with greater BMI, percent body fat, and height at 
baseline. A lower level of parental education and higher percentage of parental 
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smoking were more frequent in the early menarche group for white girls, but not 
for African-American girls. 
Longitudinal	  Analysis	  
 
In longitudinal analyses, there were 20,609 visits for these 2,122 girls, with 
an average of 9.7 visits per participant. Figures 6 and 7 display the cross-
sectional means for percent body fat, BMI, total cholesterol, LDL-C, HDL-C, 
triglycerides, and systolic blood pressure for African-American and white girls at 
each visit by menarche group (early, average, and late), as well as the main 
effect for menarche category over the entire study period, and the influence of 
menarche on changes in each risk factor over time (menarche*time interactions). 
The mean values in Figure 6 are adjusted for age, clinical center, parental 
education, and parental smoking, while means in Figure 7are additionally 
adjusted for percent body fat. For all groups, we found a dip in total cholesterol 
and LDL-C, but an increase in HDL-C during mid-adolescence. The pattern in 
triglycerides was more complex, but levels were generally higher in early 
adolescence compared with late adolescence after adjusting for percent body fat 
(Figure 7). Systolic blood pressure, percent body fat, and BMI all increased 
during adolescence.  
Table 5 shows the results (beta+/-SE and p-value) of the repeated 
measures mixed regression models, which tested whether each one year earlier 
age at menarche was a predictor of the overall main effect values and the age-
related change in each risk factor during adolescence after adjustment for age, 
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race, clinical center, parental education, and parental smoking (Model 1), and 
then additionally adjusted for percent body fat (Model 2, except percent body fat 
and BMI). For simplicity, only the menarche main effect and menarche*time 
slope terms are reported in the table as these coefficients best captured the story 
of the overall levels of risk factors and pattern of change during adolescence. 
The quadratic and cubic time interaction terms indicated that there were no 
meaningful differences by age at menarche category in the concave or convex 
pattern of change in the risk factors with age during adolescence. 
 Overall during adolescence, each one year earlier age at menarche was 
associated with lower mean total cholesterol and HDL-C, but higher body fat, 
BMI, and systolic blood pressure (Table 5, Model 1 main menarche effects). 
After adjustment for percent body fat, total cholesterol and LDL-C were lower and 
systolic blood pressure was higher per one-year earlier age at menarche (Table 
5, Model 2 main menarche effects). There were no race differences in the 
influence of age at menarche on any of the CVD risk factors. 
When examining age at menarche in categories of early, mid, and late in 
Figure 6, girls in the early menarche category had higher percent body fat, BMI, 
and systolic blood pressure compared with later maturing girls overall during 
adolescence. After adjustment for percent body fat (Figure 7), girls with early 
menarche had higher systolic blood pressure, and African-American girls with 
early menarche had lower HDL-C, compared with the later menarche categories. 
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As shown by the menarche*age interaction terms in Table 5, there was an 
age-related pattern of convergence in the levels of total cholesterol, LDL-C, HDL-
C, and systolic blood pressure, but a divergence in percent body fat, 
(menarche*age interactions p<0.005) per one-year earlier age at menarche over 
the course of adolescence. There were no race differences with regard to the 
influence of age at menarche on the age-related rate of change in the other CVD 
risk factors. 
When the participants were stratified by pre-menarche BMI category 
(Table 6), each one-year earlier age at menarche was associated with lower total 
and LDL cholesterol and higher systolic blood pressure, percent body fat, and 
BMI among girls with pre-menarche BMI <85th percentile only. The BMI 
category*menarche interaction p-values for systolic blood pressure, percent body 
fat, and BMI all reached statistical significance at the p<0.005 level.  There were 
no differences by race in the influence of age at menarche on the CVD risk 
factors within in BMI category.  
Cross-­‐Sectional	  Analyses	  
 
 Table 7 shows the cross-sectional associations of each one-year younger 
age at menarche with each risk factor at mean age 19 years, and Table 8 shows 
the BMI-stratified results. Each one-year earlier age at menarche was associated 
with higher percent body fat, BMI, systolic blood pressure, and insulin resistance 
at age 19 (Table 7). After adjustment for percent body fat at mean age 19 years, 
age at menarche was no longer associated with any of the CVD risk factors. Age 
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at menarche was associated with higher percent body fat and BMI among girls 
who had pre-menarche BMI <85th percentile only (Table 8), and there were no 
other statistically significant associations in the BMI-stratified models. The 
influence of the timing of menarche did not differ by race for any of the risk 
factors.  
Discussion 
 
This study extends the findings from past studies by looking at race-specific, 
longitudinal changes in a number of CVD risk factors by menarche status during 
a time in which the obesity epidemic was taking hold in the population, and race 
disparities in pubertal timing and adiposity were becoming more evident. The 
study results show that earlier menarche was associated with greater adiposity 
throughout adolescence. There were also some weak associations of earlier 
menarche with lower total cholesterol, LDL-C, and HDL-C, but higher systolic 
blood pressure overall during adolescence before considering the greater degree 
of adiposity among earlier maturing girls. By the end of the 10-year follow-up, 
early menarche was associated with higher systolic blood pressure and insulin, 
but all associations were attenuated and no longer statistically significant after 
adjustment for percent body fat. There was no indication of an association of 
early menarche with triglycerides or glucose. Examination of associations by pre-
menarcheal BMI category suggested that earlier menarche might have a greater 
influence more adverse levels of systolic blood pressure and adiposity 
accumulation post-menarche among normal vs. obese girls. Contrary to 
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expectations, there were no differences by race in the influence of age at 
menarche in the levels or change in the CVD risk factors despite higher average 
levels of obesity and earlier age at menarche among African-American girls. 
As in other studies, this study demonstrated that levels of CVD risk factors 
change during adolescence with growth and development [202, 209-212].  This 
study showed a mid-adolescent decline in total cholesterol, LDL-C, and 
triglycerides, but an increase in HDL-C, systolic blood pressure, percent body fat, 
and BMI with advancing pubertal stage. The tendency toward a more healthy 
lipid profile during mid-puberty may be the result of increased oestradiol and 
growth hormone concentrations during this developmental stage [213]. In late 
adolescence, total cholesterol, LDL-C, and triglycerides increased, while HDL-C 
and blood pressure tended to decrease, all while adiposity continued its upward 
climb.  
Also in agreement with past studies [91, 92, 174, 177] was the finding that 
earlier menarche was associated with higher levels of adiposity for both African-
American and white girls during adolescence. A study that also used NGHS data 
previously reported on changes in a wide variety of body composition measures 
by age at menarche, including BMI and percent body fat, but the authors did not 
present results adjusted for potential confounding factors and used different 
menarche categories by race, which made comparisons difficult [91]. New in the 
current analysis regarding adiposity was that earlier menarche was more strongly 
associated with greater percent body fat and BMI overall during adolescence 
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among girls who were normal vs. overweight prior to menarche; earlier menarche 
did not appear to influence adiposity levels among girls who were already 
overweight prior to menarche even after adjusting for overall pubertal status at 
baseline. Furthermore, the current study showed that although adiposity 
remained higher overall for African-American girls, there were not any meaningful 
race differences in the relationship between earlier menarche and adiposity.  
 Earlier studies are mixed with regard to the role of early maturation on 
blood lipid levels during adolescence or adulthood, but like us, most have found 
that earlier menarche is not detrimental for blood lipids [173, 174, 177]. For 
example, in the Bogalusa Heart Study, mean levels of lipoproteins were similar 
for girls with menarche <12 and 12+ years [177]. However, the authors noted that 
even through the girls reporting later menarche had relatively less adiposity 
compared to those reporting early menarche, the later maturing girls were not 
lean, and so incomplete adiposity adjustment may have masked subtle 
differences in lipid levels. There was also no association between earlier 
menarche and lipids in the Fels Longitudinal Study [174], but as pointed out in 
reference [168], findings might have been subject to a cohort effect due to the 
variation in the timing of baseline measurements. In the current study, which was 
not subject to cohort effects, we found that earlier menarche was associated with 
lower total cholesterol and LDL-C overall during adolescence for African-
American and white girls, but by mean age 19, total cholesterol and LDL-C did 
not differ by menarche groups. We found a significant main effect of earlier 
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menarche with lower HDL-C in the longitudinal models before but not after 
adjustment for percent body fat. Previous studies are mixed with regard to HDL-
C, with at least three studies reporting no association of earlier menarche with 
HDL-C levels during adolescence or adulthood [173, 174, 177], and one 
reporting that early menarche was associated with lower HDL-C in adulthood 
[179].  
Insulin and glucose were not measured throughout adolescence in the overall 
NGHS, and so we examined cross-sectional associations at age 19 only. Similar 
to other studies that have reported that earlier menarche is associated with 
higher insulin levels or insulin resistance during adolescence and adulthood [168, 
174, 177-179], we found that early menarche was associated with higher mean 
insulin before adiposity adjustment. The association was completely attenuated 
after adjustment for adiposity, which has also been found by others [168]. 
Adverse levels of metabolic factors tend to cluster together (blood pressure, 
insulin, obesity, and blood lipids) [150]. This clustering changes with growth and 
development, and levels increase during preadolescence, decrease over the 
course of puberty, and increase again in young adulthood, independently of race 
or timing of pubertal maturation [212]. The clustering of metabolic risk factors has 
also been shown to track into adulthood, so adverse levels during adolescence 
have implications for long-term health [214]. Therefore, we examined the 
association of earlier age at menarche and the clustering of these risk factors 
using a metabolic syndrome cluster score.  Before adjusting for percent body fat, 
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there was an inverse association between age at menarche and the metabolic 
syndrome cluster score (Beta=0.10 µU/ml [SE 0.04], p=0.01) that did not quite 
meet the Bonferroni-adjusted threshold, but the association was completely 
attenuated after adjustment for percent body fat. Other studies have reported that 
age at menarche was inversely associated with metabolic syndrome in 
adolescence [177] and adulthood [168, 176, 177, 179], although associations 
were attenuated, sometimes completely (as in [168]) after adjustment for 
adiposity.  
Methodological	  Considerations	  
 
Our study has certain limitations worth noting. First, age at menarche was 
based on self-report. However, the validity and reliability of self-report is well 
established, especially in the short term [12, 201]. We expect that any 
misclassification of age at menarche would be random with respect to the 
outcomes, which would tend to underestimate the true differences between 
groups. The publically available NGHS dataset also lacks serial measurements 
of insulin and glucose, so we were unable to estimate the change during 
adolescence for these measures, or for the metabolic syndrome cluster score 
that incorporates glucose. 
 Additionally, measurements in the NGHS began at mean age 10 and some 
girls (close to 50% of the cohort) had already started puberty. Therefore, our 
study is unable to examine if higher adiposity preceded the onset of puberty, or 
vice versa, making it unclear if adiposity should be considered a confounder or a 
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mediator in the relationship between early menarche and later CVD risk. Some 
evidence suggests that higher weight gain in infancy and higher levels of 
adiposity levels in childhood initiate estrogen production and cause earlier onset 
of puberty in girls [15, 75, 76]. Other evidence suggests that adiposity may be a 
downstream consequence of pubertal maturation [7, 83]. Earlier pubertal onset 
may initiate adipose tissue accumulation during later stages of development, 
making temporality of the association between pubertal and adiposity 
development unclear [83, 84]. Furthermore, it is unclear if prepubertal body 
composition is more relevant to the actual onset of puberty or to the duration of 
puberty [85].  
 Lastly, several outcomes were included in our analyses, raising concern 
over multiple comparisons and an increased risk for false-positive (type 1 error) 
results. Although we based our hypotheses on a priori evidence, we present both 
the Bonferroni adjusted and traditional significance levels to account for multiple 
comparisons.  
 The strengths of the study include the use of both cross-sectional and 
longitudinal methods to examine the influence of earlier menarche on CVD risk 
factor levels and changes during adolescence. The cohort included a large 
sample size of roughly equal numbers of African-American and white girls, 
making race-specific analyses possible. Furthermore, the data were collected 
from a relatively recent cohort of girls during a period of time in which the 
prevalence of obesity was increasing and age at menarche was decreasing. In 
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addition, the study collected information on a large number of CVD risk factors, 
allowing us to look not only at individual factors, but to calculate a metabolic 
syndrome cluster score for a more comprehensive look at CVD risk during late 
adolescence. Finally, we adjusted directly for adiposity using percent body fat, 
instead of BMI or waist circumference, both of which might be influenced by body 
composition factors other than adiposity during adolescence.    
Conclusion 
 
In summary, the association of early maturation with CVD risk factors during 
adolescence was subtle and appeared to be driven primarily by higher adiposity 
levels among earlier maturing girls (as found in reference [168]). Even among 
girls who were normal weight prior to menarche, earlier age at menarche was 
associated with greater adiposity overall during adolescence. Age at menarche 
did not seem to influence adiposity levels during adolescence among girls who 
were already overweight prior to menarche. There were no important differences 
in the influence of early menarche on CVD risk factors by race. A focus on 
healthy lifestyle and prevention of adiposity accumulation starting early in 
childhood and prior to menarche may be helpful in the primordial prevention of 
CVD into adulthood.   
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Table 2. Number of participants included in analyses for each follow-up 
visit in the NGHS 
Visit year Baseline 2 3 4 5 6 7 8 9 10 
Mean age 
(yrs) 
10 11 12 13 14 15 16 17 18 19 
N* 2,101 2,113 2,102 2,098 2,070 2,059 2,020 1,989 1,975 2,067 
           
*N=number of participants who reported menarche 8-17 years, did not have diagnosed diabetes, 
had data available for all covariates, and who had measurements available for at least one 
cardiometabolic outcome at that visit 
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Table 3. Number of measurements for each cardiometabolic outcome 
in the NGHS 
      
Variable N* 
Mean # of 
measures 
Std 
Dev Minimum Maximum 
      Total cholesterol 2,087 3.6 1.1 1 5 
LDL-C 2,087 3.6 1.1 1 5 
HDL-C 2,087 3.6 1.1 1 5 
Triglycerides 2,087 3.6 1.1 1 5 
Systolic blood 
pressure 2,122 9.7 0.7 5 10 
BMI 2,122 9.7 0.7 5 10 
Percent body fat 2,122 9.7 0.7 5 10 
Insulin  1,542 1 NA 1 1 
Glucose 1,588 1 NA 1 1 
Metabolic syndrome 1,352 1 NA 1 1 
      *N=participants with at least one measurement for the outcome over the study period after 
exclusions 
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Table 4. Baseline characteristics by age at menarche category in the NGHS 
  
  Menarche Category 
 8.0-11.9 years 12.0-13.9 years 14.0-17.0 years  
 Mean (SD) or  (%) Mean (SD) or  (%) Mean (SD) or  (%) p-trend  
African-American  
N (%) (n=1,046) 511 (48.9) 493 (47.1) 42 (4.0)  
Age at menarche 
(yrs) 10.6 (0.7) 12.3 (0.5) 14.2 (0.4)  
Age (years)  10.1 (0.6) 10.1 (0.6) 10.2 (0.5) 0.09 
BMI (kg/m2)  19.9 (4.1) 18.6 (4.2) 17.8 (4.1) <.0001 
Percent body fat 
(%)  22.7 (8.9) 20.8 (9.1) 18.6 (9.4) <.0001 
Height (cm)  145.5 (8.0) 140.8 (6.9) 137.2 (5.7) <.0001 
Parental smoking 
(ever=yes) 52.3 57.4 52.4 0.21 
Parent Education  
  
0.27 
     HS or less 31.3 28.0 16.7  
Total calories 
(kcal/day)       1868.3 (562.8) 1867.5 (637.5) 1791.8 (683.9) 0.70 
Screen time  
(h/week) 36.2 (16.9) 37.2 (18.4) 36.1 (20.1) 0.54 
Physical activity 
(MET-h/week)  29.5 (19.8) 31.6 (19.4) 30.3 (15.2) 0.14 
          
White 
N (%) (n=1,076) 304 (28.3) 648 (60.2) 124 (11.5)  
Age at menarche 
(yrs) 10.7 (0.6) 12.4 (0.5) 14.3 (0.6)  
Age (years) 9.9 (0.5) 10.0 (0.6) 10.0 (0.6) 0.16 
BMI (kg/m2)  18.8 (3.3) 17.7 (3.2) 16.5 (2.6) <.0001 
Percent body fat 
(%) 22.2 (7.1) 20.6 (7.6) 17.6 (7.0) <.0001 
Height (cm)  142.0 (7.6) 139.1 (6.8) 137.1 (6.2) <.0001 
Parental smoking 
(ever yes)  58.9 57.9 42.7 0.01 
Parent Education  
  
0.005 
     HS or less 21.1 18.2 12.1  
Total calories 
(kcal/day)     1837.9 (504.6) 1796.1 (428.9) 1803.3 (421.2) 0.30 
Screen time 
(h/week) 25.5 (14.3) 25.0 (14.5) 22.5 (13.7) 0.08 
Physical activity 
(MET-hr/week)  32.7 (19.2) 33.5 (19.1) 34.4 (20.1) 0.38 
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Table 5. Main effect and annual age-related change in levels of 
cardiometabolic risk factors during adolescence according to each 1-year 
younger age at menarche in the NGHS 
 All girls 
African-
American White  
 beta+/-SE (P) beta+/-SE (P) beta+/-SE (P) 
p-
interaction 
(race) 
Total Cholesterol (mg/dl) 
Model 1     
Main menarche 
effect  
-1.61+/-0.47 
(0.0006) 
-2.13+/-0.71 
(0.003) 
-1.24+/-0.62 
(0.05) 0.39 
Menarche*age 
 
0.30+/-0.06 
(<.0001) 
0.30+/-0.10 
(0.002) 
0.38+/-0.09 
(<.0001) 0.57 
     Model 2 
    Main menarche 
effect  
-2.08+/-0.47 
(<.0001) 
-2.45+/-0.71 
(0.0005) 
-1.87+/-0.62 
(0.003) 0.38 
Menarche*age 
 
0.28/-0.06 
(<.0001) 
0.28+/-0.10 
(0.002) 
0.30+/-0.08 
(<.0001) 0.49 
LDL-C (mg/dl) 
Model 1     
Main menarche 
effect  
-0.96+/- 0.43 
(0.02) 
-1.39+/-0.67 
(0.04) 
-0.65+/-0.57 
(0.26) 0.41 
  Menarche*age 
 
0.22+/-0.06 
(0.002) 
0.17+/-0.09 
(0.06) 
0.30+/-0.09 
(0.0004) 0.25 
Model 2 
    Main menarche 
effect  
-1.58+/-0.42 
(0.0002) 
-1.94+/-0.66 
(0.003) 
-1.30+/-0.57 
(0.02) 0.40 
Menarche*age 
 
0.20+/-0.06 
(0.0009) 
0.15+/-0.09 
(0.10) 
0.30+/-0.08 
(0.0004) 0.18 
HDL-C (mg/dl) 
Model 1     
Main menarche 
effect  
-0.63+/-0.18 
(0.0004) 
-0.66+/-0.28 
(0.02) 
-0.58+/-0.23 
(0.01) 0.93 
Menarche*age  
 
0.10+/-0.03 
(0.0003) 
0.13+/-0.04 
(0.002) 
0.09+/-0.04 
(0.01) 0.46 
     Model 2 
    Main menarche 
effect  
-0.31+/-0.17  
(0.07) 
-0.29+/-0.27 
(0.28) 
-0.32+/-0.22 
(0.15) 0.96 
Menarche*age 
 
0.11+/-0.03 
0.15+/-0.04 
(0.0004) 
0.10+/-0.04 
(0.008) 0.33 
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(<.0001) 
Triglycerides (mg/dl) 
Model 1 
    Main menarche 
effect  
0.27+/-0.60 
(0.65) 
-0.13+/-0.64 
(0.84) 
0.30+/-1.00 
(0.77) 0.70 
Menarche*age 
 
-0.25+/-0.11 
(0.02) 
-0.13+/-0.12 
(0.29) 
-0.21+/-17 
(0.21) 0.73 
     Model 2 
    Main menarche 
effect  
-0.95+/-0.05 
(0.11) 
-0.97+/-0.62 
(0.12) 
-1.36+/-0.96 
(0.16) 0.66 
Menarche*age 
 
-0.30+/-0.10 
(0.003) 
-0.17+/-0.12 
(0.16) 
-0.22+/-0.16 
(0.18) 0.89 
Systolic Blood Pressure (mmHg) 
Model 1 
    Main menarche 
effect  
0.76+/-0.11 
(<.0001) 
0.61+/-0.16 
(0.0002) 
0.90+/-0.14 
(<.0001) 0.19 
Menarche*age 
 
-0.07+/-0.02 
(<.0001) 
-0.07+/-0.08 
(0.01) 
-0.09+/-0.02 
(0.0001) 0.49 
     Model 2 
    Main menarche 
effect  
0.45+/-0.10 
(<.0001) 
0.30+/-0.15 
(0.05) 
0.61+/-0.14 
(<.0001) 0.14 
Menarche*age 
 
-0.09+/-0.2 
(<.0001) 
-0.09+/-0.02 
(0.0004) 
-0.16+/-0.08 
(0.04) 0.78 
Percent Body Fat (%) 
Model 1 
    Main menarche 
effect  
1.35+/-0.15 
(<.0001) 
1.40+/-0.25 
(<.0001) 
1.24+/-0.18 
(<.0001) 0.82 
Menarche*age 
 
0.07+/-0.02 
(<.0001) 
0.07+/-0.03 
(0.01) 
0.02+/-0.02 
(0.44) 0.12 
BMI (kg/m2) 
Model 1 
    Main menarche 
effect  
0.77+/-0.08 
(<.0001) 
0.87+/-0.14 
(<.0001) 
0.69+/-0.09 
(<.0001) 0.34 
Menarche*age 
 
0.02+/-0.01   
(0.01) 
0.02+/-0.02 
(0.12) 
-0.01+/-0.01 
(0.44) 0.07 
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Notes: 
Main menarche effect is the average effect per one year younger age at menarche on 
the outcomes over the entire study period. 
 
Menarche*age estimates are interpreted as the predicted change per year of age in an 
outcome variable assuming a 1-year decrease in age at menarche while the other 
predictor variables are held constant. 
 
Model 1 adjusted for age, race, study year, parental education, parental smoking, and 
study center.  
 
Model 2 additionally adjusted for percent body fat.  
 
Year (the time variable) modeled as linear and quadratic terms in the main effect 
models, except for triglycerides, where a cubic time term was the best fit for the change 
over time.  
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Table 6. Main effect of each 1-year younger age at menarche on 
cardiometabolic risk factors from mean age 10 through 19 year in the 
NGHS, by pre-menarche BMI category* at baseline 
 
BMI<85th Percentile 
(n=1,431) 
BMI>=85th Percentile 
(n=622) 
P-
Interaction 
BMI*Age at 
Menarche Outcome Beta (SE) 
P-
value Beta (SE) 
P-
value 
All girls 
(n=2,053) 
     Total Cholesterol 
(mg/dl) -2.11 (0.62) 0.0006 -0.59 (1.02) 0.56 0.06 
LDL-C (mg/dl) -1.56 (0.56) 0.005 -0.21 (0.94) 0.82 0.11 
HDL-C (mg/dl) -0.56 (0.23) 0.02 0.12 (0.37) 0.73 0.009 
Triglycerides 
(mg/dl) -0.30 (0.61) 0.62 -2.45 (1.75) 0.16 0.006 
Systolic Blood 
Pressure (mmHg) 0.67 (0.14) <.0001 0.12 (0.22) 0.58 0.0002 
Percent Body Fat 
(%) 0.99 (0.12) <.0001 -0.64 (0.28) 0.02 <.0001 
BMI (kg/m2) 0.49 (0.05) <.0001 -0.48 (0.29) 0.09 0.0009 
      Notes:  
*Analysis excludes girls who reported reaching menarche at the baseline visit (n=69) 
 
Models adjusted for age, clinical center, parental education, parental smoking status, BMI at 
baseline, pubertal stage at baseline, and race. 
 
BMI cut at 85th percentile for age 9-10 according to CDC guideline:  
http://www.cdc.gov/growthcharts/percentile_data_files.htm 
  
No significant interactions by race 
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Table 7. Cross-sectional associations of each 1-year younger age at 
menarche with cardiometabolic risk factors at mean age 19 years, the 
NGHS 
MODEL 1 Beta SE p-value 
All girls (n=2,082) 
   Total Cholesterol (mg/dl) 0.31 0.77 0.69 
LDL-C (mg/dl) 0.44 0.67 0.51 
HDL-C (mg/dl) -0.23 0.26 0.37 
Triglycerides (mg/dl) -0.04 0.91 0.97 
Systolic blood pressure (mmHg) 0.46 0.17 0.007 
Insulin (µ U/ml)* 0.05 0.02 0.003 
Glucose(mg/dl) 0.36 0.46 0.45 
Metabolic syndrome cluster score (z-score) 0.10 0.04 0.01 
Adiposity 
   Percent body fat (%)  1.63 0.22 <.0001 
BMI (kg/m2) 0.84 0.12 <.0001 
African-American (n=1,030) 
   Total Cholesterol (mg/dl) -0.44 1.07 0.68 
LDL-C (mg/dl) -0.54 0.95 0.57 
HDL-C (mg/dl) -0.04 0.39 0.92 
Triglycerides (mg/dl) -0.17 1.10 0.88 
Systolic blood pressure (mmHg) 0.32 0.25 0.21 
Insulin (µ U/ml)* 0.06 0.03 0.01 
Glucose(mg/dl) -0.23 0.76 0.77 
Metabolic syndrome cluster score (z-score) 0.12 0.05 0.04 
Adiposity 
   Percent body fat (%)  1.83 0.36 <.0001 
BMI (kg/m2) 0.99 0.20 <.0001 
White (n=1,052) 
   Total Cholesterol (mg/dl) 1.00 1.12 0.38 
LDL-C (mg/dl) 1.30 0.95 0.17 
HDL-C (mg/dl) -0.40 0.36 0.27 
Triglycerides (mg/dl) -0.02 1.46 0.99 
Systolic blood pressure (mmHg) 0.57 0.22 0.01 
Insulin (µ U/ml)* 0.03 0.02 0.12 
Glucose(mg/dl) 0.76 0.56 0.17 
Metabolic syndrome cluster score (z-score)  0.07 0.05 0.15 
Adiposity 
   Percent body fat (%) 1.39 0.26 <.0001 
BMI (kg/m2) 0.67 0.13 <.0001 
MODEL 2 
   All girls (n=2,067) 
   Total Cholesterol (mg/dl) -0.48 0.77 0.54 
LDL-C (mg/dl) -0.46 0.66 0.48 
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HDL-C (mg/dl) 0.11 0.28 0.65 
Triglycerides (mg/dl) -1.09 0.90 0.23 
Systolic blood pressure (mmHg) 0.05 0.16 0.74 
Insulin (µ U/ml)*  -0.004 0.02 0.80 
Glucose(mg/dl) -0.18 0.46 0.70 
Metabolic syndrome cluster score (z-score)  -0.01 0.03 0.72 
African-American (n=1,021) 
   Total Cholesterol (mg/dl) -1.25 1.06 0.24 
LDL-C (mg/dl) -1.52 0.94 0.11 
HDL-C (mg/dl) 0.37 0.39 0.34 
Triglycerides (mg/dl) -1.21 1.09 0.27 
Systolic blood pressure (mmHg) -0.13 0.24 0.58 
Insulin (µ U/ml)* 0.003 0.02 0.90 
Glucose(mg/dl) -0.89 0.75 0.24 
Metabolic syndrome cluster score (z-score)  0.02 0.05 0.73 
White (n=1,046) 
   Total Cholesterol (mg/dl) 0.19 1.12 0.86 
LDL-C (mg/dl) 0.45 0.94 0.62 
HDL-C (mg/dl) -0.12 0.35 0.74 
Triglycerides (mg/dl) -1.10 1.45 0.45 
Systolic blood pressure (mmHg) 0.22 0.22 0.32 
Insulin (µ U/ml)* -0.01 0.02 0.69 
Glucose(mg/dl) 0.41 0.57 0.47 
Metabolic syndrome cluster score (z-score)  0.01 0.05 0.85 
    Notes: 
   Model 1 adjusted for age, center, parental education, parental smoking 
Model 2 additionally adjusted for percent body fat.  
*Log-transformed value  
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Table 8. Cross-sectional associations of each 1-year younger age at 
menarche with cardiometabolic risk factors at mean age 19 years in the 
NGHS by pre-menarche BMI category* at baseline 
 
BMI <85th 
Percentile(n=1,414) 
BMI >=85th 
Percentile (n=601) P-Interaction 
BMI*Age at 
Menarche 
 
Beta (SE) P-value Beta (SE) P-value 
All girls (n=2,015) 
     Total Cholesterol (mg/dl) -1.72 (1.02) 0.27 1.27 (1.67) 0.44 0.11 
LDL-C (mg/dl) -0.89 (0.88) 0.31 1.17 (1.50) 0.43 0.13 
HDL-C (mg/dl) -0.17 (0.36) 0.64 0.68 (0.54) 0.21 0.05 
Triglycerides (mg/dl) -0.89 (1.20) 0.46 -1.88 (2.05) 0.36 0.33 
Systolic blood pressure 
(mmHg) 0.37 (0.21) 0.07 -0.01 (0.35) 0.98 0.18 
Insulin (µ U/ml)** 0.01 (0.02) 0.44 0.03 (0.03) 0.25 0.72 
Glucose(mg/dl) 0.28 (0.57) 0.62 -0.42 (1.20) 0.72 0.27 
Metabolic syndrome 
cluster score (z-score) 0.06 (0.05) 0.19 -0.02 (0.07) 0.81 0.21 
Adiposity 
     Percent body fat (%)  1.06 (0.21) <.0001 -0.19 (0.50) 0.71 0.07 
BMI (kg/m2) 0.45 (0.10) <.0001 -0.12 (0.28) 0.67 0.28 
      Notes: 
     *Analysis excludes girls who reported menarche at the baseline visit (n=67) 
**Log transformed 
 Adjusted for age at year 10, center, race, parental education, parental smoking, 
pubertal stage at baseline, and BMI at year 10 (except for adiposity measures) 
 
BMI cut at 85th percentile for age 9-10 according to CDC guideline:   
No significant interactions by race 
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Figure 6. Longitudinal age-related changes in cardiovascular disease risk 
factors during adolescence by age at menarche category in the NGHS 
*=mean age at menarche for each category 	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Notes:  
Adjusted for age, clinical center, parental education, and parental smoking. 
Menarche categories: early= 8.0-11.9 years, mid=12.0-13.9 years, late=14.0-17.0 
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Figure 7. Longitudinal age-related changes in cardiovascular disease risk factors 
during adolescence by age at menarche category in the NGHS, adjusted for 
percent body fat 
*=mean age at menarche for each category 
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Notes:   
Adjusted for age, clinical center, parental education, parental smoking, and percent body fat. 
Menarche categories: early= <12.0 years, mid=12.0-13.9 years, late=14.0-17.0. 
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CHAPTER 4. MANUSCRIPT #2 - AGE AT MENARCHE AND 
CARDIOMETABOLIC RISK IN ADULTHOOD: THE CARDIA 
STUDY  
 
Introduction 
 
 A number of studies have demonstrated an association between early 
pubertal development among girls, measured using age at menarche, and 
increased risk for cardiovascular disease (CVD) and some of its risk factors, such 
as type 2 diabetes, high blood pressure, and metabolic syndrome [3, 5, 6, 28, 
176].  However, early menarche is also strongly associated with obesity, which 
increases the risk for these adulthood diseases [60, 97]. Recent studies conflict 
about the confounding or mediating role of childhood and adulthood obesity in 
the relationship between earlier puberty and CVD risk [2-6]. One potential reason 
for the uncertainty is that childhood obesity and puberty likely influence each 
other through certain common pathways such as hormonal changes, insulin 
resistance, and hyperinsulinemia, and pubertal timing may have an additional 
subtle influence on adult obesity and CVD risk among women [28, 139]. Another 
reason is that multiple factors (e.g. infant weight gain and nutrition) likely work 
together in the timing of puberty [28], simultaneously influencing accumulation of 
adiposity in childhood, the onset of puberty, and later CVD risk [28, 85, 139].  
Additionally, the influence of obesity in driving the relationship between pubertal 
timing and cardiometabolic risk may differ depending on when in the life course 
adiposity and risk factors are measured. A recent meta-analysis [28] concluded 
that the balance of evidence suggests that early puberty is associated with 
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increased risk of adult obesity and some cardiometabolic disorders (e.g. higher 
blood pressure, abnormal glycemia, and metabolic syndrome) independently of 
childhood obesity, but that it is not clear if the relationships are causal. 
Furthermore, longitudinal data are limited for the CVD risk factors outside of 
obesity. 
Although race appears to be an independent risk factor for early menarche 
[14, 30], as well as for certain cardiometablic conditions [215], the relationship of 
age at menarche with cardiometabolic risk among African-American women has 
not been well studied. Most reports have included women of European descent 
only [1, 2, 4, 8, 9, 168, 182], or did not look at risk of disease separately for 
African-American and white women [3, 175, 183]. We previously showed that in 
the Atherosclerosis Risk in Communities (ARIC) study, age at menarche was 
associated with prevalent diabetes at baseline and incident diabetes during 
follow-up for white, but not African-American women during mid to late-adulthood 
[6]. Manuscript # I of this dissertation showed that age at menarche was 
inversely associated with adiposity throughout adolescence, as well as with 
systolic blood pressure and insulin levels before, but not after, adjustment for 
percent body fat. There were no meaningful differences between African-
American and white girls in the association of age at menarche with any of the 
CVD risk factors. 
Building on that work, this study evaluates the association between age at 
menarche and cardiovascular risk factors in the longitudinal CARDIA cohort of 
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young to middle-aged women. The specific aims of this study were to 1) assess 
race-specific associations between age at menarche and incident type 2 
diabetes, impaired fasting glucose (IFG), and metabolic syndrome over 25 years 
of follow-up in the CARDIA study; and 2) examine how race-specific associations 
of age at menarche with fasting glucose, insulin, and additional components of 
cardiometabolic risk (adiposity, blood pressure, and blood lipids) change with 
age. We also considered if associations were independent of adiposity. The 
hypothesis is that earlier age at menarche will be associated with adverse levels 
of CVD risk factors among white and African-American women. Our analysis 
adds to the literature because CARDIA includes a biracial cohort of women with 
serial measurements available for a variety of cardiometabolic outcomes starting 
in early adulthood through middle-age. The results might help clarify the timing 
and mechanisms underlying the relationship between pubertal timing and 
cardiometabolic conditions. 
Materials and Methods 
Study	  Design	  and	  Population	  
 
The CARDIA study is a prospective cohort of 5,115 African-American and 
white men (n=2,328) and women (n=2,787) aged 18-30 years at baseline, 
originally designed to examine the development of heart disease in adults. The 
details of the study cohort, including eligibility criteria, sources and methods of 
recruitment and follow-up have been described in detail elsewhere [216]. Briefly, 
participants were recruited from four communities in the USA: Birmingham, AL; 
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Chicago, IL; Minneapolis, MN; Oakland, CA. Data for our analyses were 
collected during home interviews and clinic visits at the baseline and follow-up 
exams over 25 years (1985-2011). The institutional review boards at each of the 
study sites approved the study, and participants provided informed consent. 
All analyses excluded women with missing age at menarche (n=118), or 
who reported their age at menarche as <8 (n=1) or >17 (n=9) years as we are 
interested in studying women within the normal range of menarche timing. Other 
exclusions were those with diabetes (n=20), missing diabetes status (n=45), or 
missing BMI (n=11) at the baseline visit, for an overall sample size of 2,583 
women (African-American=1,333, white=1,250). For incident impaired fasting 
glucose and metabolic syndrome, women with those conditions at baseline were 
also excluded (IFG: n=38; metabolic syndrome: n=49). The final sample for the 
IFG analysis was 2,545, and for metabolic syndrome the sample size was 2,534. 
For the longitudinal analysis of cardiometabolic risk factors during follow-up, time 
points were excluded for patients who were pregnant or missing an outcome 
variable, or who had developed diabetes at any time prior to the visit. 
 
Clinical	  Measures	  and	  Data	  Collection	  
 
Age	  at	  menarche	  
Age at menarche was assessed at baseline via self-report on a 
questionnaire by asking “How old where you when you began menstruating?”.  
For this manuscript, age at menarche is defined as the age in whole years at the 
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first menstrual period.  The same question was asked at the second visit and 
reliability was high (r=0.84). We included age at menarche as both continuous 
and categorical variables in separate models, using the categories of early (8-11 
years), average (12-13 years), and late (14-17 years) menarche. 
Outcomes	  
Diabetes status was assessed at baseline and at each CARDIA clinic visit. 
All participants were asked to fast for 12 hours before the clinical examination. 
Type 2 diabetes was defined using blood glucose measurements and self-
reported medication use at each visit. Specifically, diabetes was defined among 
non-pregnant women as fasting blood glucose ≥ 126 mg/dl, HbA1c ≥ 6.5%, 2-
hour oral glucose tolerance ≥ 200 mg/dl, or use of diabetes medication.  A 2-hour 
oral glucose tolerance test (OGTT) was administered at visit years 10, 20, and 25 
only, and HbA1c was measured at years 20 and 25 only.   
Impaired fasting glucose was defined as fasting blood glucose (FPG) ≥ 
100 mg/dl but <126 mg/dl and not taking diabetes medication. Metabolic 
syndrome was defined according to the NCEP ATP-III revised criteria of 3 or 
more of the following factors: waist circumference >88 cm, systolic blood 
pressure ≥130/85 mmHg (or use of anti-hypertensive medication), HDL-C < 50 
mg/dL, triglycerides ≥150 mg/dL (or use of lipid-lowering medication), or fasting 
glucose ≥ 100 mg/dL (or use of hypoglycemic medication) [217].  
Measurements	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Blood pressure was measured three times at each visit after a 5-minute 
rest, and the mean of the last two measurements were used in this analysis. 
Waist circumference was measured laterally at the point midway between the 
iliac crest and the lowest lateral portion of the rib cage and anteriorly at the point 
midway between the xiphoid process of the sternum and the umbilicus [218]. An 
enzymatic method was used to measure plasma concentrations of total 
cholesterol, HDL cholesterol, and triglycerides. HDL cholesterol was measured 
after dextran-magnesium precipitation [219], and LDL cholesterol was calculated 
by using the Friedewald equation [220]. The test-retest reliability coefficients for 
split specimens of total, HDL cholesterol, LDL cholesterol, and triglycerides were 
high, at >0.98 [221]. A radioimmunoassay (Linco Research, St Charles, MO) was 
used to measure fasting insulin. Additional details of the CARDIA examination 
procedures were published previously [221, 222]. 
 
Covariates	  
 
The covariates of age at baseline (years), race (African-American or 
white), parental history of diabetes (yes/no), oral contraceptive use (yes/no), 
smoking status (never, former, current), physical activity level (MET-hours/week), 
alcohol consumption (g/day), and level of education (<high school, high school, 
>high school) were all measured via self-report at baseline.  Physical activity 
prior to high school (or 14 years of age) and during high school (or 14-18 years of 
age) was measured using an activity scale of 1 (physically inactive) to 5 (very 
active) and assessed via recall at the baseline visit. Anti-hypertensive and 
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hypoglycemic medication use was assessed at all visits, and lipid-lowering 
medication use beginning at exam year 5. Menopause status (yes/no) was 
obtained at visit years 15, 20, and 25. Weight (kg) and height (cm) were 
measured at each of the clinic visits while participants dressed in scrub suits and 
removed shoes. Body height (cm) and weight (kg) were measured with a 
calibrated scale and a vertical ruler. BMI was calculated as weight (kg)/baseline 
height2 (m2).  
Statistical	  Methods	  
 
Baseline characteristics of the study population by race and by age at 
menarche category (early menarche [8-11 years], average menarche [12-13 
years], and late menarche [14-17 years]) were summarized using mean (SD) for 
continuous variables or n (%) for categorical variables. The linear trend was 
tested using the likelihood ratio test by modeling the value in each menarche 
category as a continuous variable. All outcome variables were assessed for 
normality. Triglycerides and insulin were skewed and therefore log transformed 
for analyses. However, there were no qualitative differences between the 
associations for transformed and non-transformed values and so the non-
transformed data are presented for simplicity. 
Cox proportional models were used to estimate hazard ratios (HR) for 
incident diabetes (diabetes yes/no), impaired fasting glucose (yes/no), or 
metabolic syndrome (yes/no) according to continuous and categorical age at 
menarche. Estimates (hazard ratio [HR] and 95% CI) were calculated for all 
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women, and stratified by race as our a priori research question was about race 
differences in associations. The proportional hazards assumption was tested and 
verified by generating a time dependent predictor and creating interactions of age 
at menarche and a log function of survival time, and then the Wald chi-square 
procedure tested whether the coefficients were equal to 0.  
Separate repeated measures linear regression models (PROC MIXED in 
SAS) were used to examine the association of age at menarche with each 
cardiometabolic risk factor over 25 years of follow-up. Participants with at least 
one outcome measurement were included in the analysis for each risk factor. We 
used the compound symmetry (CS) covariance structure because the models did 
not converge with the unstructured covariance structure, and CS fit the data 
better than other, more complex structures that were appropriate for unequally 
spaced measurements. 
All mixed models included the independent variables of age at menarche, 
follow-up year (the time variable), current age and age2, and clinical center. The 
cardiometabolic risk factors were the dependent continuous variable in each of 
the separate models. Higher order time variables were included to determine if 
there was a non-linear change in cardiometabolic risk factors during adulthood 
and retained only if statistically significant. Models were run in a series by adding 
covariates, starting with minimally adjusted Model 1 (age, age2, center, and 
time). Model 2 also included the following covariates that were chosen a priori 
and have been found to be associated with age at menarche and/or 
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cardiometabolic risk factors: race (other than for race-stratified models), alcohol 
use, education level, smoking status, physical activity prior to high school, 
physical activity during high school, baseline physical activity, parental history of 
diabetes, oral contraceptive use, and menopause status. Blood pressure models 
were also adjusted for anti-hypertensive medication use and lipid models for 
cholesterol-lowering medications use. Finally, to test whether associations were 
independent of body composition, the models were further adjusted by the 
addition of baseline BMI (kg/m2) in Model 3. Estimated adjusted means were 
calculated and plotted in Figure 8 for the minimally adjusted Model 1 and in 
Figure 9 for the fully adjusted Model 3 for each risk factor at each CARDIA visit. 
For most outcomes, the models indicated linear, dose-response effects of 
age at menarche. Therefore, age at menarche was included as a continuous 
variable in the longitudinal and Cox models. Age at menarche was also included 
as a categorical variable (early, average, late) to calculate adjusted means for 
ease of interpretation in figures, and for comparison with other studies. To test for 
differences by race, adjusted models were run with an interaction term 
(race*menarche age). Even if the interactions are not statistically significant, 
race-stratified results were presented, as this was an a priori study objective.  
All analyses were run in SAS version 9.2. The Cox proportional hazard 
models were assessed with the statistical significance level for alpha set at 
p<0.05. Because of the multiple comparisons included in our longitudinal 
analyses, Bonferroni corrected p-values <0.005 (p=0.05/10 outcomes) were 
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considered to be statistically significant for the purposes of the longitudinal 
analyses. 
Results 
 
The overall cohort of 2,583 women had a mean age of 26.9 years at 
baseline (range=18-35 years) and 50.2 years at the final visit (range=42-59 
years). The mean age at menarche was 12.6 years (SD=1.5) for the total sample, 
and was younger for African-American (12.5 years, SD=1.5) compared with white 
(12.7 years, SD=1.5) women (t=-3.66, p-value=0.0003). At baseline, mean BMI 
was 24.4 kg/m2 (SD=5.7) and mean waist circumference was 74.1 cm (SD=11.6). 
Baseline adiposity was significantly higher among African-American (BMI: 25.8 
kg/m2, SD=6.4; waist: 76.4 cm, SD=13.1) compared with white (BMI: 23.1 kg/m2, 
SD=4.3; waist cm: 71.8, SD=9.2) women (BMI: t=12.5, p<.0001; waist: t=10.4, 
p<.0001).   
Table 9 shows the unadjusted baseline characteristics of the study 
sample by age at menarche category. For both African-American and white 
women, earlier menarche was associated with lower physical activity level during 
high school, as well as greater BMI, waist circumference, and insulin at baseline. 
Glucose and systolic blood pressure were higher, and physical activity level prior 
to higher school was lower among African-American women with early vs. late 
menarche. Shorter stature, less alcohol consumption, more frequent parental 
history of diabetes, and lower HDL-C were more frequent among white women 
with early menarche.  
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Age	  at	  Menarche	  and	  Type	  2	  Diabetes	  	  
 
We identified 271 incident cases of type 2 diabetes (n=193 African-
American, n=78 white) over 25 years of follow-up (Table 10). Each one-year 
earlier age at menarche was associated with an increased risk for type 2 
diabetes in Models 1 and 2 among all women, but the association was 
completely attenuated after adjustment for baseline BMI (Model 3). Examining 
menarche in categories, early age at menarche (8-11 years) was associated with 
greater risk of diabetes during follow-up compared with menarche at age 14-17 
years in Models 1 and 2, but not in fully adjusted Model 3.  For white women, 
early age at menarche was associated with greater risk for type 2 diabetes in the 
minimally adjusted Model 1 only. Age at menarche was not associated with type 
2 diabetes among African-American women in any of the models. There was no 
evidence of interaction between age at menarche and race for type 2 diabetes.  
Age	  at	  Menarche	  and	  Impaired	  Fasting	  Glucose	  
 
There were a total of 613 incident cases of IFG over 25 years of follow-up 
(n= 348 African-American, n=265 white) (Table 10). Continuous age at 
menarche was inversely associated with risk for IFG over follow-up among all 
women, even after adjustment for BMI. When examining menarche in categories, 
early menarche (8-11 years) was associated with greater risk of IFG before 
(Models 1 and 2) but not after adjustment for BMI (Model 3). For white women, 
there was an inverse association between age at menarche and IFG that was 
independent of all covariates including baseline BMI. There was also an inverse 
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association of continuous age menarche with IFG in Models 1 and 2 for African-
American women, but the association was attenuated after adjustment for 
baseline BMI. There were no associations with IFG for African-American women 
when considering menarche in categories.   
Age	  at	  Menarche	  and	  Metabolic	  Syndrome	  
 
 There were a total of 629 incident cases of metabolic syndrome over 25 
years of follow-up (n= 388 African-American, n=241 white) (Table 10). Age at 
menarche was inversely associated with risk for metabolic syndrome over follow-
up, and associations were approximately two to three times as strong among 
white compared with African-American women. There was strong evidence for 
interaction between age at menarche and race both before and after adjustment 
for adiposity (Model 1 p-interaction for race = 0.0002, Model 3 p-interaction for 
race <.0001). Associations were independent of BMI for white but not African-
American women. The results after adjustment for waist circumference (which is 
one component of metabolic syndrome) at baseline instead of BMI at baseline in 
Model 3 (all women: HR=1.10, 95% CI 1.05, 1.15; white: 1.20, 95% CI 1.12, 1.27; 
African-American: 1.05, 95% CI 0.98, 1.10) were nearly identical to the Model 3 
results that adjusted for baseline BMI (all women: HR=1.09, 95% CI 1.04, 1.14; 
white: HR=1.19, 95% CI 1.11, 1.26; African-American: HR 1.03, 95% CI 0.97, 
1.09).  
Longitudinal	  Analysis	  of	  Continuous	  Cardiometabolic	  Risk	  Factor	  Measures	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After exclusions, there were 16,078 observations for the 2,583 women 
included in the longitudinal analyses, with a mean of 6.2 visits per participant. 
The mean number of measurements was 6.1 for lipids, 6.2 for blood pressure, 
5.6 for insulin, 6.2 for glucose, and 6.2 for BMI and waist circumference. Figures 
8 and 9 display the cross-sectional adjusted means for BMI, waist circumference, 
total cholesterol, LDL-C, HDL-C, triglycerides, diastolic blood pressure, systolic 
blood pressure, glucose, and insulin for African-American and white women at 
each visit by categorical menarche group (early, average, and late). The mean 
values in Figure 8 are adjusted for age, age2, and clinical center only, while 
means in Figure 9 are fully adjusted for lifestyle factors, BMI, and height. Tables 
11 and 12 show the main effect and linear age-related change in the risk factors 
per each one-year younger age at menarche. The quadratic or cubic time terms 
were included in the main effects models, but the higher order time coefficients 
are not reported in the tables or figures unless they reached the Bonferroni-
adjusted threshold for significance and there were meaningful differences in the 
concave or convex shapes of the curves upon visual inspection of the figures. 
Main	  effect	  of	  age	  at	  menarche	  on	  CVD	  risk	  factors	  
 
The figures and tables show that women with earlier menarche had 
greater overall mean BMI and waist circumference throughout the 25 year follow-
up period (menarche main effect p<.0001 in all models). Among white women 
specifically, earlier age at menarche was also associated with higher 
triglycerides, diastolic blood pressure, systolic blood pressure, glucose, and 
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insulin, but lower HDL-C in the minimally adjusted models (Figure 8 and Table 
11).  For African-American women, age at menarche was inversely associated 
with insulin in the continuous, unadjusted model only (Table 11). The inverse 
association between continuous age at menarche and triglycerides was stronger 
for white compared with African-American women (p-race interaction=0.0003), 
but otherwise there were no statistically significant differences in the association 
of age at menarche with other CVD risk factors by race. After adjusting for BMI, 
the main effects of menarche timing on all risk factors were attenuated and no 
longer statistically significant (Figure 9 and Table 12).  
Change	  over	  time	  in	  the	  association	  of	  age	  at	  menarche	  with	  CVD	  risk	  factors	  
 
Earlier menarche was associated with steeper increases in BMI and waist 
circumference over the study period for white women only (Figure 8 and Table 
11), and the slopes indicated a strengthening of the association between early 
menarche and adiposity over time. In fact, there were essentially no changes in 
waist circumference or BMI over the study period for white women with late 
menarche (Figure 8), but those with early menarche continued to accumulate 
adiposity until leveling off around visit year 15. Earlier menarche did not appear 
to influence the slope in adiposity measures for African-American women, and 
there was a significant menarche*race*time interaction for both BMI and waist (p-
interaction<.0001).  
In minimally adjusted models, each one-year earlier age at menarche was 
associated with steeper increases in insulin for both white and African-American 
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women (Table 11), but when considering menarche in categories (Figure 8), 
early menarche (8-11 years) was associated with greater increases in insulin 
compared with later menarche for white women only. Among white women only, 
age at menarche was negatively associated with change in HDL-C, but inversely 
associated with change in triglycerides, systolic blood pressure, diastolic blood 
pressure, and glucose (Figure 8 and Table 11) over 25 years.  
After adjustment for BMI, each one year earlier age at menarche was 
associated with steeper increases in triglycerides, diastolic blood pressure, and 
insulin for white women only (Table 12). For African-American women, earlier 
menarche was associated with a faster decline in LDL-C over follow-up (Table 
12 and Figure 9). The only significant difference by race was for diastolic blood 
pressure; earlier menarche was associated with steeper increases over time for 
white compared with African-American women (p-race interaction=0.001).  
Discussion 
 
 The findings from this biethnic cohort study of young to middle-aged women 
suggest that each one year earlier age at menarche is associated with increased 
risk for metabolic syndrome, type 2 diabetes, and IFG, as well as greater 
adiposity. The associations with IFG and metabolic syndrome remained 
statistically significant after adjusting for baseline BMI for white women only. 
Each one year earlier age at menarche was also associated with lower mean 
HDL-C and higher mean triglycerides, blood pressure, insulin, and glucose, but 
these associations were driven by higher BMI among earlier maturing women. 
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Earlier age at menarche was also associated with greater increases in 
triglycerides and insulin over time after adjustment for adiposity, specifically 
among white women. Earlier menarche did not appear to be detrimental for 
change over time in CVD risk factors for African-American women.  
 There were a few differences by race in the relationship between age at 
menarche and CVD risk factors. Associations were stronger between early 
menarche and risk for metabolic syndrome, higher mean triglycerides, greater 
accumulation of adiposity, and increases in blood pressure and insulin during 
adulthood among white compared with African-American women.  After 
adjustment for adiposity, the association of earlier menarche with increases over 
time in blood pressure was stronger for white compared with African-American 
women.  
 Our finding that early age at menarche was associated with greater waist 
circumference and BMI over 25 years for both African-American and white 
women is supported by numerous other studies [28, 168, 176-178]. Accumulation 
of adiposity with age was faster for earlier vs. later maturing white women in our 
study, while African-American women in all menarche categories experienced 
near parallel increases in BMI and waist. Reports about race differences in the 
role of pubertal timing in adulthood adiposity are limited [28]. As far as we are 
aware, only the Bogalusa Heart Study reported findings separately for African-
American and white women [27]. In that study the significant association between 
early menarche and higher adulthood BMI disappeared when childhood BMI was 
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accounted for in African-Americans, and early menarche remained an 
independent predictor of adulthood BMI for white women. Furthermore, early 
menarche was more strongly associated with body fatness among white 
compared with African-American adolescents in that study, which is in agreement 
with our findings for adults [177]. New in our study was the finding that white, but 
not African-American women, reporting menarche between 14-17 years of age 
did not experience the increases in adiposity over time that was evident for the 
earlier menarche groups or for African-American women in general. These later 
maturing white women subsequently had lower risk for type 2 diabetes, IFG, and 
metabolic syndrome compared with the earlier maturing women. Others have 
also reported a potentially protective role of later pubertal onset against obesity 
and cardiometabolic risk [223]. 
The associations of early menarche with IFG and metabolic syndrome 
remained after adjusting for BMI among white women only. Others have also 
found independent associations between earlier menarche and these factors [5, 
9, 28, 176, 177, 179]. An independent association between earlier pubertal onset 
and glucose dysregulation and overall metabolic syndrome is biologically 
plausible through increased hormone exposure and metabolic changes among 
earlier maturing girls during a window of susceptibility, but these mechanisms are 
not necessarily causal for overall cardiometabolic risk in adulthood [8, 28]. 
Residual confounding by adiposity in childhood or at other points in the life 
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obesity is one of the strongest risk factors for these conditions. The recent 
genome-wide association studies [35, 223] that have found genetic variants 
related to timing of menarche and obesity might help elucidate possible causal 
pathway in these relationships [28]. 
The results from examining the individual components of metabolic 
syndrome (i.e. waist circumference, lipids, insulin, glucose, and blood pressure) 
in CARDIA suggest that insulin resistance and greater waist circumference 
probably drive the metabolic syndrome associations, but synergy resulting from 
weak associations between early menarche and the other risk factors might also 
contribute to the overall metabolic syndrome risk. Of note is that results did not 
change materially when waist circumference was included in the models instead 
of, or along with, BMI. Studies have reported that a clustering of metabolic risk 
factors increases the risk for CVD over and above the risk conferred by each of 
the individual risk factors, with the clustering of risk factors tending to have an 
additive effect on CVD risk [150, 217]. Therefore our findings related to metabolic 
syndrome have public health implications, even if they are explained largely by 
adiposity.  
The reason for the stronger associations for metabolic syndrome and 
some of its components among white compared with African-American women is 
unclear, but might relate to the fact that African-American women in all menarche 
categories had high adiposity overall during adulthood. By year 25, the adjusted 
mean BMI in all three menarche categories for African-American women reached 
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obese status (≥30 kg/m2). Therefore, any independent influence of pubertal 
timing (i.e. outside of body composition) on metabolic syndrome risk was 
probably less relevant in comparison to the influence of adult obesity on overall 
cardiometabolic risk for African-American women. 
  As far as we are aware, this is the first study to examine both the level and 
serial changes in individual cardiometabolic risk factors by age at menarche over 
the long-term in young to mid-adulthood in biracial cohort. Although early 
menarche had strong associations with several of the risk factors in the minimally 
adjusted models, it did not have any meaningful, independent influence on lipids, 
blood pressure, insulin, or glucose among non-diabetic women outside of its 
influence on BMI and waist circumference. Others have found associations 
primarily with insulin, glucose, systolic blood pressure, triglycerides, and HDL in 
various age groups and populations [28, 176, 224], but in most cases the 
relationships were attenuated after adjusting for adiposity.  
Methodological	  Considerations	  
 
  One of the main limitations of this study is that age at menarche was 
recalled, and is therefore subject to misclassification. The validity of recall for age 
at menarche in middle age is moderate (r=0.67) [53]. In one longitudinal study, 
approximately 84% of women, mean age 50, were able to recall their age at 
menarche to within one year of the actual date [53, 54]. Reliability between 
reported age at menarche at baseline and at the second visit was high in this 
study (r=0.84), and because women recalled age at menarche in early adulthood 
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(18-30 years), we expect that validity was higher than what was reported in these 
studies for middle-age women. Another limitation is that power is low to detect 
interactions by race/ethnicity at modest effect levels. Because our a priori 
research question was related to associations by race, race-specific results were 
provided even when interactions are not statistically significant. Finally, we were 
not able to adjust for potential early life factors, which might confound the 
association between early pubertal development and later disease risk. CARDIA 
did not include measures of growth rate or adiposity prior to age 18, and so we 
are unable to investigate whether observed observations between early pubertal 
onset and adulthood adiposity and CVD risk were independent of childhood BMI.   
 We investigated several outcomes, raising concern about multiple testing. 
Although we based our hypotheses on a priori evidence, both the Bonferroni 
adjusted and traditional significance levels are presented to decrease the risk of 
false-positive (type 1 error) results. 
 Bias in this study was possible if error in the recall of menarche age was 
differential according to cardiometabolic condition status. There is no reason to 
believe that women with diabetes or other cardiometabolic conditions recalled 
age at menarche any differently than those without these conditions, and such 
bias would be unlikely in our analysis of incident diabetes, impaired fasting 
glucose, or metabolic syndrome. Nondifferential misclassification of menarche 
age and covariates might bias associations, likely toward the null. It is also 
possible that there was misclassification of diabetes cases because our definition 
   114 
 
for diabetes was less stringent than that used in clinical practice, which requires 
confirmation of elevated glucose or presence of symptoms [225, 226]. Such 
misclassification will likely be nondifferential and unlikely to impact HR estimates. 
There is also potential for selection bias if women with younger age at menarche 
were less likely to enroll in CARDIA compared to their later-maturing 
counterparts.  
There are several strengths in our study design. First, CARDIA included a 
relatively large, biethnic sample, which allowed investigation of race-specific 
associations. Furthermore, the prospective design of CARDIA permitted 
determination of the temporality of associations and reduced several sources of 
bias. There were also robust, serial measures of exposures and outcomes, 
including objective measures for diabetes, body composition, blood pressure, 
and cholesterol.  
Conclusion 
 
The results from this study suggest that early menarche is associated with 
higher adiposity in adulthood, as well as the related conditions of metabolic 
syndrome, type 2 diabetes, and IFG. Associations with accumulation of adiposity 
and metabolic syndrome were stronger among white compared with African-
American women. Among white women, associations with metabolic syndrome 
and IFG remained after adjustment for BMI. It is not clear if there is an underlying 
causal mechanism between early menarche and these conditions, but residual 
confounding by adiposity, especially during childhood and adolescence, could 
   115 
 
not be ruled out in this study. Earlier age at menarche was also associated with 
deleterious levels of other CVD risk factors (i.e. HDL-C, triglycerides, blood 
pressure, insulin, and glucose) during early and middle adulthood, but the greater 
adiposity that developed earlier in life for earlier maturing women largely 
explained those relationships. Our findings suggest that targeted nutrition, 
lifestyle counseling, and obesity prevention efforts focusing on girls prior to 
menarche might help to reduce the burden of obesity and its sequelae in the 
population. 
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Table 9. Baseline characteristics of the study population by age at 
menarche category: the CARDIA Study 
 Age at Menarche (years)   
 8-11 12-13 14-17   
African-American  
(n=1,333) Mean (SD) 
or n (%) 
Mean (SD) 
or n (%) 
Mean 
(SD) or n 
(%) 
p-
trend 
n (%) 294 (22.1) 749 (56.2) 290 (21.8)   
Age at menarche 
(years) 10.5 (0.8) 12.5 (0.5) 14.7 (0.8)  
Age at baseline (years) 24.3 (3.8) 24.6 (3.8) 23.9 (4.0) 0.35 
BMI (kg/m2) 27.6 (6.6) 25.8 (6.4) 24.0 (5.7) <.0001 
Waist circumference 
(cm) 79.4 (13.7) 76.4 (13.1) 73.5 (11.7) <.0001 
Height (cm) 163.0 (7.0) 163.8 (6.5) 163.8 (7.3) 0.14 
Physical activity at 
baseline (MET h/week) 
283.4 
(206.5) 
270.3 
(234.2) 
294.1 
(231.5) 0.60 
Physical activity prior to 
high school (activity 
index) 3.5 (1.2) 3.7 (1.2) 3.9 (1.2) 0.0005 
Physical activity during 
high school (activity 
index) 3.7 (1.2) 3.9 (1.1) 3.9 (1.1) 0.01 
Smoking status 
   
0.97 
Never 177 (60.2) 461 (61.6) 173 (59.9) 
 Former 25 (8.5) 67 (9.0) 26 (9.0) 
 Current   92 (31.3) 221 (29.5) 90 (31.1)   
Alcohol (g/day) 5.1 (11.1) 4.9 (10.7) 6.5 (16.5) 0.15 
Ever used oral 
contraceptives (yes) 240 (82.0) 590 (78.8) 225 (77.6) 0.20 
Education 
   
0.21 
<High school 27 (9.2) 70 (9.3) 28 (9.7) 
 High school 200 (68.0) 537 (71.6) 209 (72.1) 
 
>High school 
67 (22.8) 143 (19.1) 53 (18.2)   
Parental history of 
diabetes (yes) 83 (28.1) 186 (24.7) 63 (21.7) 0.07 
Impaired fasting 
glucose (yes) 4 (1.4) 16 (2.1) 3 (1.0) 0.77 
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Glucose  (mg/dl) 80.3 (7.5) 79.3 (8.5) 79.0 (8.0) 0.05 
Insulin (uU/ml) 14.6 (7.6) 13.0 (6.3) 12.8 (5.5) 0.004 
LDL-C (mg/dl) 110.0 (31.8) 110.9 (31.5) 
110.4 
(33.0) 0.87 
HDL-C (mg/dl) 54.8 (13.4) 55.4 (12.7) 55.7 (13.0) 0.33 
Triglycerides (mg/dl) 62.8 (30.5) 63.1 (30.8) 63.2 (37.6) 0.92 
Total cholesterol (md/dl) 177.3 (34.7) 178.9 (33.3) 
178.7 
(34.8) 0.58 
Systolic blood pressure 
(mmHg) 109.0 (10.3) 108.4 (10.1) 106.6 (9,1) 0.003 
Diastolic blood pressure 
(mmHg) 68.2 (9.6) 67.5 (9,3) 66.6 (9.4) 0.03 
          
White  (n=1,250) Mean (SD) 
or n (%) 
Mean (SD) 
or n (%) 
Mean 
(SD) or n 
(%) 
p-
trend 
n (%) 213 (17.0) 736 (58.9) 301 (24.1)   
Age at menarche 
(years) 10.6 (0.7) 12.5 (0.5) 14.7 (0.9)  
Age at baseline (years) 25.4 (3.6) 25.5 (3.4) 25.4 (3.3) 0.99 
 BMI (kg/m2) 24.4 (5.4) 23.1 (4.3) 22.0 (3.3) <.0001 
Waist circumference 
(cm) 73.8 (11.1) 71.9 (9.1) 70.0 (7.4) <.0001 
Height (cm) 164.0 (6.2) 165.4 (6.4) 165.4 (6.5) 0.02 
Physical activity (MET-
h/week) 
385.9 
(237.9) 
395.8 
(261.8) 
417.9 
(271.2) 0.15 
Physical activity prior to 
high school  3.5 (1.1) 3.6 (1.1) 3.7 (1.1) 0.19 
Physical activity in high 
school  3.5 (1.1) 3.6 (1.1) 3.8 (1.0) 0.0001 
Current smoker 
   
0.35 
Never 126 (59.2) 378 (51.4) 162 (53.8) 
 Former 37 (17.5) 160 (21.7) 55 (18.3) 
 Current 50 (23.5) 198 (26.9) 84 (27.9)   
Alcohol (g/day) 6.7 (12.3) 10.2 (4.6) 10.5 (17.1) 0.01 
Ever used oral 
contraceptives 158 (74.2) 560 (75.6) 218 (72.4) 0.55 
Education 
   
0.90 
<High school 10 (4.7) 27 (3.7) 14 (4.7) 
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High school 112 (52.2) 344 (46.7) 152 (50.5) 
 >High school 91 (43.0) 365 (49.6) 135 (44.9)   
Parental history of 
diabetes (yes) 38 (17.8) 112 (15.1) 35 (11.6) 0.05 
Impaired fasting 
glucose (yes) 6 (2.8) 10 (1.4) 3 (1.0) 0.12 
Glucose  (mg/dl) 81.4 (8.1) 80.6 (7.4) 80.2 (7.0) 0.08 
Insulin (uU/ml) 11.1 (5.6) 10.2 (4.6) 10.1 (4.6) 0.04 
LDL-C (mg/dl) 106.0 (29.7) 106.6 (29.2) 
104.0 
(27.7) 0.41 
HDL-C (mg/dl) 55.0 (13.4) 55.7 (12.8) 58.3 (13.1) 0.002 
Triglycerides (mg/dl) 71.9 (36.0) 69.2 (39.4) 67.4 (35.4) 0.19 
Total cholesterol (md/dl) 175.3 (31.2) 176.1 (31.3) 
175.8 
(30.4) 0.84 
Systolic blood pressure 
(mmHg) 105.1 (9.3) 105.1 (9.4) 104.2 (9,2) 0.24 
Diastolic blood pressure 
(mmHg) 66.9 (8.1) 66.1 (8.7) 65.9 (8.2) 0.26 
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Table 10. Adjusted HRs for incident type 2 diabetes, impaired fasting 
glucose, and metabolic syndrome according to age at menarche: The 
CARDIA Study  
 
HR 95% CI HR 95% CI HR 95% CI HR 95% CI p-interaction (race)
Type 2 Diabetes (n=271)
Model 1 1.69 1.16, 2.29 1.38 0.99, 1.94 1.10 1.02, 1.17 0.20
Model 2 1.61 1.09, 2.37 1.35 0.96, 1.89 1.08 1.00, 1.16 0.31
Model 3 1.33 0.90, 1.96 1.24 0.88, 1.75 1.04 0.95, 1.12 0.37
IFG (n=613)
Model 1 1.49 1.16, 1.91 1.29 1.05, 1.60 1.11 1.07, 1.16 0.08
Model 2 1.50 1.17, 1.94 1.31 1.06, 1.62 1.11 1.06, 1.16 0.17
Model 3 1.28 0.99, 1.62 1.22 0.98, 1.51 1.08 1.02, 1.13 0.05
Metabolic syndrome (n=629)
Model 1 1.96 1.54, 2.48 1.50 1.22, 1.85 1.15 1.10, 1.20 0.0002
Model 2 1.95 1.53, 2.47 1.49 1.20, 1.84 1.15 1.10, 1.19 0.0005
Model 3 1.45 1.14, 1.85 1.31 1.06, 1.62 1.09 1.04, 1.14 <.0001
Type 2 Diabetes (n=193)
Model 1 1.50 0.96, 2.36 1.33 0.90, 1.98 1.07 0.97, 1.15
Model 2 1.47 0.93, 2.33 1.29 0.87, 1.93 1.06 0.96, 1.15
Model 3 1.28 0.80, 2.04 1.28 0.86, 1.92 1.03 0.92, 1.12
IFG (n=348)
Model 1 1.30 0.96, 1.77 1.03 0.78, 1.35 1.08 1.01, 1.14
Model 2 1.29 0.94, 1.77 1.02 0.77, 1.34 1.07 1.01, 1.14
Model 3 1.12 0.81, 1.54 0.97 0.73, 1.28 1.04 0.97, 1.11
Metabolic syndrome (n=388)
Model 1 1.58 1.18, 2.09 1.23 0.95, 1.58 1.09 1.03, 1.14
Model 2 1.55 1.17, 2.08 1.20 0.93, 1.55 1.09 1.03, 1.15
Model 3 1.17 0.87, 1.57 1.07 0.83, 1.38 1.03 0.97, 1.09
Type 2 Diabetes (N=78)
Model 1 2.31 1.13, 4.71 1.48 0.78, 2.81 1.17 1.03, 1.29
Model 2 1.98 0.96, 4.13 1.41 0.74, 2.70 1.12 0.97, 1.24
Model 3 1.14 0.53, 2.46 1.00 0.51, 1.96 1.00 0.82, 1.15
IFG (n=265)
Model 1 1.79 1.18, 2.69 1.75 1.25, 2.46 1.16 1.09, 1.23
Model 2 1.84 1.21, 2.80 1.89 1.21, 2.66 1.16 1.08, 1.23
Model 3 1.52 0.99, 2.33 1.63 1.16, 2.31 1.13 1.04, 1.20
Metabolic syndrome (n=241)
Model 1 3.04 1.97, 4.69 2.26 1.53, 3.32 1.26 1.19, 1.32
Model 2 3.04 1.96, 4.72 2.35 1.59, 3.46 1.25 1.18, 1.32
Model 3 2.15 1.36, 3.39 2.02 1.37, 2.98 1.19 1.11, 1.26
Notes:
Model 2 = Model 1+parental history of diabetes (Y/N), educational status (<HS, HS, >HS), pre-high school
 physical activity, high school physical activity,smoking status (current, former, never), 
oral contraceptive use (yes/no), physical activity level (METS), and alcohol intake (g/day). 
Model 3 =  Model 2+BMI and height
Diabetes models exclude women with diabetes at baseline.
IFG models exclude women with diabetes or IFG at baseline.
Metabolic syndrome models exclude women with diabetes or metabolic syndrome at baseline.
Model 1 = age, center, and race adjusted
n=45n=21
n=50 n=173
n=57 n=156
n=12
REF
REF
REF
REF
n=42
REF
REF
REF
REF
REF
REF
REF
REF
n=28
African-American
n=103
REF
REF
REF
n=31
REF
REF
REF
REF
REF
n=70
REF
n=182
n=101 n=212
REF
REF
n=75
White
n=43
n=112n=355n=146
REF
REF
REF
REF
n=69 n=159
n=158 n=368
n=48 n=114
n=96
8-11 years 12-13 years 14-17 years
Categorical Age at Menarche
All women 
Continuous Age at Manarche 
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Table 11. Main effect and per year change in cardiometabolic risk factors among 
women without diabetes over 25 years according to each 1-year earlier age at 
menarche in CARDIA, age and center adjusted models.  
	   	  
Beta se p-value Beta se p-value Beta se p-value p-race interaction
BMI (kg/m2)
Menarche main effect 0.88 0.08 <.0001 0.88 0.12 <.0001 0.89 0.10 <.0001 0.99
Menarche*time 0.02 0.002 <.0001 0.004 0.003 0.18 0.03 0.002 <.0001 <.0001
Waist (cm)
Menarche main effect 1.52 0.16 <.0001 1.44 0.23 <.0001 1.60 0.21 <.0001 0.68
Menarche*time 0.04 0.004 <.0001 0.01 0.01 0.27 0.06 0.01 <.0001 <.0001
Total cholesterol (mg/dl)
Menarche main effect 0.04 0.35 0.90 -0.48 0.52 0.35 0.58 0.5 0.25 0.13
Menarche*time -0.01 0.01 0.43 -0.02 0.02 0.28 0.01 0.02 0.81 0.34
LDL-C (mg/dl)
Menarche main effect 0.34 0.34 0.32 -0.25 0.49 0.61 0.94 0.48 0.05 0.07
Menarche*time -0.02 0.01 0.14 -0.04 0.02 0.02 0.00 0.02 0.80 0.06
HDL-C (mg/dl)
Menarche main effect -0.72 0.16 <.0001 -0.35 0.21 0.10 -1.09 0.24 <.0001 0.02
Menarche*time -0.02 0.01 0.0003 0.004 0.01 0.62 -0.04 0.01 <.0001 <.0001
Triglycerides (mg/dl)
Menarche main effect 2.12 0.45 <.0001 0.56 0.58 0.34 3.71 0.7 <.0001 0.0003
Menarche*time 0.90 0.5 <.0001 0.07 0.03 0.02 0.20 0.03 <.0001 0.007
Systolic blood pressure 
(mmHg)
Menarche main effect 0.42 0.12 0.001 0.36 0.18 0.05 0.49 0.16 0.002 0.57
Menarche*time 0.01 0.01 0.07 -0.02 0.01 0.05 0.02 0.01 0.002 0.0005
Diastolic blood pressure 
(mmHg)
Menarche main effect 0.37 0.09 0.0001 0.31 0.14 0.03 0.46 0.13 0.0004 0.43
Menarche*time 0.02 0.01 0.0005 -0.01 0.01 0.18 0.04 0.01 <.0001 <.0001
Insulin (µ U/ml)
Menarche main effect 0.35 0.06 <.0001 0.29 0.1 0.003 0.43 0.07 <.0001 0.26
Menarche*time 0.02 0.003 <.0001 0.001 0.01 0.89 0.03 0.002 <.0001 0.002
Glucose (mg/dl)
Menarche main effect 0.42 0.08 <.0001 0.32 0.12 0.01 0.55 0.11 <.0001 0.19
Menarche*time 0.01 0.004 0.01 0.001 0.01 0.91 0.02 0.01 0.002 0.06
*Adjusted for age and center
Statistical significance assessed at the Bonferonni corrected threshold of p<.0005.
All women African-American White
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Table 12. Main effect and per year change in cardiometabolic risk factors among 
women without diabetes over 25 years according to each 1-year earlier age at 
menarche in CARDIA, fully adjusted models  
 
  
Outcome Beta se p-value Beta se p-value Beta se p-value p-race interaction
Total cholesterol (mg/dl)
Menarche main effect -0.69 0.37 0.06 -0.93 0.53 0.08 -0.67 0.51 0.19 0.14
Menarche*time -0.03 0.01 0.03 -0.04 0.02 0.03 0.01 0.06 0.24 0.06
LDL-C (mg/dl)
Menarche main effect -0.83 0.35 0.02 -1.26 0.49 0.01 -0.57 0.48 0.24 0.09
Menarche*time -0.05 0.01 0.0001 -0.06 0.02 0.0002 -0.03 0.02 0.08 0.06
HDL-C (mg/dl)
Menarche main effect 0.12 0.15 0.43 0.42 0.21 0.04 -0.17 0.22 0.45 0.01
Menarche*time -0.01 0.01 0.16 0.01 0.01 0.54 -0.02 0.01 0.02 0.03
Triglycerides (mg/dl)
Menarche main effect 0.33 0.44 0.47 -0.25 0.57 0.66 0.48 0.67 0.47 0.0009
Menarche*time 0.11 0.02 <.0001 0.08 0.03 0.02 0.11 0.03 0.0003 0.12
Systolic blood pressure 
(mmHg)
Menarche main effect -0.01 0.11 0.92 0.08 0.16 0.63 -0.07 0.14 0.62 0.55
Menarche*time 0.01 0.01 0.32 -0.02 0.01 0.07 0.01 0.01 0.13 0.007
Diastolic blood pressure 
(mmHg)
Menarche main effect -0.02 0.09 0.81 -0.04 0.14 0.97 0.01 0.13 0.92 0.29
Menarche*time 0.01 0.01 0.06 -0.01 0.01 0.13 0.02 0.01 0.004 0.001
Insulin (µ U/ml)
Menarche main effect -0.04 0.05 0.43 -0.07 0.09 0.41 0.01 0.05 0.87 0.49
Menarche*time 0.01 0 0.0004 0.01 0.01 0.34 0.01 0 <.0001 0.16
Glucose (mg/dl)
Menarche main effect 0.07 0.08 0.38 0.001 0.12 0.99 0.19 0.11 0.07 0.17
Menarche*time 0.01 0.26 0.30 0.0004 0.01 0.95 0.01 0.01 0.24 0.44
Adjusted for age, center, race, parental history of diabetes, education, smoking, physical activity, oral contraceptives, 
menopause status, alcohol intake, BMI, height, blood pressure lowering medications, and lipid-lowering medications
Statistical significance assessed at the Bonferonni corrected threshold of p<.0005.
All women African-American White
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Figure 8. Age- and center-adjusted longitudinal changes in cardiovascular 
disease risk factors during adulthood by age at menarche category in the 
CARDIA Study 
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Notes: 
Includes women who reported menarche 8-17 years, were non-diabetic at baseline, and who had 
data available on covariates.   
Excludes the visits for women who were pregnant or developed diabetes. 
Adjusted for age, age2, and clinical center. 
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Figure 9. Fully adjusted longitudinal changes in cardiovascular disease risk 
factors during adulthood by age at menarche category in the CARDIA 
Study 
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Notes: 
Includes women who reported menarche 8-17 years, were non-diabetic at baseline, and who had 
data available on covariates.   
Excluded the visits for women who were pregnant or developed diabetes. 
Adjusted for age, age2, center, smoking (never, former, current), parental diabetes (yes/no), 
education (<HS, HS, >HS), alcohol use (g/day), physical activity (METS), physical activity prior to 
high school, physical activity during high school, use of oral contraceptives (yes/no), menopause 
status (yes/no), and BMI. Lipid models additionally adjusted for cholesterol lowering medications. 
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CHAPTER 5. MANUSCRIPT #3 - MENDELIAN RANDOMIZATION 
STUDY OF THE ASSOCIATION OF AGE AT MENARCHE AND 
TYPE 2 DIABETES  
Introduction  
	  
Recent studies have reported that early age at menarche increases the 
risk of type 2 diabetes [2-6]. However, early menarche is also strongly related to 
higher childhood and adulthood adiposity [60, 97], prompting uncertainty 
regarding the independent role of the timing of menarche in the risk of type 2 
diabetes. In the CARDIA study, we found that each 1-year younger age at 
menarche was associated with 17% (HR=1.17, 95% CI 1.03, 1.29) greater risk of 
type 2 diabetes over 25 years of follow-up among white women; however, the 
results were attenuated and no longer statistically significant after adjustment for 
baseline BMI (see Manuscript #2 of this dissertation). Others have also reported 
that adiposity completely attenuates the association between menarche and 
diabetes [2, 4, 175]. However, data from some large studies such as the German 
KORA study [5], Atherosclerosis Risk in Communities (ARIC) study [6], and the 
Nurses Health Study (NHS) [3], suggest that the association between earlier 
menarche and type 2 diabetes may be independent of adiposity in populations of 
primarily European ancestry, and in the case of ARIC and NHS, might be 
stronger among younger versus older cohorts of women. Due to concern about 
the declining age at menarche in the population [15, 64], as well as increasing 
prevalence of type 2 diabetes and the need to intervene in the disease process 
earlier in the life course, it seems important to determine if early puberty itself 
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might be a causal factor for diabetes, or if associations are purely the result of 
other confounding factors among early maturing girls.  
One possible reason for the uncertainty about the independent role of the 
timing of menarche in the risk of type 2 diabetes is that menarche occurs early in 
the life course, while type 2 diabetes onset typically occurs decades later. This 
lag between exposure and outcome leaves open the possibility for a number of 
factors, including adiposity, during childhood and adulthood to confound or 
mediate the association. Most studies have not included measures of early-life 
factors that are potential confounders in the association, and residual 
confounding could result from unobserved or imprecisely measured variables.  
As more and more genetic variants for common diseases are identified, 
Mendelian randomization has emerged as a tool to strengthen causal inference 
and to help overcome the issues of confounding and selection bias inherent in 
observational research [227]. Mendelian randomization takes advantage of the 
theory that genetic alleles are randomly distributed at gamete formation, and 
relies on the assumption that genetic variants are distributed independently with 
respect to behavioral and environmental factors [227]. Therefore, the association 
of the genetic variants with an outcome should not be subject to traditional 
epidemiologic biases and confounding. Under certain circumstances, Mendelian 
randomization is akin to a natural randomized controlled trial [228]. 
Mendelian randomization has its roots in the econometric method of 
instrumental variables (IV) analysis, wherein genetic variants are considered to 
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be instruments for an intermediate risk factor (or phenotype), and thus can be 
used to distinguish between a causal and non-causal association of that 
intermediate variable with an outcome. Figure 10 illustrates how a genetic 
variant (Z) is related to the outcome (Y), through an intermediate exposure 
variable (X) in Mendelian randomization [228, 229]. U represents confounders, 
which should be unrelated to the genetic variant. Note that Z (the instrument) 
should not directly cause Y (the outcome), but rather Z is correlated with Y via an 
indirect path through X (the risk factor).    
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Figure 10. Relationship of the instrumental variable with an intermediate 
risk factor and outcome in Mendelian Randomization 
 
Z (Instrument: genetic variant)        X (risk factor)             Y (outcome) 
             
     
                           U (confounders) 
 
The question about an independent role of the timing of menarche in the 
risk for type 2 diabetes is a suitable candidate for a Mendelian randomization 
study because twin and family studies have reported high heritability for 
menarcheal age [34, 230-232]. Furthermore, a recent genome-wide association 
study (GWAS) by the CHARGE-ReproGen consortium identified numerous 
independent single nucleotide polymorphisms (SNPs) in genes associated with 
age of menarche [35].  
Given that 1) several studies, including our own analyses of ARIC and 
CARDIA data, have replicated the association of early menarche and type 2 
diabetes, 2) there is uncertainty regarding the role of adiposity (e.g. mediating or 
confounding), and other childhood factors in the association, and 3) age at 
menarche has strong genetic underpinnings, the objective of this study was to 
use a Mendelian randomization approach to explore the association between age 
at menarche and type 2 diabetes using a genetic risk (GRS) as an instrumental 
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variable and uconfounded proxy for age at menarche. The GRS includes the set 
of SNPs that were associated with younger age at menarche in a published 
GWAS study [35]. The hypothesis is that younger age at menarche will be 
associated with a greater probability of prevalent type 2 diabetes in IV regression 
models employing the GRS as an instrument for age at menarche, and that the 
association will be attenuated after considering adiposity as a mediator. This 
analysis might help to clarify if early age at menarche is an independent risk 
factor for type 2 diabetes, and it might contribute to the understanding of 
mechanisms underlying the association of growth and pubertal timing with risk of 
diabetes.  
Materials and Methods 
Study	  Design	  and	  Population	  
This study involved analyses of baseline and visit 4 data from the ARIC 
Study. The ARIC Study is a prospective cohort of 15,792 participants (8,710 
women) aged 45-65 at baseline, originally designed to identify risk factors for 
atherosclerosis and cardiovascular disease. The details of the study cohort, 
including eligibility criteria, sources and methods of recruitment, and methods for 
follow-up have been described in detail elsewhere [216]. Briefly, participants 
were selected from four communities:  Forsyth County, NC (n=4,035); Jackson, 
MS (African-American only, n=3,728); northwest suburbs of Minneapolis, MN 
(n=4,009); and Washington County, MD (n=4,020). Data for these analyses were 
collected during home interviews and clinic visits at the baseline examination 
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(1987-1989) and three follow-up visits (1990-1992, 1993-1995, and 1996-1998). 
The response rate was 60% to the baseline exam in the four communities, and 
ranged from 80%-93% for follow-up of the cohort over four visits. The ARIC study 
was approved by the institutional review boards at each of the study sites and 
informed consent was obtained from each participant.  
The current analysis included all women of European ancestry with 
genetic, age at menarche, and diabetes status information at baseline. In ARIC, 
a total of 4,939 white women had genetic information for the SNPs of interest in 
this analysis. Those with missing age at menarche (n=23) or reporting age at 
menarche <8 or >17 years at the baseline visit (n=21) were excluded as we were 
interested in women within the normal range of pubertal development. Also 
excluded were those missing diabetes status at baseline (n=3) or with diabetes 
diagnosed prior to age 30 years (n=13), as these women were assumed to have 
type 1 diabetes. For the analysis of prevalent diabetes at visit 4, those with 
missing information at visit 4 (n=894) were also excluded. Participants from 
race/ethnic groups other than white were not included in this analysis because 
the SNPs for early menarche have only been replicated in non-Hispanic white 
women. Furthermore, there was not a statistically significant association between 
age at menarche and diabetes risk among African-American women in our 
published analysis that used ARIC data [6] or in Manuscript #2 of this dissertation 
that used CARDIA data. The final sample size for the analysis of prevalent 
diabetes at baseline was 4,879, and for prevalent diabetes at visit 4 n=3,985. 
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Clinical	  Measures	  and	  Data	  Collection	  
This section summarizes the definitions used for the instrumental variable 
(GRS), intermediate risk factor (age at menarche), outcome (type 2 diabetes), 
and covariates in the IV analyses. Figure 11 shows the relationships of interest 
in this analysis. 
	  
Figure 11. Relationship of the GRS to age at menarche and type 2 diabetes 
       
GRS    Age at menarche            Type 2 diabetes 
             
     
               Confounders 
 
The use of Mendelian randomization to estimate the causal effect of age 
at menarche on type 2 diabetes using the menarche-GRS as an instrument relies 
on the following three main assumptions [227, 229]. 
1. The GRS must be robustly associated with age at menarche, also known 
as the “relevance assumption” in IV analysis. 
2. The GRS must not be associated with confounders that may bias the 
association between age at menarche and type 2 diabetes. 
 
A
Adiposity? 
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3. The GRS must exert its effect on type 2 diabetes only through age at 
menarche and not through other pathways. This is known as the 
“exclusion restriction assumption”. 
These three assumptions formed the framework for the data that were chosen 
for inclusion in this study, and were addressed as part of the analyses. 
Genetic	  Risk	  Score	  (Instrumental	  Variable)	  
 
The GRS included the SNPs that are positively associated with early 
menarche among cases and noncases of diabetes in ARIC.  Appendix 1 shows 
the list of the 42 SNPs that were included in the GRS. The information for the 
GRS comes from the ReproGen consortium [35] and includes the SNPs that are 
associated with age at menarche at p-values <5X10-8 from stage 1 and 
replication meta-analysis. Genotyping in ARIC was performed using an 
Affymetrix 6.0 Array and genetic variants with a call rate ≤90%, minor allele 
frequency ≤0.01, or Hardy-Weinberg Equilibrium p-value ≤1x10-6 were excluded. 
Imputation and analysis were performed with MACH and ProbABEL software.  
First, a “GRS-42” was calculated for each participant by summing the 
number of risk alleles they had for each of the 42 SNPs (0, 1, 2). The risk allele is 
that which was associated with younger age at menarche, regardless of which 
allele was the minor allele or the effect allele in the ReproGen analysis. Following 
is the equation for the GRS-42: 
GRS-42 = (# SNP1 risk alleles) + (# SNP2 risk alleles) + … + (# SNP42 risk 
alleles) 
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The minimum possible value for the GRS-42 would be 0 risk alleles, and 
the maximum possible value would be 84 risk alleles (42 x 2). Some SNPs in the 
GRS are located in/near genes that are also hypothesized to regulate BMI, 
energy homeostasis, adult height, eating behavior, pituitary regulation, and 
estrogen encoding [233]. As mentioned, adiposity is an outcome (and possibly a 
predictor) of early menarche, and it is also a strong risk factor for type 2 diabetes. 
Furthermore, several of the SNPs in the menarche GRS-42 are associated with 
BMI during various points in the life course. This pleiotropy would violate the third 
key condition of IV analyses (i.e. the instrument exerts it effect on the outcome 
only through the intermediate risk factor and not through other pathways). 
Therefore, the association of a reduced GRS that excluded 13 SNPs with 
possible pleiotropic effects on childhood or adulthood adiposity (“GRS-29”) was 
also examined, defined as in the paper by W. Johnson et al (2013) [234]. The 
excluded SNPs were those previously reported to be associated with adulthood 
or childhood BMI [35, 235, 236], and those located in or near genes involved in 
body weight and energy homeostasis in animal models [237-240]. See appendix 
A for the list of SNPs included in the GRS-29. The GRS-29 variable was 
calculated using the same method as described for the GRS-42 variable. The IV 
analyses that use the GRS-29 as an instrument for age at menarche provided a 
sensitivity test of whether associations that included the GRS-42 as an 
instrument were the result of the pleiotropic effects of menarcheal genes on 
adiposity. 
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Age	  at	  Menarche	  (Intermediate	  Risk	  Factor/Phenotype)	  
 
Age at menarche was measured via self-report in whole years at the 
baseline visit in ARIC by asking women at what age their menstrual periods 
began. The validity of recall for age at menarche in middle age is moderate. For 
example, in one retrospective study, approximately 84% of women who were 
mean age 50 years, recalled their age at menarche to within one year of the 
actual date based on prior records [53, 54]. Age at menarche was modeled as a 
continuous variable in whole years in all models. 
Type	  2	  Diabetes	  (Outcome)	  
 
Diabetes status was assessed during each clinic visit. As mentioned, there 
appears to be a stronger association between early menarche and diabetes 
diagnosed at younger vs. older ages [3, 6], possibly because the outcome is 
closer to the timing of exposure or different physiological pathways to diabetes. 
Therefore, we first evaluated the association of age at menarche with prevalent 
diabetes at the baseline visit (i.e. the time during which the cohort was the 
youngest) and then with prevalent diabetes at visit 4 to obtain the largest number 
of diabetes cases that were objectively assessed in ARIC. Diabetes was defined 
by either self-reported history of diabetes diagnosis outside of pregnancy, blood 
glucose measurements (fasting glucose ≥ 7.0 mmol/l [126 mg/dl], non-fasting 
glucose >11.1 mmol/l [200 mg/ dl]), or self-reported use of hypoglycemic 
medication in the 2 weeks prior to the visit. Fasting glucose was measured by a 
hexokinase/glucose-6-phosphate dehydrogenase method at the Central Clinical 
   150 
 
Chemistry Laboratory in Minneapolis, Minnesota, and the Central Lipid 
Laboratory in Houston, Texas.  
Covariates	  
 
Although Mendelian randomization is based on the theory that genetic 
variants are distributed randomly with regard to potential environmental and 
behavior confounders, the use of covariates can increase the efficiency of IV 
estimators [241]. Furthermore, adjustment for covariates in Mendelian 
randomization analyses is relevant when a variable is both a confounder and 
suspected of modifying the effect of phenotype on outcome [241], which is the 
case for BMI. The covariates in adjusted models included age at baseline 
(years), field center, baseline BMI, BMI at age 25 (kg), and height. Weight (kg) 
and height (cm) were measured at the clinic visits with participants dressed in 
scrub suits and shoeless. Baseline BMI was calculated as baseline weight 
(kg)/baseline height2 (m2). BMI at age 25 was calculated as self-reported weight 
at age 25 (kg)/baseline height2 (m2). Because weight at age 25 was based on 
self-reported recall, it may be subject to misclassification. However, in the 
Nurses’ Health Study II Cohort, the correlation between recalled weight in 
adulthood and measured weight at age 18 years was high at 0.87 [242].  
Statistical	  Methods	  
 
Statistical analyses were performed with STATA, version SE 12 (College 
Station, TX) and SAS version 9.2 (Cary, NC). All statistical tests were 2-sided 
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and significance was defined as p<0.05. As done in some IV analyses in the field 
of health economics [243], marginal significance was set at a threshold of p<0.10 
for the IV estimates only. Means (SD) for continuous variables, and n (%) for 
categorical variables (Table 13) summarized the characteristics of the study 
populations by age at menarche category (8-11, 12-13, 14-17 years). P-trend 
was calculated using chi-square for categorical variables or chi-squared test for 
Pearson’s correlation coefficient for continuous variables. 
To explore the causal role of age at menarche and type 2 diabetes, a 
series of Mendelian randomization IV-regression analyses were estimated as 
described below. By using the GRS in place of age at menarche, the IV statistical 
method relates the variation in age at menarche (the risk factor) that is influenced 
by the GRS (the instrument) to type 2 diabetes (the outcome). The method 
produces an estimate of the causal effect of the exposure on the outcome that is 
similar to an intention to treat analysis in a randomized controlled trial, assuming 
that the three assumptions of IV analyses are met [244, 245].     
 Traditionally, IV analysis is performed using a 2-stage least squares (2SLS) 
model that predicts risk differences. However, economists often use probit 
structural models for dichotomous outcomes because 2SLS is analogous to 
linear regression and is more appropriate for continuous outcomes [246] [247]. 
Of note is that standard errors in all IV models are larger (i.e. point estimates are 
less precise) than in their corresponding standard regression approaches [246].   
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We started by testing the relevance assumption of Mendelian 
randomization (i.e. the GRS is associated with age at menarche) by evaluating 
the basic associations of the GRS-42 and GRS-29 with age at menarche using 
linear regression (beta [SE] and 95% CI per 1-SD increase in the GRS) (Table 
14). The F statistics from this linear regression were used to evaluate the 
strength of the association of the instrument (GRS-42 or GRS-29) with age at 
menarche, with values greater than the conventional threshold of 10 indicating 
sufficient strength of the instrument to ensure the validity of IV methods (Staiger-
Stock rule) [248, 249]. The F-statistic is considered an indicator of instrument 
strength because in the presence of X-Y confounding, the IV estimates will be 
biased towards the confounded X-Y association, and the magnitude of that bias 
is inverse to F [250]. The ratio of the IV bias to the bias in the X-Y association is 
referred to as ‘relative bias’. The threshold of F>10 to indicate a strong 
instrument in MR analysis is based on the observation that values greater than 
this threshold ensures a relative bias of <10% at least 95% of the time [250]. 
To test the assumption that the GRS is not associated with potential 
confounders, linear or logistic regression evaluated the associations (beta [SE] or 
OR, 95% CI per 1-SD increase in the GRS) of the GRS-42 and GRS-29 with 
potential confounding characteristics (Table 15).  While it is not possible to test 
for the association of the GRS with unobserved confounders, guidelines for IV 
studies state that associations with observed factors should be tested and 
reported [251]. 
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Next, IV probit regression analysis with a maximum likelihood estimator 
explored the causal role of age at menarche in type 2 diabetes by examining 
whether 1-SD increases in the GRS-42 or GRS-29 predicted absolute risk 
probabilities for prevalent type 2 diabetes at baseline or prevalent diabetes at 
visit 4 through their association with age at menarche. First, a standard probit 
model without the instrumental variable (GRS) was estimated using the “probit” 
function in STATA. Logistic regression models were also run so that the standard 
odds ratios (ORs) could be compared with other epidemiologic studies of the 
association of age at menarche and type 2 diabetes. Then, the IV probit 
regression models with robust standard errors (to account for heteroscedasticity 
of the outcome, as recommended in [251]) were estimated using the “ivprobit” 
command. The probit model is defined as Pr(y=1|x) = Φ(xb), where Φ is the 
standard cumulative normal probability distribution and xb is the probit coefficient 
[252]. Therefore, the probit model provided the predicted probability of diabetes 
based on all predictors, using the cumulative distribution function of the standard 
normal. The Mendelian randomization analyses were repeated with covariates 
for adjusted estimates.  
 Logistic regression models, in which the β!’s are interpretable as log (odds 
ratios), are usually preferred in the field of epidemiology over probit regression 
because the β!’s in probit are models somewhat more difficult to interpret [246]. 
With logistic regression, a one-unit change in X1 corresponds with a β1 change in 
the log odds of disease, assuming all else is equal. With probit, the one unit 
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change in X1 corresponds with a 1-unit change of β1 z's [246]. To help with 
interpretation of probit coefficients, the marginal effect of age at menarche 
evaluated at the mean values of covariates are reported. To obtain the 
postestimation marginal values, “margins, dydx(menage) predict(pr)” was added 
to the STATA code. The marginal effect is interpreted as the change in the slope 
of the probability function, and is comparable to a risk difference from a 2SLS 
model [246]. In the tables, each 1-year decrease in age at menarche changes 
the absolute risk of diabetes by the marginal value when all other independent 
variables are held constant at their mean level.  
 The standard and IV regression models were run in a series, starting with 
an unadjusted model, then adding baseline age and BMI at age 25 (Model 1), 
and then baseline age and BMI at baseline in place of BMI at age 25 (Model 2) to 
examine the potential mediating role of BMI at different times in the life course. In 
standard regression models, interaction terms including age at menarche and 
age at baseline tested if the association of age at menarche with diabetes 
differed by age at the baseline visit. Interaction terms including age at menarche 
and BMI at baseline tested if associations differed by BMI.  
Results 
 
Table 13 shows the characteristics of the 4,879 study participants 
included in the baseline analysis by age at menarche category. Women with 
earlier menarche were younger, shorter, had greater adiposity, higher GRS-42 
and GRS-29 scores, and greater prevalences of type 2 diabetes at baseline and 
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visit 4 compared with women reporting later menarche. The mean age of the 
cohort was 53.9 years (SD=5.7, range 44-66) at the baseline visit, and 62.8 years 
(SD=5.6, range 53-75) at visit 4. The mean age at menarche in the entire cohort 
was 12.9 years (SD=1.6). Menarche before the age of 12 years (the age used in 
many studies to define early menarche) was reported by 17.5% of the 
participants (n=857).  
There were no meaningful differences in the baseline characteristics by 
menarche category for the subsample (n=3,985) used for the analysis of 
prevalent diabetes at visit 4, and the mean age at menarche was the same for 
women who did vs. did not return at visit 4 (12.9 years). However, the prevalence 
of diabetes at baseline was higher among women who did not return (12.5%) 
versus those who did return (6.5%) at visit 4. There were 371 cases of type 2 
diabetes identified at the baseline visit (mean age at diagnosis=51 years), 302 
incident cases identified between baseline and follow-up year 9 (mean age at 
diagnosis=58 years), and 562 prevalent cases remaining at visit 4 (260 of which 
were from baseline; mean age at diagnosis=53 years).  
Genetic	  Risk	  Score	  
 
The mean GRS-42 was 41 risk alleles (SD 3.9, range 27-55 risk alleles), 
and the mean GRS-29 was 35 risk alleles (SD 3.5, range 22-47). Figure 12 
shows the inverse association between the GRS-42 and age at menarche. As 
shown in Table 14, the F-statistics from the first stage regression of the 
instrumental variable analyses were 96.2 for the GRS-42 (R2=0.02) and 85.4 for 
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the GRS-29 (R2=0.02), suggesting that these were credible instrumental 
variables for age at menarche according to conventional standards in IV 
analyses. Each 1-SD increase in the GRS-42 or GRS-29 was associated with 
approximately 11 weeks younger age at menarche.  
Table 15 shows that the GRS was not associated with any baseline 
behavioral characteristics, as expected because it is a randomly allocated 
variable. However, the GRS was associated with body composition 
characteristics. Each 1-SD increase in the GRS-42 was associated with 0.24 cm 
(SD=0.08, p=0.004) shorter stature at baseline, and 0.11 kg/m2 (SD=0.05, 
p=0.01) greater BMI at age 25. Each 1-SD increase in the GRS-29 was 
associated with 0.21 cm (SD=0.08, p=0.01) shorter stature, but not with any 
adiposity variables. 
Standard	  Regression	  for	  Age	  at	  Menarche	  and	  Type	  2	  Diabetes	  
 
 The standard probit regression analyses indicated increased probability of 
type 2 diabetes per 1-year younger age at menarche at both baseline and at visit 
4 in unadjusted models and in models adjusted for BMI at age 25 (Table 16). 
The association remained only for prevalent diabetes at baseline after adjusting 
for baseline BMI (Model 2). According to the marginal values in the standard 
probit regression models, each 1-year earlier age at menarche increased the risk 
of type 2 diabetes at baseline and at visit by approximately 1% in all of the 
standard regression models. 
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The interaction term between age at menarche and age at baseline 
suggested that the association of younger age at menarche with diabetes at visit 
4 was weaker among women who were older at baseline (p-interaction=0.05). 
There was no indication of interaction between menarche age and baseline age 
for prevalent diabetes at the baseline visit (p>0.10). There were also no 
differences in the association of age at menarche with type 2 diabetes at 
baseline or at visit 4 by BMI at baseline (p-interaction>0.29). 
Instrumental	  Variables	  Regression	  for	  Age	  at	  Menarche	  and	  Type	  2	  Diabetes	  
 
As shown in Table 16, the IV probit estimates for the effect of age at 
menarche on type 2 diabetes at baseline were three to five times stronger using 
the GRS-42 or GRS-29 as instruments compared with the standard probit 
regression estimates for diabetes at baseline. However, only the unadjusted 
estimate of diabetes at baseline using the GRS-42 reached statistical 
significance at conventional p<0.05 level (coefficient=0.23, 95% CI 0.01, 0.42). IV 
estimates using the GRS-29 before adjustment for baseline BMI were suggestive 
of an association at the p<0.1 level. According to the marginal IV probit values, 
each 1-year earlier age at menarche increased the risk of type 2 diabetes at 
baseline by 3% in all of the IV models. Overall, the GRS-42 and GRS-29 
instrumented coefficients were similar. 
None of the IV estimates for prevalent diabetes at visit 4 were not 
statistically significant. Furthermore, the confidence intervals for the IV models 
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fully included the confidence intervals from standard probit models, indicating 
that the standard and IV estimates were not different. 
Discussion 
 
The IV methods applied in the current study were used to estimate the 
causal effect of age at menarche on type 2 diabetes using Mendelian 
randomization to avoid uncontrolled confounding and selection bias. Looking 
strictly at the point estimates, the results provide some suggestion for a causal 
role for earlier age at menarche in the risk of type 2 diabetes at the baseline visit, 
as well as mediation by adiposity. However, the standard and instrumented 
regression results for diabetes at visit 4 do not support a causal role of earlier 
menarche in the probability for diabetes overall in later life. There was a 
significant interaction between age at baseline and age at menarche for 
prevalent diabetes at visit 4, indicating that the association of age at menarche 
with type 2 diabetes might differ by age. However, larger sample sizes would be 
required to further investigate this age interaction with IV analyses. The standard 
regression estimates had narrow confidence intervals compared with the wide 
confidence intervals for the IV estimates, which was the result of the small 
proportion of the variation in age at menarche explained by the GRS (~2%) and 
the weak effect sizes for age at menarche on type 2 diabetes.  
The estimates from the IV analyses for diabetes at baseline were 
substantially higher than the estimates from the standard probit regression, 
suggesting that standard observational studies might underestimate the 
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association between early age at menarche and type 2 diabetes at the baseline 
visit. Mendelian randomization might better characterize the effects of menarche 
on diabetes risk because it reflects lifetime exposure to hormones and metabolic 
changes associated with earlier maturation, including a lifetime with greater 
adiposity. Also, Mendelian randomization avoids the underestimation of risk 
associations caused by regression dilution in traditional prospective studies 
[253].  
However, the influence of an exposure on an outcome might lessen with 
time, and so the lack of any association at visit 4 in the IV estimates might reflect 
less influence of the weak association of age at menarche and type 2 diabetes 
risk as women age, possibly because of the decline in beta cell function and the 
increase in insulin resistance that occur naturally as part of the aging process. 
Furthermore, genetic associations with health outcomes tend to weaken with age 
as the overall aging process takes over [254]. The finding in the current study 
corresponds with results from the NHS I and II, which reported stronger 
associations in the younger versus older cohorts [3]. Finally, the lack of 
association at visit 4 might simply support the null hypothesis of no causal effect 
of age at menarche on type 2 diabetes.  
Methodological	  Considerations	  
 
The use of Mendelian Randomization and IV methods for causal inference 
relies on a number of assumptions [229, 251]. Unfortunately, it is not possible to 
directly test some of these conditions, such as the key assumption of no 
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pleiotropic effects of the genetic variants on multiple phenotypic traits. If the 
menarche SNPs have other effects (such as increasing or decreasing childhood 
or adult adiposity outside of the influence of age at menarche on these 
characteristics) which in turn affect risk of diabetes, then we cannot necessarily 
infer that the Mendelian Randomization models are measuring the causal 
association of early menarche with diabetes. The findings that the GRS-42 was 
associated with BMI at age 25, and both the GRS-42 and GRS-29 were 
associated with height, suggests possible pleiotropy by these characteristics and 
reinforces the shared biological underpinnings of age at menarche and body 
composition. Height is closely tied to pubertal timing [255], and girls who reach 
menarche early tend to be taller in earlier adolescence, but then attain shorter 
stature in adulthood [91]. Although shorter stature is associated with type 2 
diabetes, one possible pathway is through early childhood environment, such as 
intrauterine and early childhood nutrition, or levels of insulin like growth factor-I, 
instead of height itself being on the causal pathway to diabetes [256].  
In contrast, greater adiposity is on the causal pathway to type 2 diabetes. 
Consequently, the GRS might independently exert its effect on diabetes via an 
adiposity pathway that is separate from age at menarche. Although the GRS-42 
was not associated with weight at age 25 or with waist or BMI at baseline (and 
the associations with BMI at age 25 could have been driven by height), in an 
attempt to address possible pleiotropy with adiposity, we analyzed the GRS with 
and without adiposity-related SNPs. The point estimates were similar using both 
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the GRS-42 and GRS-29 as instruments. This suggests limited pleiotropic effects 
of the GRS on type 2 diabetes directly through adiposity, although there is no 
way to rule out possible pleiotropic effects of the GRS-29. Nonetheless, the 
GRS-29 excludes those adiposity SNPs that have been replicated in a number of 
large GWAS studies of obesity with extremely large sample sizes, and so any 
effect of the remaining SNPs in the GRS-29 on adiposity would be tiny. 
Another key assumption that is unverifiable is that the GRS is not 
associated with unmeasured confounders between age at menarche and type 2 
diabetes. We examined associations with known lifestyle confounders and found 
that the GRS was not associated with some behavioral factors that might affect 
diabetes risk, providing some reassurance that that the randomly assigned GRS 
is unlikely to be associated with other unmeasured behavioral confounders. 
However, the associations of the GRS-42 and GRS-29 with shorter stature and 
the GRS-42 with higher BMI at age 25 do not clarify if these factors should be 
considered confounders or mediators of the association. Therefore, models were 
adjusted for these covariates to try to parse out the independent influence of 
menarche on diabetes. After controlling for body composition, effect sizes were 
only slightly attenuated in the IV models. This suggests a small amount of 
confounding or, more likely, mediation given the lack of evidence of pleiotropy by 
adiposity.  
 As is usual with Mendelian randomization studies, power was limited to 
detect a true effect, if one existed, and therefore the results should be considered 
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as preliminary and replicated with a larger sample size. Reasons for low power 
included the small R2 (~2%) for the association between the GRS and age at 
menarche, and the weak to moderate effect size for age at menarche and type 2 
diabetes. However, our R2 was well with the range found in other Mendelian 
randomization studies [250]. The imprecision in the IV models provides low 
confidence in conclusions of Mendelian randomization studies such as ours 
without a very large N (in the realm of 20k to 40k participants to increase power 
above 80%). Nonetheless, the IV point estimates from this study are of value to 
compare with the standard regression estimates, and the results from this study 
provide data for better power calculations for further study [250, 257]. This study 
also demonstrated how Mendelian randomization might be used in studies with 
larger sample sizes to evaluate the effect of pubertal timing on other disease 
outcomes with stronger effect sizes. 
The main strength of the Mendelian randomization approach is that the 
method is not subject to traditional epidemiologic biases, such as selection or 
information bias, under the plausible assumption that the genotype is randomly 
allocated before the exposure of interest, in this case menarche. Other strengths 
of this study include the objective measurement of diabetes to avoid 
misclassification and robust measurement of a number of possible confounders. 
Finally, combining the genetic alleles into a GRS as we did decreases bias and 
helps to alleviate weak IV problems [250].  
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Conclusions 
 
Use of a GRS as an instrument for age at menarche supported 
observational studies that have found a stronger role for earlier age at menarche 
in the risk of type 2 diabetes in younger versus older cohorts of women, with 
possible mediation of the association by adiposity. However, the lack of 
association in the IV estimates at visit 4 suggests that early menarche may not 
be a causal factor for type 2 diabetes overall in adulthood. From an etiologic 
point of view, although the overall IV findings were not statistically significant, 
their direction and magnitude and the possible differences by age might warrant 
further study with Mendelian randomization in larger samples with improved 
statistical power and a wider age range to replicate findings. 
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Table 13. Characteristicsa of the sample participants (n=4,879) 
according to age at menarche category: the ARIC Study	  
  Age at Menarche (years)   
  8-11 12-13 14-17   
  % or Mean (SD) % or Mean (SD) 
% or Mean 
(SD) p-trend
b 
n (%) 857 (17.6) 2,592 (53.1) 1,430 (29.3)   
Baseline age 
(years) 53.2 (5.5) 53.8 (5.6) 54.6 (5.8) <.0001 
Baseline BMI 
(kg/m2) 27.9 (6.0) 26.6 (5.4) 25.9 (5.1) <.0001 
BMI at age 25 
(kg/m2) 22.7 (3.6) 21.9 (3.2) 21.4 (3.0) <.0001 
Waist 
circumference 
(cm) 
95.9 (16.0) 92.8 (14.5) 91.6 (14.3) <.0001 
Height (cm) 161.1 (5.9) 162.3 (5.8) 162.2 (5.9) <.0001 
Current smoking 
(yes) 5.1 12.4 7.8 0.26 
Physical activity 
(leisure index) 2.5 (0.6) 2.5 (0.5) 2.5 (0.5) 0.57 
Alcohol 
consumption 
(g/day) 
3.3 (10.0) 3.2 (7.3) 3.0 (7.1) 0.89 
Education (<HS) 18.3 13.4 17.2 0.95 
Glucose (mg/dl) 105.1 (33.9) 102. 6 (30.3) 101.3 (26.0) 0.04 
Diabetes at 
baseline (yes) 10.4 7.5 6.2 0.001 
Diabetes at visit 
4 (yes) 19.5 13.9 13.8 0.001 
GRS-42 (# risk 
alleles) 42.2 (3.7) 41.4 (3.9) 40.6 (3.9) <.0001 
GRS-29 (# risk 
alleles) 35.6 (3.4) 35.1 (3.5) 34.4 (3.5) <.0001 
Notes: 
	   	   	   	  aCharacteristics are from baseline unless otherwise noted. 
bp-trend from chi-square for categorical variables, or chi-squared test for Pearson’s 
correlation coefficient for continuous variables 
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Table 14. Testing the strength of the IV: associations of GRS-42 and GRS-
29 with age at menarche: the ARIC Study 
 
β (SE) per 1-
SD increase 
in GRS* 
95% CI F-statistic R2 
GRS-42 -0.22 (0.02) -0.26, -0.18 96.2 0.02 
GRS-29 -0.20 (0.02) -0.25, -0.16 85.4 0.02 
     Notes: β, standardized linear regression coefficient; CI, confidence 
interval; R2, fraction of explained variance (%). 
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Table 15. Associations of GRS-42 and GRS-29 with 
potential confounders: the ARIC Study 
Covariate 
β (SE) or OR 
per 1-SD 
increase in 
GRS 
95% CI p-value 
GRS-42       
Age (years) 0.09 (0.08) -0.07, 0.25 0.25 
Education (<HS)* 1.06 (0.04) 0.98, 1.14 0.15 
Current smoking 
(yes)* 1.01 (0.03) 0.95, 1.08 0.67 
Alcohol consumption 
(g/day) -0.09 (0.12) -0.31, 0.14 0.46 
Baseline BMI (kg/m2) 0.05 (0.07) -0.10, 0.21 0.50 
Baseline weight (lbs) -0.18 (0.47) -1.09, 0.73 0.69 
Baseline waist   
circumference (cm) 0.07 (0.21) -0.34, 0.49 0.73 
Baseline height (cm) -0.24 (0.08) -0.41, -0.08 0.004 
BMI at age 25 (kg/m2) 0.11 (0.05) 0.02, 0.21 0.01 
Weight at age 25 (lbs) 0.28 (0.28) -0.28, 0.83 0.33 
Physical activity 
(leisure index) -0.002 (0.008) -0.02, 0.01 0.83 
GRS-29       
Age (years) 0.09 (0.08) -0.06, 0.25 0.24 
Education (<HS)* 1.05 (0.04) 0.97, 1.14 0.21 
Current smoking 
(yes)* 1.00 (0.03) 0.94, 1.07 0.90 
Alcohol consumption 
(g/day) -0.003 (0.12) -0.23, 0.23 0.98 
Baseline BMI (kg/m2) -0.02 (0.08) -0.17, 0.14 0.82 
Baseline weight (lbs) -0.50 (0.47) -1.41, 0.41 0.28 
Baseline waist 
circumference (cm) -0.009 (0.21) -0.42, 0.41 0.96 
Baseline height (cm) -0.21 (0.08) -0.38 -0.05 0.01 
BMI at age 25 (kg/m2) 0.03 (0.05) -0.06, 0.13 0.46 
Weight at age 25 (lbs) -0.13 (0.28) -0.68, 0.43 0.65 
Physical activity 
(leisure index) -0.003 (0.01) -0.02, 0.01 0.68 
Notes: β, standardized linear regression coefficient; CI, 
confidence interval. 
*Regression coefficient expressed as odds ratios. 
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Table 16. Results from standard and GRS-instrumented analysis of the 
association of age at menarche (per year younger) and type 2 diabetes: the 
ARIC Study 
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Figure 12. Mean GRS-42 by age at menarche in the ARIC study 
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Chapter 6. Summary and Conclusions 
Summary of Manuscript Results 
 
The trend toward earlier age at menarche in recent decades, as well as 
widening race disparities in the timing of puberty, has raised concern in the public 
because of reports of the link between earlier maturation and a number of 
adverse health outcomes. This dissertation focused on the cardiometabolic 
health consequences at various points in the life course of earlier age at 
menarche using three different cohorts. Although previous studies have 
investigated the association of early age at menarche with several of the CVD 
risk factors included in this thesis, results conflict about independence of 
associations from adiposity, and data for ethnic minority groups are limited.  
Therefore, the objectives of the manuscripts in this thesis were to 1) 
comprehensively examine the relationship between earlier age at menarche and 
a wide variety of inter-related CVD risk factors at different points in the life 
course, 2) account for the role of adiposity in associations, and 3) explore 
possible race differences in associations. The hypotheses were that 1) earlier 
age at menarche would be associated with a more adverse cardiometabolic 
profile, 2) lifetime accumulated adiposity would largely explain the associations, 
and 3) there would be differences by race in associations. The public health 
related goal was to identify if puberty might be a sensitive time in the life course 
for targeted lifestyle interventions to prevent overt disease in adulthood. 
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The first manuscript examined the longitudinal and cross-sectional 
associations of age at menarche with CVD risk factors from age 9-19 years in the 
NGHS, comparing African-American and white girls. The main finding was that 
there were no differences by race in the influence of earlier menarche with levels 
or change in the CVD risk factors during adolescence, despite higher levels of 
adiposity and earlier menarche among African-American compared with white 
girls. As expected, age at menarche was associated with greater adiposity during 
adolescence, but the association was stronger and statistically significant 
specifically only among girls who were normal weight prior to menarche. Earlier 
menarche was not associated with level of adiposity overall during adolescence 
or at age 19 among girls who were already overweight prior to menarche even 
after considering pubertal stage at the baseline visit. In addition, earlier 
menarche was associated with adverse levels of systolic blood pressure and 
insulin during adolescence, but there were no clinically meaningful associations 
between earlier menarche and other CVD risk factors by average age 19 after 
adjusting for age 19 adiposity.  
 The second manuscript compared African-American and white women and 
examined the association of the timing of menarche with cardiometabolic risk 
factors during early to mid-adulthood in CARDIA, picking up at the age where the 
NGHS left off (18-30 years).  Early menarche continued to be associated with 
greater adiposity throughout adulthood, as well as with the related conditions of 
metabolic syndrome, type 2 diabetes, and IFG. Each one year earlier age at 
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menarche was also associated with more adverse levels of HDL-C, triglycerides, 
blood pressure, insulin, and glucose before adjustment for BMI. Greater adiposity 
explained the associations with adverse levels of CVD risk factors, except for 
metabolic syndrome and IFG, which remained statistically significant for white 
women even after adjustment for BMI at the baseline visit. Contrary to the 
findings from the NGHS, some differences by race emerged in the adult cohort. 
Specifically, the associations of early menarche with accumulation of adiposity 
and risk for metabolic syndrome were stronger among white compared with 
African-American women.  
  The third manuscript addressed the uncertainty about an independent role of 
early maturation in the risk for the increasingly prevalent cardiometabolic 
condition of type 2 diabetes, and the potential for unmeasured confounding in the 
relationship. A Mendelian randomization approach was employed to explore a 
potential causal association between age at menarche and type 2 diabetes using 
a genetic risk score (GRS) as an instrumental variable and uconfounded proxy 
for age at menarche in the ARIC study, which included women who were aged 
45-65 years at baseline. This study showed that earlier age at menarche was 
associated with prevalent type 2 diabetes at the baseline visit, but not at visit 4, 
when the cohort was approximately a decade older. There was a significant 
interaction between age at baseline and age at menarche in the odds for type 2 
diabetes at visit 4, which might merit further study. The standard and IV 
regression results supported findings from the Nurse’s Health Study that showed 
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a stronger association of earlier age at menarche with diabetes in younger 
versus older cohorts. However, given the lack of association at visit 4 and wide 
confidence intervals for the IV estimates, it remains unclear if earlier age at 
menarche plays a role in diabetes risk overall during adulthood. From an etiologic 
viewpoint, more may be learned about the relationship of earlier pubertal 
development with type 2 diabetes at various points in the life course from a 
Mendelian randomization study with a larger sample size, perhaps including 
cohorts of both younger and older women. 
Limitations and Strengths 
 
There are number of strengths and limitations in the three studies included 
in this thesis, and those for the specific studies were outlined in the individual 
manuscripts. In general, the observational nature of the three studies had certain 
limitations, such as selection bias, information bias, and residual confounding. 
We were also unable to establish temporality of some risk factors such as 
adiposity and insulin levels with the timing of menarche. Furthermore, none of the 
studies had information available on early life factors or measurements of body 
composition that preceded the onset of puberty. Therefore, important body 
composition and lifestyle factors could not be adjusted for prior to puberty.  
 Another limitation of all of three studies was that misclassification of age 
at menarche was possible because they all relied on self-reported recall of 
menarche. However, this misclassification would have been minimal in the 
NGHS as menarche status was ascertained annually, and in CARDIA 
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ascertainment took place during early adulthood. Furthermore, even studies that 
included women of middle age have shown high validity and reliability for self-
reported age at menarche.  
The strengths of the studies used in this thesis included their prospective 
design and that each study included a cohort of women from different points in 
the life course, starting at age 9 years in the NGHS. This provided a life course 
perspective of the association of age at menarche with various related 
cardiometabolic risk factors and confounders. The longitudinal nature of the 
analyses for the NGHS and CARDIA studies allowed examination of the 
trajectories of CVD risk factors according to menarche timing. Another strength of 
all three studies was that they included both African-American and white 
participants from several different communities around the United States, 
providing some generalizability of the results. 
Future Directions 
 
Examining the association between earlier pubertal development and 
cardiometabolic risk factors is challenging because puberty and body 
composition are so closely tied together. It is difficult to say what came first in the 
cohorts included in this thesis, greater adiposity or onset of puberty, without 
measures of body composition prior to the onset of puberty. Therefore, future 
studies might include measurements starting in infancy to measure body 
composition and possibly hormones, insulin, and other early cardiometabolic 
changes related to changes in the HPO axis to assess when greater adiposity 
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first develops and at what point during development cardiometabolic changes 
begin. Furthermore, this thesis included girls only, and so future studies might 
look at the cardiometabolic consequences of altered pubertal timing among boys. 
The Mendelian randomization analysis had limited power to detect true 
associations, and so future studies should include larger sample sizes and 
possibly outcomes with stronger associations with age at menarche. As age at 
menarche appears to be more strongly associated with type 2 diabetes in 
younger cohorts, any future Mendelian randomization study of this association 
should include a younger age-range than ARIC. One possible future analysis 
might be a Mendelian randomization study of age at menarche with metabolic 
syndrome given the moderate association we saw in CARDIA.  Another possible 
future direction might be a clinical trial of lifestyle interventions prior to menarche 
that follows girls after menarche to see if changes early in life might beneficially 
delay menarche, subsequent adiposity accumulation, and onset of CVD risk 
factors.  
Conclusions 
 
Considering the results from all three manuscripts, this thesis largely 
supports the hypothesis that earlier age at menarche is associated with a more 
adverse cardiometabolic profile over the life course, but that increased adiposity 
among early maturing girls explains most associations. The only associations 
that were not explained by adiposity in the manuscripts were with metabolic 
syndrome and impaired fasting glucose (which is part of metabolic syndrome) 
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among white women in CARDIA. Given that this clustering of metabolic factors 
has been shown to have a synergistic effect on CVD risk over and above the risk 
from each of the individual risk factors included in the metabolic syndrome, this 
finding points to a potential role of earlier maturation in overall cardiometabolic 
risk for white women, but not for an important role of early maturation in the 
individual risk factors.  
 There were very few race differences in the association of earlier menarche 
with cardiometabolic outcomes. Earlier age at menarche was more strongly 
associated with accumulation of adiposity and metabolic syndrome in adulthood 
among white women despite higher prevalence of obesity and average earlier 
age at menarche among African-American girls. This finding, along with the 
general overall weak to null associations for the other outcomes among African-
American women, suggest that earlier maturation per se is unlikely to be 
contributing to racial disparities in the prevalence of cardiometabolic conditions 
such as type 2 diabetes and metabolic syndrome in adulthood. One would have 
expected associations at least as strong, or stronger, between early menarche 
and these outcomes among African-American compared with white women if 
early maturation itself was a factor in racial disparities in cardiometabolic health. 
Therefore, with regard to cardiometabolic outcomes, focus should probably be on 
the racial disparities in obesity starting early in life rather than on racial disparities 
in the timing of puberty. However, early maturation has other negative health 
consequences, such as greater risk for breast cancer and more risky health 
   176 
 
behaviors, and so disparities in menarche timing may still warrant public health 
concern for other reasons. 
Results from the three studies included in this thesis replicate findings 
from a number of past studies showing that earlier age at menarche is 
associated with higher adiposity in both adolescence and adulthood. The findings 
that earlier menarche was associated with greater adiposity accumulation in 
adulthood specifically among white women, as well as among girls who were 
normal weight, but not overweight, prior to menarche, provide further insight into 
the role of pubertal timing in adiposity development over the life course. The 
propensity for greater adiposity among earlier maturing girls had cardiometabolic 
consequences beginning in adolescence in the NGHS, including higher blood 
pressure and insulin levels, and then subsequently greater risk for type 2 
diabetes, prediabetes, and metabolic syndrome in adulthood in CARDIA. 
Furthermore, the greater degree of adiposity earlier in life appears to set earlier 
maturing women up for adverse levels of blood pressure, HDL-C, triglycerides, 
insulin, and glucose in adulthood.  
In summary, this thesis contributed to the understanding of the influence 
of maturational timing among women on levels and changes in CVD risk factors 
with age from adolescence through adulthood, taking into consideration the 
greater degree of adiposity among earlier maturing women. The findings suggest 
that puberty might be a sensitive point in the life course for interventions to 
reduce the burden of obesity and its sequeale among women. Therefore, 
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obesity-reducing strategies such as improved nutrition and increased physical 
activity that begin prior to menarche, and possibly also targeted at girls maturing 
early even if they are normal weight, might be helpful for primordial prevention of 
CVD disease and its risk factors in adulthood. 
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Appendix A. List of 42 SNPs included in the GRS for Manuscript #3 
Adapted from reference [35] 
 
	  	   	   	  	   	  	   	  	   	  	   	  	   Stage	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  +	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SNP	  
	   	  
	  
GRS-­‐29	  
Nearest	  
gene(s)	  
Distance	  
from	  gene	  
(kb)	   Chr.	   MAFa	   Allelesb	   Betac	   se	   Directiond	   p-­‐valuee	  
rs10423674	   N	   CRTC1	   intronic	   19	   0.35	   A/C	   2.3	   0.4	   +/+	   8.70E-­‐09	  
rs1079866	   Y	   INHBA	  	   ~250KB	   7	   0.15	   G/C	   4.2	   0.5	   +/+	   2.00E-­‐14	  
rs10899489	   N	   GAB2	   intronic	   11	   0.15	   A/C	   3.2	   0.6	   +/+	   8.40E-­‐09	  
rs10980926	   Y	   ZNF483	   intronic	   9	   0.36	   A/G	   2.6	   0.4	   +/+	   3.90E-­‐11	  
rs12472911	   Y	   LRP1B	   intronic	   2	   0.20	   C/T	   2.5	   0.5	   +/+	   1.50E-­‐07	  
rs12617311	   Y	   PLCL1	   ~195kb	   2	   0.32	   A/G	   -­‐3.1	   0.4	   -­‐/-­‐	   1.10E-­‐12	  
rs13187289	   N	   PHF15	   ~12kb	   5	   0.20	   G/C	   3.1	   0.5	   +/+	   4.20E-­‐10	  
rs1361108	  
	  
Y	   C6orf173,	  
TRMT11	  
~98kb,	  
~407kb	   6	   0.46	   C/T	   2.1	   0.4	   +/+	   2.20E-­‐08	  
rs1364063	   Y	   NFAT5	   ~10kb	   16	   0.43	   C/T	   2.1	   0.4	   +/+	   1.80E-­‐08	  
rs1398217	   Y	   FUSSEL18	   intron	   18	   0.43	   G/C	   -­‐2.6	   0.4	   -­‐/-­‐	   2.90E-­‐12	  
rs1659127	   Y	   MKL2	   ~28kb	   16	   0.34	   A/G	   2.4	   0.4	   +/+	   3.20E-­‐08	  
rs16938437	   Y	   PHF21A	   intronic	   11	   0.09	   T/C	   -­‐3.8	   0.7	   -­‐/-­‐	   6.20E-­‐08	  
rs17188434	   Y	   NR4A2	   ~84kb	   2	   0.07	   C/T	   -­‐4.7	   0.8	   -­‐/-­‐	   7.30E-­‐10	  
rs17268785	   Y	   CCDC85A	   intronic	   2	   0.17	   G/A	   3.3	   0.5	   +/+	   1.40E-­‐10	  
rs1862471	   Y	   OLFM2	   intronic	   19	   0.47	   G/C	   2.2	   0.4	   -­‐/+	   6.80E-­‐08	  
rs2002675	  
	  
	  
N	  
TRA2B,	  
ETV5	  
~4kb,	  
~135kb	   3	   0.42	   G/A	   2.3	   0.4	   +/+	   2.80E-­‐09	  
rs2090409	   Y	   TMEM38B	   ~400kb	   9	   0.31	   A/C	   -­‐4.7	   0.4	   -­‐/-­‐	   4.40E-­‐31	  
rs2243803	   Y	   SLC14A2	   ~238kb	   18	   0.40	   A/T	   2.0	   0.4	   +/+	   3.40E-­‐07	  
rs2687729	   Y	   EEFSEC	   intronic	   3	   0.27	   G/A	   2.3	   0.4	   +/+	   1.30E-­‐07	  
rs2947411	   N	   TMEM18	   ~53kb	   2	   0.17	   A/G	   2.8	   0.5	   +/+	   1.70E-­‐08	  
rs3743266	   Y	   RORA	   3'UTR	   15	   0.32	   C/T	   -­‐2.0	   0.4	   -­‐/-­‐	   8.00E-­‐07	  
rs3914188	   N	   ECE2	   3'UTR	   3	   0.27	   G/C	   -­‐2.5	   0.4	   -­‐/-­‐	   9.60E-­‐09	  
rs466639	   N	   RXRG	   intronic	   1	   0.13	   T/C	   -­‐4.2	   0.6	   -­‐/-­‐	   5.00E-­‐13	  
rs4840086	  
	  
N	   PRDM13,	  
MCHR2	  
~145kb,	  
~160	  kb	   6	   0.42	   G/A	   -­‐2.1	   0.4	   -­‐/-­‐	   2.40E-­‐08	  
rs4929923	   N	   TRIM66	   3'UTR	   11	   0.36	   T/C	   2.3	   0.4	   +/+	   1.20E-­‐08	  
rs633715	   N	   SEC16B	   ~44kb	   1	   0.46	   T/C	   2.7	   0.5	   +/+	   4.70E-­‐08	  
rs6438424	   Y	   3q13.32	   intergenic	   3	   0.50	   A/C	   -­‐2.7	   0.4	   -­‐/-­‐	   1.40E-­‐13	  
rs6439371	  
	  
Y	   TMEM108,	  
NPHP3	  
~146kb,	  
~170kb	   3	   0.66	   A/G	   -­‐2.3	   0.4	   -­‐/-­‐	   1.30E-­‐08	  
rs6575793	   Y	   BEGAIN	   intronic	   14	   0.42	   C/T	   2.4	   0.4	   +/+	   5.70E-­‐09	  
rs6589964	   N	   BSX	   ~18kb	   11	   0.48	   A/C	   -­‐2.7	   0.4	   -­‐/-­‐	   1.10E+11	  
rs6762477	   Y	   RBM6	   intronic	   3	   0.44	   G/A	   2.6	   0.5	   +/+	   2.00E-­‐08	  
rs7359257	   N	   IQCH	   intronic	   15	   0.45	   A/C	   1.8	   0.4	   +/-­‐	   8.90E-­‐07	  
rs757647	   Y	   KDM3B	   intronic	   5	   0.22	   A/G	   -­‐2.4	   0.5	   -­‐/-­‐	   8.80E-­‐08	  
rs7617480	   Y	   KLHDC8B	   intronic	   3	   0.22	   A/C	   2.5	   0.4	   +/+	   2.50E-­‐08	  
rs7642134	   Y	   VGLL3	   ~70kb	   3	   0.38	   A/G	   -­‐2.5	   0.4	   -­‐/-­‐	   3.00E-­‐10	  
rs7759938	   Y	   LIN28B	   ~26kb	   6	   0.32	   C/T	   6.5	   0.4	   +/+	   8.20E-­‐57	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rs7821178	   Y	   PXMP3	   ~181kb	   8	   0.34	   A/C	   -­‐2.5	   0.4	   -­‐/-­‐	   1.90E-­‐09	  
rs852069	   Y	   PCSK2	   ~84kb	   20	   0.37	   A/G	   -­‐2.2	   0.4	   -­‐/-­‐	   9.30E-­‐09	  
rs900145	   Y	   ARNTL	   ~5kb	   11	   0.30	   C/T	   2.3	   0.4	   +/+	   1.60E-­‐08	  
rs9555810	  
	  
Y	   C13orf16,	  
ARHGEF7	  
~185kb,	  
~223KB	   13	   0.28	   G/C	   2.5	   0.4	   +/+	   1.80E-­‐08	  
rs9635759	   Y	   CA10	  	   ~94kb	   17	   0.32	   A/G	   2.9	   0.4	   +/+	   1.90E-­‐11	  
rs9939609	   N	   FTO	   intronic	   16	   0.40	   A/T	   -­‐2.1	   0.4	   -­‐/+	   3.10E-­‐08	  
Notes:	   	  
	   	   	   	   	   	   	   	   	  aMinor	  allele	  frequency	  
bMinor/Major	  allele	   	   	   	   	   	  
	   	   	  cPer	  allele	  change	  in	  age	  at	  menarche	  (weeks)	  obtained	  from	  meta	  analysis	  of	  Stage	  1	  +	  replication	  cohorts	  
	  dDirection	  of	  the	  minor	  allele	  association	  with	  age	  at	  menarche	  in	  Stage	  1/replication	  studies	  
	   	   	  eP-­‐value	  from	  meta-­‐analysis	  of	  Stage	  1	  +	  replication	  cohorts	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Appendix B. Abbreviations 
 
ARIC – Atherosclerosis Risk in Communities Study 
BioLINCC - Biologic Specimen and Data Repository Information Coordinating Center 
BMI – Body mass index 
BPA – Bisphenol-A 
CARDIA - Coronary Artery Risk Development in Young Adults 
CRP - C-reactive protein 
CVD – Cardiovascular disease 
DBP – Diastolic blood pressure 
DONALD – Dortmund Nutritional and Anthropometrical Longitudinally Designed Study 
EPIC - European Prospective Investigation of Cancer 
FSH - Follicle stimulating hormone 
GH – Growth hormone 
GnRH - Gonadotropin-releasing hormone 
GRS – Genetic risk score 
GWAS - Genome-wide association studies 
HDL – High-density lipoprotein 
HOMA - Homeostasis model assessment of insulin resistance 
HPG - Hypothalamic-pituitary-gonadal 
HPO - Hypothalamic-pituitary- ovarian 
HR – Hazard ratio 
IFG – Impaired fasting glucose 
IGF - Insulin-like growth factors 
IR – Insulin resistance 
IV – Instrumental variable 
KORA - Cooperative Health Research in the Augsburg Region 
LDL – Low-density lipoprotein 
LH - Luteinizing hormone 
MAF – Minor allele frequency 
NCEP: ATP III – National Cholesterol Education Program's Adult Treatment Panel III 
NCS – National Children’s Study 
NGHS – National Growth and Health Survey 
NHANES – National Health and Nutrition Examination Survey 
NHLBI – National Heart, Lung, and Blood Institute 
NHS- Nurses Health Study 
OR – Odds ratio 
PBDE - Polybrominated diphenyl ethers 
PCBs – Polychlorinated biphenyls 
SD – Standard deviation 
SE – Standard error 
SES – Socioeconomic status 
SBP – Systolic blood pressure 
SNP - Single nucleotide polymorphisms 
SSB – Sugar sweetened beverages 
SSF – Sum of skin folds 
TG - Triglycerides 
2SLS – 2-stage least squares 
